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Chapter 1 
General introduction 
Outline ofthe introduction 
Normal fetal development requires the presence of thyroid hormone. Disruption of any of the 
processes regulating the bioavailability of thyroid hormone may contribute to congenital 
anomalies. This thesis is focussed a) on the importance of thyroid hormone sulfation during fetal 
development, and b) on the potential sulfation-disrupting effects of environmental chemicals such 
as hydroxylated polychlorinated biphenyls (PCBs), because of potential pathogenetic 
consequences of disturbed thyroid hormone sulfation for the development of organs, such as 
lungs and brain. 
In this general introduction, first some information is given on the development of fetal thyroid 
status, and the importance of thyroid hormone for the development of organs such as the brain is 
discussed. Secondly, Ihyroid hormone synthesis, transport and metabolism, which are all 
processes regulating thyroid hormone bioavailability, are reviewed. Additionally, the role of 
sulfation in thyroid hormone metabOlism, especially during fetal development, is addressed. 
Furthermore, some general information on PCBs and other polyhalogenated aromatic 
hydrocarbons is given, and their potential estrogen and thyroid hormone-disrupting effects are 
discussed. Finally, the outline of this thesis is presented. 
Thyroid hormone and fetal development 
The biological activity of thyroid hormone is largely mediated by specific nuclear T3 receptors 
in target tissues. The T3 receptors belong to the nuclear hormone receptor superfamily that also 
include steroid, retinoic acid and vitamin D3 receptors, and contain a central DNA-binding domain 
and a C-terminal ligand-binding domain (1-5). Several thyroid hormone receptor (TR) isoforms 
exist, among which TRa1, a2, TR~1, ~2 and the recently identified TR~3 (6), which are 
expression products from the TRa and TR~ genes. Whereas TRa2 does not bind T3, TRa1, ~1, 
~2 and ~3 act as functional receptors. The thyroid hormone receptors bind to the DNA as 
homodimers or as heterodimers in association with the retinoid X receptor; the dimers regulate 
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gene-expression via binding to thyroid hormone response elements present in the promoter 
region of target genes (1-5). Expression patterns for the different receptor isoforms differ. While 
TRa1 is widely expressed from early embryonic stages, TR~1 is present later in development, 
baSically in the same tissues as TRa1. TR~2 is predominantly expressed in the developing retina 
and inner ear, and in the pituitary gland and hypothalamus (3-5); this TR-isoform plays an 
important role in the feedback regulation of the hypothalamic-pituitary-thyroid axis (7,8). The 
ontogenic expression pattern of TR~3 remains to be investigated. 
Thyroid hormone is essential for normal development of organs such as the brain (9). Severe 
iodine deficiency during the first half of pregnancy is clearly related to neurological cretinism (10). 
Moreover, also undiagnosed maternal hypothyroidism has been suggested to adversely affect 
neurological development of the child (11,12). The T4 and T3 that are present in the fetus before 
the onset of fetal thyroid function are of maternal origin; if pregnant rats are thyroidectomized, no 
T4 and T3 is detected in the offspring before the onset of fetal thyroid function (13), and when 
early in pregnancy dams are injected with labeled T4 and T3, the labeled thyroid hormones are 
found in the fetal compartment (14,15). In rats, fetal thyroid function starts at gestational day 
17.5-18; at this time a sudden increase in tissue and plasma T4 and T3 pools is found (16). In 
humans, secondary to the development of fetal hypothalamic-pituitary function, active thyroidal 
secretion starts at week 18-22 (17-19). However, also after the onset of fetal thyroid function 
transfer of thyroid hormones from mother to fetus continues. Thus, fetal thyroid status remains 
dependent on the thyroid status of the mother until birth (20). 
T3 has been demonstrated in extracts from fetal human brain of 9-10 weeks gestational age 
(21,22). By midgestation, fetal brain T3 level reaches about 30% of the T3 level in the adult 
human brain. This fetal brain T3 level is much higher than the fetal serum T3 level at this stage, 
which may indicate that brain type II deiodinase (D2), which is important for the local conversion 
of T4 to T3, is already important in the human fetal brain (23). Nuclear TRs are present in human 
brain by week 10, and steadily increase until week 16 (21). Also in other human fetal tissues such 
as the lung, T4, T3 and the nuclear TR are already found early in gestation (22). Serum T4 and 
free T4 levels steadily increase during development, until adult levels are reached at the end of 
gestation; whereas normal adult serum T3 amounts to 2 nM and normal adult serum rT3 to 
0.25 nM (17-19), serum T3 is low (-0.5 nM), and serum rT3 is high (2-4 nM) in the human fetus, 
indicating that the ratio of outer ring deiodination versus inner ring deiodination is low in the fetus 
compared to the adult, as will be explained in the next paragraph. 
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Thyroid hormone synthesis, transport and metabolism 
Thyroid hormones are synthesized in the follicular cells of the thyroid gland. The follicular cells 
take iodide up from the blood, and after thyroid peroxidase-catalyzed oxidation at the apical 
membrane the iodine is bound to tyrosyl residues of thyroglobulin, yielding monoiodotyrosyl (MIT) 
and diiodotyrosyl (OIT) residues. Subsequently, T4 is formed by thyroid peroxidase-catalyzed 
coupling of two OIT residues within thyroglobulin, and T3 by coupling of a MIT and a OIT residue. 
Following endocytosis of the thyroglobulin molecule from the follicular lumen, the molecule is 
hydrolyzed by lysosomal hydrolases, liberating thyroid hormones, which are then secreted into 
the blood stream (24). Normally, T4 is the main product of the thyroid gland. Besides T4, also 
20% of the daily amount of T3 is synthesized in the thyroid gland. The remaining 80% of plasma 
T3 is formed in tissues such as liver and kidney by outer ring deiodination of the prohormone T4 
(25,26). Thyroid hormone synthesis is under positive control of hypophyseal TSH (thyroid 
stimulating hormone) or thyrotropin (27,28). In turn, TSH release is stimulated by hypothalamic 
TRH (thyrotropin releasing hormone) (28,29). Negative feedback of this regulation takes place via 
inhibition ofTRH and TSH secretion by thyroid hormones (28,30,31). 
lodothyronines circulate in blood plasma bound to the plasma transport proteins thyroxine-
binding globulin (TBG), transthyretin (TTR), formerly known as thyroxine-binding prealbumin 
(TBPA), and albumin. In humans, TBG, TTR and albumin carry about 75%, 15% and 10%, 
respectively, of plasma T4 and T3 (26,32-34). Of these transport proteins, TTR may play an 
active role in tissue thyroid hormone supply (35). Since normal adult rats lack TBG, TTR is the 
main plasma transport protein in rat serum (34). 
In normal human serum free T4 (FT4) and free T3 (FT3) comprise only about 0.02 and 
0.2% of total T4 and T3 levels, respectively (26,32-34). The free fraction determines the amount 
of thyroid hormone taken up by cells. Although the hydrophobic thyroid hormones were 
originally believed to pass the cell membrane by passive diffusion (36), evidence has 
accumulated that cellular uptake of T4 and T3 into different organs is a saturable and energy-
dependent process (reviewed by Hennemann et at. (37)). Plasma membrane transporters may 
be different in different organs. For instance, in the liver T4 and T3 are transported into the cell 
by different carrier systems (38-40), whereas in the pituitary and the heart only one transport 
mechanism has been identified, in the pituitary for both T4 and T3 (41-43) and in the heart only 
for T3 (44). Recently, several organic anion transporters and L-type amino acid transporters 
have been shown to facilitate the cellular uptake of thyroid hormone (45-51). The physiological 
relevance of these transporters, their tissue distribution, and the mechanisms by which they 
regulate the bioavailability of thyroid hormone remain to be established. 
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Besides thyroidal hormone secretion and the exchange of thyroid honmone between tissue 
and plasma, the bioavailability of T3 depends on the intracellular iodothyronine metabolism. T4 
is converted by outer ring deiodination (ORO) to the receptor-active T3, or by inner ring 
deiodination to the metabolite rT3. (25). T3 and rT3 are further deiodinated, by IRO and ORO, 
respectively, to 3,3'-T2 (Fig. 1). Oeiodination is catalyzed by a family of three iodothyronine 
deiodinases (01-3), which all have the amino acid selenocysteine (Sec) in their catalytic center 
(52,53). 
I I NH, 
, \ I HO-O- O-Q-CH,-CH-COOH 
/ / 
, , 
01,OY T4 ~1,03 
1\ '" ~H, I I NHJ 
HO-O- O-O-Cli,-~-COOH 
,/ 
rT3 
\ \ I 
HO -0- 0 -0- CH,-CH -CooH 
,/ 
T3 "'-
01,03 ~ /01,02 
I I NH, 
\ \ I 
HO -0-0-0- Cli,-CH --cooH 
3,3'-T2 
Fig. 1 Stepwise deiodination of thyroxine (T4). 
01 catalyzes both ORO and IRO, and is expressed in liver, kidney and thyroid (52-54). 01 
is the main site for plasma T3 production and plasma rT3 clearance in adults, but its expression 
is low in fetal tissues (19,55). HepatiC and renal 01 gene expression is increased in 
hyperthyroidism and decreased in hypothyroidism (52,53). Recent studies have revealed the 
presence of two functional T3 response elements in the 01 gene promoter (56,57). 
02 has only ORO activity and, thus, converts T4 solely to active T3. It is mainly expressed 
in brain, pituitary and brown adipose tissue (BAT), but 02 mRNA is also found in the human 
heart and skeletal muscle (58-60). The physiological role of 02 lies in the local production of T3 
in these tissues. Its activity shows tissue-specific, development stage-dependent patterns, 
generally increasing in the late fetal period and peaking in the neonatal period (19). 02 activity 
in the different tissues is down-regulated in hyperthyroidism and up-regulated in 
hypothyroidism. Although 02 mRNA levels may also be decreased by T3, the negative control 
of 02 activity by thyroid state is predominantly a post-translational mechanism involving 
substrate (T4, rT3)-induced enzyme inactivation (52,53,61). 
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03 has only IRO activity. It is predominantly localized in brain, placenta, pregnant uterus 
and fetal tissues (55,62-68), and is important for the inactivation of tissue and plasma T3, as 
well as for the production of plasma rT3. Brain 03 activity is up-regulated in hyperthyroidism 
and down-regulated in hypothyroidism (19,69). 03 activity shows tissue-specific, development 
stage-dependent profiles, i.e., rat brain 03 activity is higher in the fetus than in the adult, rat 
skin 03 peaks in the neonatal period, and human liver 03 activity is high in the fetus and 
becomes undetectable after birth (19,55,69). The high levels of 03 in the placenta have been 
demonstrated to limit transplacental passage of T4 and T3 from mother to fetus (70,71). The 
very high 03 levels that have recently been found in the rat uterus indicate that also the uterus 
is involved in the regulation of fetal thyroid state (64). 
T4G 
3:lucuronidation I I NH~ sulfation \ - \0 ' 
T4S ~--- HO-O- 0 -: _) -CHz-CH-COOH 
/ T4 ,/ 
outer ring \ / '" inner ring 
deiodination (ORDV ~ deiodination (IRD) 
T3 rT3 
Fig. 2. Pathways of thyroid hormone metabolism. 
Besides deiodination, glucuronidation and sulfation are important pathways in thyroid 
hormone metabolism (Fig. 2) (72,73). These conjugation reactions facilitate the urinary and 
biliary excretion of iodothyronines by increasing their water-solubility (72,73). However, 
excretion of iodothyronine glucuronides is only partial, since, subsequent to their secretion in 
the bile, at least part of the iodothyronines are reabsorbed after hydrolysis by ~-glucuronidases 
present in the intestine (73). Glucuronidation is catalyzed by multispecific uridine diphosphate-
glucuronyltransferases (UGTs), which are located in the endoplasmic reticulum of tissues such 
as the liver. UGTs catalyze the transfer of glucuronic acid from the cofactor uridine 
diphosphate-glucuronic acid to the hydroxyl group of iodothyronines. Based on sequence 
homology, two families of UGTs have been identified (74,75). So far, the bilirubin UGT1A1, and 
phenol UGT1A9 are known to be involved in the glucuronidation of T4 in humans (74-76). 
Whereas in the rat androsterone UGT seems largely responsible for the glucuronidation of T3, 
no human UGT preferring 3,3',5-triiodothyronine over T4 has been found yet (75-77). Since the 
enzymes catalyzing the glucuronidation of thyroid hormone mostly develop around or after birth, 
they do not play an important role in thyroid hormone metabolism in the developing fetus (78). 
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" " ~H, T3 0- 0- I HO-\ '-0-1 \-CH~-CH-COOH , " - ./ ~ 
PAPS YsULT ,/ ) ARS 
PAPA 
I I NH2 
'0 '0- I HSOO-./ \ -0- 1 -CH -CH-COOH 3 \ _ I \ _ ./ 2 
,/ T3S 
Fig. 3. Formation and hydrolysis of 
triiodothyronine sulfate (T3S), catalysed 
by suJfotransferases (SUL T) and 
ary!sulfatase (ARS) respectively. 
3'-Phosphoadenosine~5'-phosphosulfate 
(PAPS) is used as sulfate donor. 
Like glucuronidation, sulfation is an important detoxification mechanism for exogenous 
chemicals (79,80). Apart from this, sulfation is involved in the regulation of the biological activity 
of endogenous compounds such as steroids and thyroid hormone (80,81). Sulfotransferases 
catalyze the sulfation of the hydroxyl group of the compounds, uSing 3'-phosphoadenosine-5'-
phoshosulfate (PAPS) as the universal sulfate donor (Fig. 3) (82). This cofactor PAPS is 
synthesized from 2 ATP molecules and inorganic sulfate. All cytosolic sulfotransferases are 
members of a large gene superfamily (Fig. 4) (79,81,83-85). They are located in different 
tissues such as liver, kidney and brain, have a molecular weight of about 32 kDa, and exist 
predominantly as homodimers (86). Before sulfotransferase cDNAs were cloned, three different 
human cytosolic sulfotransferases were defined on the basis of biochemical characteristics: a 
thermostable phenol sulfotransferase that catalyzes the sulfation of 4-nitrophenol and other 
phenolic compounds in the micromolar range (later called hSUL T1A 1), a thermolabile phenol 
sulfotransferase that prefers dopamine as substrate (later called hSUL T1A3), and a 
hydroxysteroid sulfotransferase that catalyzes the sulfation of cholesterol, bile acids and 
3~-hydroxysteroids such as DHEA (later called hSULT2A1) (81,83-85). In addition to 
hSULT1A1, 1A3 and 2A1 (87-94), eight other human sulfotransferases have been identified by 
cDNA and gene cloning strategies: hSULT1A2, 1B1, 1C2 and 1C4, 1E1, 2B1a, 2B1b and 4A1 
(95-105). The sulfotransferases, which show overlapping substrate specificities, are classified 
on the basis of amino acid homology. The phylogenetic tree depicted in Figure 4 shows the 
homologies between the various mammalian sulfotransferases. Except for hSULT2B1a and 
2B1 b, which are splice variants of the same gene (104), all sulfotransferases are encoded by 
different genes. So far, functionally relevant polymorphisms have been found for hSULT1A1 
and 1A2 (96,106-109); in the hSULT2A1 gene polymorph isms have been detected which could 
not be associated with enzyme activity levels (110). 
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.--_______ mouSUlT5A1 
rabSUlT2A1 
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mouSUlT2A1 
mouSUlT2A2 
gpiSULT2A2 
L_-I[ gp1SUlT2A1 
mouSULT2B1 
humSULT2B1a 
humSUlT2B1b 
chkSUlTSA1 
mouSUlT3A1 
rabSULT3A1 
humSUlT4A1 
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ratSUlT4A1 
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Fig. 4. Phylogenetic tree of mammalian cytoso!ic sulfotransferases 
(courtesy of Dr. M.W.H. Coughtrie). AU human SULT1 enzymes catalyze 
iodothyronine sulfation, in the rat only SULT1B1 and 1C1 are known to 
catalyze iodothyronine sulfation. Abbreviations: bov = bovine; can = canine; 
chk = chicken; gpi = guinea pig; hum = human; mon = monkey; mou = mouse: 
rab = rabbit. 
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Importance of sulfation in thyroid hormone metabolism 
The role of suWation in thyroid hormone metabolism is fascinating. Figure 5 shows the 
interaction between the deiodination and sulfation pathways. Neither 02 nor 03 are capable of 
catalyzing the deiodination of sulfated iodothyronines. However, sulfation strongly facilitates the 
inner ring deiodination of T4 and T3 (inactivation) by 01, but blocks the outer ring deiodination of 
T4 (activation) by this enzyme (111-113). The outer ring deiodination of rT3 by 01 is not affected 
by sulfation (111-113). Under normal conditions, therefore, the main function of suWation is to 
induce the irreversible degradation of thyroid hormone. As a resu~ of the very rapid inner ring 
deiodination of T4S and T3S and outer ring deiodination of rT3S, the plasma concentrations of 
these sulfated iodothyronines are very low in the normal adult (114-118). However, iodothyronine 
sulfates accumulate in serum and bile when deiodination by 01 is prevented. For instance, 
increased thyroid hormone sulfate levels were observed in rats that were fed a selenium-deficient 
diet or were administered inhibitors of 01 such as propylthiouracil or iopanoic acid (119-121). 
Most likely, the high iodothyronine sulfate levels found in patients with non-thyroidal illness are 
also caused by impaired 01 activity, although reduced iodothyronine (sulfate) uptake in liver and 
kidney may play an additional role (115-118,122). 
Fig. 5. Interaction between deiodination and sulfation 
pathways (courtesy of Dr. M.W.H. Coughtrie). 
Sulfation strongly facilitates the IRD of T4 and T3 by 
01, but blocks the ORD of T 4 by 01. 
The high concentrations of the different iodothyronine sulfates, T4S, T3S, rT3S and 3,3'-T2S, 
that are found in human fetal serum and amniotic fluid (115-118,123) were also believed to be 
due to low hepatic 01 expression until after birth. However, although 01 activity in rat fetal liver is 
low, increasing just before birth (65-68), Significant 01 activity is already present in the fetal 
human liver in the second trimester (55). Little is known about the ontogeny of hepatic thyroid 
hormone transporters in the developing fetus; absent or low expression of these transporters 
would be an alternative explanation for the high iodothyronine sulfate levels in the human fetus. 
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It has been suggested that the sulfates in the fetal circulation represent a reservoir of inactive 
thyroid hormone, from which active hormone is recovered when required, by the action of 
sulfatases present in the different tissues (112,123,125). Although iodothyronine sulfate 
hydrolysis has been observed in tissues such as liver, kidney and brain (126), and several 
sulfatases have been identified (127), it is still not known which sulfatases are involved in 
iodothyronine sulfate hydrolysis, and how these sulfatases are regulated. To delineate the role of 
sulfation/desulfation in the regulation of bioactive thyroid hormone during fetal development, it is 
of crucial importance to determine the contribution of the different sulfotransferases and 
sulfatases to iodothyronine sulfation/desulfation in the fetus, and to enhance our understanding of 
the mechanisms involved in the regulation of the expression of these enzymes. 
Polyhalogenated aromatic hydrocarbons and endocrine disruption 
The existence of chemicals in our environment that may disrupt endocrine systems and affect 
developmental and other physiological processes in humans and wildlife has received much 
attention in recent years. These so called 'endocrine disrupters', among which polyhalogenated 
aromatic hydrocarbons (PHAHs) such as polychlorinated biphenyls (PCBs), dibenzo-p-dioxins 
(PCDDs) and dibenzofurans (PCDFs) (for general structures see Fig. 6), could affect the sex 
steroid systems as well as the thyroid hormone system in different ways. PCBs, PCDDs and 
PCDFs consist of two halogenated benzene rings, and comprise 209, 75 and 135 possible 
congeners, respectively. Whereas PC DDs and PCDFs are rigid planar structures, the benzene 
rings of the PCBs usually assume non-planar positions (128). 
PCB PCDO 
'~' 
,U /'-...~\/' 
/4 0" y\ 
Cl Cl 
PCOF 
Fig. 6. General structures of polychlorinated biphenyls (PCB), polychlorinated dibenzo-
p-dioxins (PCDD), and polychlorinated dibenzofurans (PCDF). 
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PCBs were used as plasticizers, as fiame retardants and as hydrolytic fiuids in transfonmers 
and capacitors, PCDDs and PCDFs are fonmed during organochlorine synthesis and combustion 
processes. Emissions of these compounds have been reduced for several years now, but the 
PHAHs are resistant to breakdown and therefore still widely present in the environment. 
Cytochrome P450-catalyzed hydroxylation is the main route of PHAH metabolism; the 
hydroxylated metabolites can be further metabolized by sulfotransferase and UDP-
glucuronyltransferase-catalyzed conjugation reactions (129). Many of the effects of PC DDs, 
PCDFs, non-ortho and mono-ortho PCBs occur via the aryl hydrocarbon receptor (AhR) pathway. 
Via binding to specific DNA sequences, so called dioxin response elements (DREs), the ligand-
AhR complex affects transcription of genes containing functional DREs in their promoter region 
(130). Di- to tetra-ortho PCBs and hydroxylated PHAH metabolites exert their effects through non-
AhR pathways. 
Disruption of the estrogen- or androgen system is generally believed to be involved in 
abnormalities in sexual development, gonadal functions, and reproduction (131-133). Exposure of 
rats to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) during development causes changes in 
gonadal development, reduced sperm counts, and feminization of male offspring (134,135). 
Administration of the PCB mixture Arocior 1254 to rats results in delayed puberty, reduced fertility 
and reduced prostate, testicular and uterine weights (134,136). In humans, during the last 50 
years a decline in semen quality and spenm count and a rise in male reproductive tract 
abnormalrties have been observed in some developed countries, which is suspected to be due to 
exposure to environmental chemicals (137,138). Furthenmore, breast cancer, prostate cancer and 
testicular cancer incidence have been suggested to be related to PHAH exposure, however, hard 
evidence for the correlation between PHAH exposure and endocrine tumors is still lacking 
(131,138-141). The mechanisms involved in disruption of the estrogen system remain unclear. At 
least in part, planar PHAHs are believed to act via the AhR pathway. Additionally, estrogenic as 
well as anti-estrogenic effects have been suggested to be induced by binding of hydroxylated 
PHAHs to the estrogen receptors, although binding affinities are low compared to the natural 
substrate E2 (142-144). Cytochrome P450 enzymes involved in estrogen metabolism, may also 
be affected by dioxin and dioxin-like PCBs. For instance, catechol estrogen fonmation is 
decreased in hepatiC microsomes obtained from 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated rats, 
and the aromatase (CYP19)-catalyzed conversion of testosterone to estradiol is inhibited by 
various PHAHs (145-147). Addrtionally, 3,3',4,4',5-pentachlorobiphenyl increases the 70.-
hydroxylation, but reduces the 20.-, 6~- and 16a-hydroxylation and 5a-reduction of progesterone 
and testosterone in rat liver microsomes (148). 
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Thyroid hormone disruption by PHAHs has been suggested to be related to impaired 
neurological development. In pregnant women exposed to background levels of PHAHs, a 
negative correlation was observed between PHAH levels and plasma T3 and T4 levels in 
newborns and their neurologic development (149-153). Also in experimental animals exposed to 
PHAHs, plasma T4 levels are reduced and neurological abnormalities have been observed (154-
157). As it is still not clear whether the reduced T4 levels contribute to the impaired brain 
development, this possible relationship needs further study. PHAHs interfere with the thyroid 
system at various levels: they affect thyroid gland morphology, thyroid hormone receptor binding, 
the thyroid hormone plasma transport system, and thyroid hormone metabolism (for detailed 
reviews see 154,156,157). In in vitro studies PHAHs and their hydroxylated metabolites inhibit the 
binding of T3 to the nuclear thyroid hormone receptors (158,159). In addition, hydroxylated 
metabolites potently inhibit the binding of T4 to the plasma transport protein TTR in rats as well as 
in humans (154,160). Regarding thyroid hormone metabolism, PHAHs strongly induce 
UDP-glucuronyltransferase activities in the rat, thus increasing the hepatic clearance of thyroid 
hormone (154,156,157), while hydroxylated PHAH metabolites inhibit D1 activity (161) and 
iodothyronine sulfotransferase activity (162). As we expect that iodothyronine sulfotransferases 
are important in the protecton of fetal tissues from excessive thyroid hormone, we speculate that 
this inhibition of iodothyronine sulfotransferase activity could result in inappropriate levels of active 
T3, leading to precocious organ development. 
Congenital diaphragmatic hemia is an anomaly characterized by a diaphragmatic defect, 
pulmonary hypoplasia, pulmonary hypertension and eventually surfactant deficiency (163,164). 
The mechanisms underlying the etiology of congenital diaphragmatic hernia remain unclear 
(different theories reviewed in 165). To study its pathogenesis, an animal model is frequently 
used, in which the administration of the herbicide nitrofen (2,4-dichlorophenyl-p-nitrophenyl ether) 
to pregnant rats during mid-gestation induces congenital diaphragmatic hernia in the offspring 
(166). Nitrofen is a halogenated diphenylether, i.e. a PHAH showing an even greater 
resemblance to thyroid hormone than the PCBs, PCDDs and PCDFs. Therefore, it may be 
speculated that nitrofen or its metabolites interfere with the thyroid hormone system in a manner 
similar to other PHAH(-OHs), and that the interference of nitrofen (metabolites) with the thyroid 
hormone system may contribute to the abnormal lung development associated with nitrofen-
induced congenital diaphragmatic hemia. 
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Outline of the thesis 
Strictly regulated thyroid hormone bioavailability is of crucial importance for normal fetal 
development. Thyroid hormone metabolism plays a key role in this regulation. The aims of the 
study described in this thesis were to test the hypotheses that sulfation is a reversible pathway for 
the inactivation of thyroid hormone during fetal development, and that inactivation of thyroid 
hormone sulfation by environmental chemicals leads to excessive levels of active T3, resulting in 
precoc',ous d',fferentiation of d',fferent organs. 
To assess the importance of thyroid hormone sulfation in thyroid hormone metabolism during 
fetal development, we studied the ontogeny of the different iodothyronine-metabolizing enzymes 
in the developing rat (Chapter 2), we identified and characterized the different rat iodothyronine 
sulfotransferases (Chapter 3), and we characterized the iodothyronine sulfatase activITies in 
human and rat liver and placenta (Chapter 4). In contrast to the situation in humans, reversible 
iodothyronine sulfation appeared not to be important in thyroid hormone metabolism in the rat. We 
also characterized the human iodothyronine sulfotransferases (Chapters 5 and 6), and identified 
the human estrogen sulfotransferase hSUL T1 E1 as an efficient iodothyronine sulfotransferase 
(Chapter 6). 
Polyhalogenated aromatic hydrocarbons are known for their endocrine-disrupting effects, 
which may lead to abnormal fetal development. Since estrogen sulfotransferase apparently 
catalyzes sulfation of both estrogens and iodothyronines (Chapter 6), effects of environmental 
chemicals on estrogen sulfotransferase could affect the estrogen as well as the thyroid hormone 
system. In the last part of the thesis, the effects of the various PHAH-OHs on estrogen 
sulfotransferase were studied (Chapters 7 and 8). In the discussion the results of the studies 
reported in this thesis are evaluated, and an outlook to future research is presented (Chapter 9). 
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Ontogeny of iodothyronine sulfotransferase, type I and type III 
deiodinase activities in the rat 
Monique HA Kester, Thirza J. Roest, Oanijela Marinkovic, Caren H. van Oijk, Hans van Toor, 
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Abstract 
Thyroid hormone-deiodinating pathways regulate the bioavailability of T3. In the human 
fetus low T3, high rT3 and high iodothyronine sulfate levels are found. The low T3 and high rT3 
levels can be explained by high 03 levels in placenta and uterus, and low 01 and high 03 
levels in the fetus compared to the adult. The high iodothyronine sulfate levels suggest an 
important role for sulfation in thyroid hormone inactivation. Whereas in the adult the sulfated 
iodothyronines are very rapidly degraded by 01, in the fetus iodothyronine sulfates form a pool 
of inactive thyroid hormone which may be reactivated by the action of sulfatases. 
In the present study we determined iodothyronine sulfotransferase, sulfatase, 01 and 03 
activities in different fetal, neonatal and maternal tissues. The tissues examined were liver, 
lung, kidney, intestine, brain, skin, heart and placenta. In most tissues 01 activity was low 
during fetal development. In the liver, however, considerable 01 activity was found from E19 
onwards. In the intestine, significant 01 activity was found from E19 to E21, becoming 
undetectable again after birth. The pattern of 01 protein expression, determined by affinity-
labeling with BrAcT3, resembled the pattern of 01 activity in the different tissues. 03 activity 
was found in placenta, in fetal and neonatal skin and intestine, and in fetal, neonatal and 
maternal brain. No significant 03 activity was found in fetal liver, which is in contrast to the 
situation in humans. Sulfotransferase activity was present in all tissues except heart and 
placenta. No significant sulfatase activity was found in any fetal or neonatal tissue. 
In conclusion, iodothyronine deiodinase and sulfotransferase activities vary in a tissue-
specific and development stage-dependent manner. 03 activity in placenta, uterus and fetal 
tissues protects the fetus from excessive T3. The considerable sulfotransferase activities in the 
fetus suggest an additional role for sulfation in the inactivation of thyroid hormone. However, 
the low sulfatase activities suggest that desulfation is not important in the reactivation of thyroid 
hormone in the fetal rat. 
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Introduction 
The tissue-specific and' development stage-dependent regulation of thyroid hormone 
bioactivity during fetal development is essential for normal organ development; disruption of 
thyroid hormone homeostasis may contribute to congenital anomalies. Oeiodination is a key 
process in the regulation of thyroid hormone homeostasis. The prohormone T4 is converted by 
outer ring deiodination (ORO) to the receptor-active T3, or inactivated by inner ring deiodination 
(IRO) to rT3. T3 and rT3 are further deiodinated, by IRO and ORO respectively, to 3,3'-T2 (1). 
Oeiodination is catalyzed by three deiodinases, which have been characterized as homologous 
transmembrane proteins containing a selenocysteine in the catalytic center. They require thiol 
as cofactor (24). Type I deiodinase (01) performs both inner ring and outer ring deiodination. In 
adults, it is predominantly expressed in liver, kidney and thyroid, and is important for the 
production of plasma T3 and for the clearance of plasma rT3 (2). Type II deiodinase (02) has 
only ORO activity. It is predominantly expressed in brain, pituitary and brown adipose tissue 
(BAT), in humans it is also expressed in the thyroid and perhaps in skeletal muscle and heart 
(3,5-7); its physiological role is the local production of T3 in these tissues (3). 03 has only IRO 
activity and is expressed in brain, skin, placenta, pregnant uterus and fetal tissues (8-16).03 is 
important for the inactivation of tissue and plasma T3 as well as for the production of plasma 
rT3. The high levels of 03 in the placenta have been demonstrated to limit transplacental 
passage of maternal T4 and T3 to the fetus (17,18). 
Besides deiodination, glucuronidation and sulfation are important pathways of thyroid 
hormone metabolism. Glucuronidation is catalyzed by uridinediphospate glucuronyl-
transferases. It facilitates the biliary excretion of iodothyronines by increasing their water 
solubility. Glucuronyltransferase expression is low during fetal development (19,20). Another 
conjugation pathway is sulfation. Members of the phenol sulfotransferase family (SUL T1) 
catalyze the transfer of a sot from the universal sulfate donor 3'-phosphoadenosine-5'-
phosphosulfate (PAPS) to various exogenous and endogenous compounds, among which 
iodothyronines (21-25). Sulfation strongly facilitates the IRO (inactivation) of T4 and T3 by 01, 
but blocks the ORO (activation) of T4 by this enzyme. Under normal conditions, therefore, 
sulfation is the primary step in the irreversible degradation of thyroid hormone (26). However, 
when 01 activity is low, sulfation may represent a pathway of reversible thyroid hormone 
inactivation, depending on activity of arylsulfatases (26-28). This situation may exist in the 
human fetus, where high levels of iodothyronine sulfates have been detected in fetal serum and 
amniotic fluid (18,29). 
The ontogeny of the different deiodinases in th e rat and in humans has been studied before 
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(10-16), but little is known about the role of sulfotransferases in thyroid hormone metabolism 
during fetal development. In the present study we determined the ontogeny of sulfotransferase, 
D1 and D3 activity in different tissues of the developing rat, to elucidate the importance of the 
different metabolic pathways in the regulation of thyroid hormone homeostasis during fetal 
development. 
Materials and Methods 
Materials 
Following approval from the Institutional Animal Care and Use Committee of the Erasmus 
University Medical Center Rotterdam, female Sprague Dawley rats were purchased from Harlan 
Olac (Oxon, England). The day the vaginal plug was observed was designated as embryonic 
day 0 (EO). At different gestational ages, after cesarian section (E14-E21) or spontaneous birth 
(NO and N1) placenta, fetal and maternal liver, kidney, lung, heart, intestine and brain and fetal 
skin were dissected for the preparation of homogenates. Tissues were washed in 0.9% NaCI, 
frozen in liquid N, and stored at -80 C until homogenization. Because of the small size, the 
tissues from different fetuses or newborns (8-1S pups) from the same litter, or from three 
different litters (E14), were pooled and homogenized on ice in 3-S volumes 0.1 M phosphate 
(pH 7.2), 2 mM EDTA, 1 mM dithiothreitol (DTT), using a polytron (Kinematica, Lucerne, 
Switzerland) and a motor-driven potter (Ika Labortechnik, Staufen, Germany). The 
homogenates were stored at -80 C until further analysis. Protein concentrations were 
determined by the method of Bradford (30), using bovine serum albumin as standard. 
[3',S'-12'I]T4 and [3'_1251]T3 were obtained from Amersham (Amersham, UK); PAPS, protein 
molecular weight markers, DTT and 6-n-propyl-2-thiouracil (PTU) were purchased from Sigma 
(St. Louis, MO, USA); T4, rT3, T3 and 3,3'-T2 were purchased from Henning Berlin GmbH 
(Berlin, Germany); Sephadex LH-20 was obtained from Pharmacia (Woerden, The 
Netherlands); electrophoresis grade SDS-PAGE reagents were obtained from Bio-Rad 
(Richmond, IL); and Coomassie Brilliant Blue R-2S0 was purchased from Merck (Darmstadt, 
Germany). 3,[3'-12'1]T2 and [3',S'-12'I]rT3 were prepared by radioiodination of 3-T1 and 3,3'-T2, 
respectively, as previously described (31). N-bromoacetyl-[3'-12'I]T3 (BrAc[12'I]T3) was prepared 
as previously described (32). 3,3'-T2S and 3,[3'-12'1]T2S were prepa,ed by reaction of unlabeled 
and 12'I-labeled 3,3'-T2 with chlorosulfonic acid in dimethylformamide. They were purified by 
LH-20 chromatography as previously described (33). 
Sulfotransferase assays 
lodothyronine sulfotransferase activities were analyzed by incubation of usually 0.1 "M 
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3,3'-T2 and 10' cpm of the "'I-labeled compound for 30 min at 37 C with the indicated amounts 
of tissue homogenate in the absence (blank) or presence of 50 flM PAPS in 0.1 ml 0.1 M 
phosphate (pH 7.2), 2 mM EDTA. The reactions were stopped by addition of 0.9 ml ice-cold 
0.1 M NaOAc (pH 5.0). The samples were analyzed for 3,3'-T2S formation by applying them to 
Sephadex LH-20 minicolumns (1 ml bed volume), equilibrated in 0.1 M NaOAc (pH 5.0). Iodide, 
iodothyronine sulfates and unconjugated iodothyronines were subsequently eluted with 2 x 1 ml 
0.1 M NaOAc (pH 5.0), 6 x 1 ml H20 and 3 x 1 ml 0.1 M NaOH/ethanol (vol/vol 1:1) 
respectively. Enzymatic sulfation was corrected for background radioactivity detected in the 
blanks. 
T2S sulfatase assays 
T2S sulfatase activities were determined by incubation of 0.1 ~M T2S and 10' cpm 
3,[3'-12'11T2S and 0.1 mM PTU (to block D1 activity) for 60 min at 37 C WITh 0.5 mg proteinlml in 
0.1 ml 0.1 M phosphate (pH 7.2), 2 mM EDTA. The reactions were stopped by addition of 0.9 
ml ice-cold 0.1 M NaOAc (pH 5.0). The mixtures were analyzed for 3,3'-T2 formation by 
chromatography on Sephadex LH-20 minicolumns as described above. Enzymatic T2S 
hydrolysis was corrected for background radioactivity detected in blanks WIThout homogenate. 
Type I deiodinase assays 
D1 activities were measured by incubation of 0.1 ~M [3',5'-"'llrT3 for 60 minutes at 37 C 
with the indicated amounts of tissue homogenates in the absence or presence of 0.1 mM PTU 
and 0.1 ~M rT3 in 0.1 ml 0.1 M phosphate (pH 7.2), 2 mM EDTA, 10 mM DTT. Reactions were 
stopped by addition of 0.1 ml 5% bovine serum albumin. The protein-bound "'I-labeled 
iodothyronines were precipitated by addition of 0.5 ml 10% trichloroacetic acid. After 
centrifugation, the supernatants were analyzed for "'I' production on Sephadex LH-20 
minicolumns (bed volume 0.25 ml), equilibrated and eluted with 0.1 M HC!. 
Type III deiodinase assays 
D3 activities were measured by incubation of 1 nM or 1 ~M [3'-"'I]T3 for 30 minutes at 37 C 
with the indicated amounts of tissue homogenates in the presence of 0.1 ~M rT3 and 0.1 mM 
PTU (to block D1 activity) in 0.1 ml 0.1 M phosphate (pH 7.2), 2 mM EDTA, 50 mM DTT. 
Reactions were stopped by addition of 0.1 ml ice-cold methanol. After centrifugation, 0.15 ml 
supernatant was mixed with 0.1 ml 0.02 M ammonium acetate (pH 4.0), and 0.1 ml of the 
mixture was applied to a 4.6 x 250 mm Symmetry C18 column connected to an Alliance HPLC 
system (Waters, Etten-Leur, The Netherlands), and eluted with a gradient of acetonitrile in 
0.02 M ammonium acetate (pH 4.0) at a flow of 1.2 ml/min. The proportion of acetonitrile was 
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increased linearly from 30% to 44% in 10 min. The radioactivity in the eluate was detenmined 
using a Radiomatic A-500 flow scintillation detector (Packard, Meriden, CT). 
Affinity-labeling 
0.1 ~Ci BrAc['25I]T3 was reacted for 15 min at 37 C with 0.1 mg protein in 75 ~I 0.1 M 
phosphate (pH 7.2), 2 mM EOTA, 3 mM OTT. The reaction was stopped by addition of 25 ~I 
SOS-PAGE loading buffer containing 10 mM OTT. Subsequently the samples were heated for 
10 min at 80 C. Proteins were separated overnight by SOS-PAGE in a 16 cm 12% 
polyacrylamide gel. Gels were stained for 2 h with Coomassie Brilliant Blue R-250 in 45% 
methanol/10% acetic acid and destained for 5 h with 45% methanol/10% acetic acid, both at 
room temperature. Gels were dried at 80 C under vacuum, and autoradiographed at room 
temperature using BioMax MS-1 film (Eastman Kodak, Rochester, NY). 
Results 
Sulfotransferase, sulfatase, 01 and D3 activities were determined in rat tissues from 
fetuses and newborns from different development stages (E14-21 and NO and 1). Enzyme 
activities were also determined in maternal rat tissue homogenates. 
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Fig. 1. D1 activities in fetal (E17-21), neonatal (NO-1) and maternal (M) rat liver, kidney, intestine or lung homogenate. 
Reaction conditions: 0.1 IJM [3',5'-125I]rT3, 10 mM OTT, 0.5 mg (fetal and neonatal tissue homogenate) or 0.1 mg 
(maternal liver and kidney homogenate) or 1 mg (maternal lung and intestine homogenate) protein/ml, 60 min 
incubation. Results are the means ± SO from 2 to 4 pools of tissue homogenate, except for E21 in Kidney, which 
represents the mean of triplicate determinations on a single pool of tissue homogenates. 35 
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Figure 1 shows 01 activtties in fetal, neonatal and maternal rat liver, kidney, intestine and 
lung. Clear development stage-dependent patterns were obselVed in the different tissues. In 
the liver, deiodinase activity is present from E19 onwards, reaching a maximum value (30 
pmol/min/mg protein) at E21. The apparent increase in 01 activity at neonatal day 0 compared 
to other stages is not significant. 01 activities in the developing kidney remain low until after 
birth, while 01 activities in maternal kidney homogenates were as high as in maternal liver. 01 
activity in rat lung is very low in the fetal, neonatal and in the adult stage. In the intestine a 
remarkable pattern was obselVed. While significant 01 activity is present from E18 to E21 
(conversion rates increasing from around 0.2 to 2 pmol/min/mg protein), 01 activity becomes 
undetectable after birth. No significant 01 activities were found in placenta, skin, brain and 
heart homogenates at any age tested (data not shown). The kinetics of 01 activity were 
measured in fetal liver, kidney and intestine homogenate from E20. The apparent Km values for 
liver, kidney and intestine were 0.17, 0.16 and 0.23 ~M, respectively, and their V"'" values 
approximately 14, 2 and 4 pmolimin/mg, respectively. 
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Fig. 2. Affinity-labeling of fetal (E14-21), neonatal (NO-1) and maternal (M) rat liver (A and B) or kidney (B) homogenate 
with BrAcr251]T3 in the absence (-) or presence (+) of 100 J..lM PTU and 10 IJM rT3. Reaction conditions: 0,1 ).lei 
BrAcr25JJT3, 1001-19 protein, 3 mM DTT, without (-) or with (+) 100 IJM PTU and 10 !-1M rT3, 15 min incubation. The 
molecular weight of the marker proteins and the labeled 01 protein (arrow) are indicated. 
Figure 2 shows the results of the affinity-labeling of fetal, neonatal and adult rat liver and 
kidney by BrAc['''I]T3. As demonstrated previously, the 27 kO band represents the affinity-
labeling of 01 (34). The 01 protein expression level, although semi-quantitative, correlates well 
with the enzyme activity patterns for the different tissues. When the liver homogenates were 
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incubated with BrAc[1251]T3 in the presence of PTU and rT3, the labeling of the 27 kD band was 
completely inhibited. In the liver, D1 protein expression is found from E19 onwards, increasing 
until birth (Fig. 2A). The ontogenic profile of D1 protein expression in the intestine was less 
clear because of the low levels of expression (data not shown). In fetal and neonatal kidney 
(E20-N1) D1 protein expression is just above background; high D1 protein expression was 
found in the maternal kidney (Fig. 2B). We were not able to identify D3 protein and 
sulfotransferase expression by affinity-labeling with BrAc[1251]T3. 
Liver 
10r-------------------, 
~ J 6' 
[:t _11111 
E14 E17 E19 E20 E21 NO N1 M 
Intestine 
2.0 r------------------
0> 1.5 t 10 
0.5 .. iii o.o~· ~~..!!'!!...!!'!~~=__'=~ 
E14 Ei7 Ei9 E20 E2i NO N1 M 
Gestational age 
Kidney 
2.0 ----------'---------
1.5 'r 
:1 _dl.1I 1 
Ei4 E17 E19 E20 E21 NO N1 M 
Lung 
20,---------~---------
" I 
::1 _I 1111 
E14 E17 E19 E20 E21 NO N1 M 
Gestational age 
Fig. 3. Sulfotransferase activities in fetal (E14-21), neonatal (NO~1) and matemal (M) rat liver, kidney, intestine or lung 
homogenate. Reaction conditions: 1 IJM 3,[3'~1251]T2, 0.5 mg (fetal and neonatal tissue homogenate and matemalliver, 
kidney and lung homogenate) or 1 mg (maternal intestine homogenate) protein/ml, 50 IJM PAPS, 30 min incubation. 
Results are the means ± SD from 2 to 3 pools of tissue homogenate, except for E14, E21, NO and N1, which represent 
the means of triplicate determinations on a single pool. 
Figure 3 presents the iodothyronine sulfotransferase activities in liver, kidney, intestine and 
lung. In the liver, sulfotransferase activity is detected from E17 onwards, increasing until E21. 
Maximum sulfation rates are reached after N1, the maternal sulfation rate of 9 pmol/min/mg 
protein being twice as high as the activity expressed around birth. Sulfotransferase activity in 
the kidney steadily increases from E17, and reaches maximum values just after birth. In the 
intestine sulfotransferase activity peaks around E19 (1.2 pmoUmin/mg protein), and has 
become undetectable again at E21, whereas in the lung sulfotransferase activity increases from 
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E17 to reach a maximum sulfation rate of 1.4 pmol/min/mg at E20. The sulfation rate in the lung 
at E20 does not significantly differ from sulfation rates at later development stages. 
Figure 4 shows the HPLC analysis of a representative 03 assay. Radiolabeled 3,3'-T2 was 
formed from [3'_125IJT3 after incubation with brain homogenate from neonatal day 0 (Fig. 4A). In 
the presence of 1 ~M unlabeled T3, conversion of labeled T3 to 3,3' -T2 was completely 
inhibited (Fig. 48). 
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Fig. 4. HPLC analysis of the inner ring deiodination of [3'_'2S ljT3 by neonatal rat brain homogenate in the absence (A) or 
presence (B) of 1 IJM n. Reaction conditions: 1 nM [3,-'25 ljT3, 0.5 mg/ml neonatal (NO) rat brain homogenate, 0.1 IJM 
rT3, 0.1 mM PTU, 50 mM DTT, without (A) or with (8) 1 )JM T3, 30 min incubation. 
High 03 activities were found in the placenta and the developing brain (Fig. 5). In the 
placenta, 03 activity is already maximal at E14, whereas in the brain maximal 03 deiodination 
activity is reached at E18. A maximum deiodination rate of 40 fmol/min/mg protein is detected 
from E18 until after birth, which is -3-fold higher than the 03 activity in the maternal brain. 
Significant 03 activities were also found in fetal and neonatal skin and in intestine at all stages 
tested (Fig. 5). 03 activity in fetal rat liver, kidney and lung was very low (results not shown); no 
03 activity was found in the fetal rat heart. 
Figure 6 depicts sulfotransferase activities in the placenta, developing brain and skin. In the 
placenta no significant sulfotransferase activity was found at any development stage. In the 
brain, basal iodothyronine sulfation rates of -250 fmol/min/mg protein were observed at all fetal 
and neonatal stages; in the maternal brain homogenates sulfation rate is >10-fold higher. In the 
skin, iodothyronine sulfotransferase activity was constant (500 fmol/min/mg protein) at all fetal 
and neonatal stages. No significant iodothyronine sulfation was detected in the fetal, neonatal 
or maternal heart. 
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Fig. 5. 03 activities in fetal (E14-21), neonatal (NO-1) and maternal (M) rat placenta, brain, skin or intestine 
homogenate. Reaction conditions: 1 nM [3'_1251JT3, 0.5 (fetal and neonatal tissue homogenate) or 1 mg (matemal tissue 
homogenate) protein/ml, 0.1 ~M rT3, 0.1 mM PTU, 50 mM OTI, 30 (placenta, brain and Skin) or 60 (intestine) min 
incubation. Results are the means ± SO from 2 to 4 pools of tissue homogenate, except for E14 and E17 in placenta 
and E14 in brain and intestine, which represent the means of triplicate determinations from a single pool. 
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Fig. 6. Sulfotransferase activities in fetal (E14-21), neonatal (NO-1) and maternal (M) rat placenta, brain or skin 
homogenate. Reaction conditions: 1 ~M 3,[3'-1251JT2, 0.5 mg protein/ml, 50 IJM PAPS, 30 min incubation. Results are 
the means ± SO from 2 to 3 pools of tissue homogenate, except for E14, E21, NO and N1, which represent the means 
of triplicate determinations from a single pool. 
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T2S sulfatase activities were also tested in the different tissues. Whereas significant 
activities were found in matemal liver and kidney homogenate, sulfatase activities in fetal and 
neonatal tissue homogenates were negligible under the conditions used. As we have recently 
found that phosphate inhibits iodothyronine sulfatase activity (Chapter 4), our assay conditions 
which included the use of phosphate buffer were not optimal. However, also under optimal 
conditions (using 0.1 M Tris/HCI, pH 7.2) fetal sulfatase activities were low (i.e. <40 fmoVmin/mg 
in fetal liver homogenate vs -200 fmol/min/mg in maternal liver homogenate). 
Discussion 
Thyroid hormone is needed for organ development. Early in pregnancy the fetus is supplied 
by maternal thyroid hormone through transport across the placenta (29,35-38). The fetal thyroid 
starts to produce thyroid hormone after 18-22 weeks of gestation in humans, and at embryonic 
day 17.5-18 in rats (29,35,36). However, the substantial T4 levels in newborns with thyroid 
hormone agenesis or a total thyroid hormone synthesis defect suggest that also after the first 
trimester the maternal supply of thyroid hormone across the placenta remains an important 
source offetal thyroid hormone (39). 
lodothyronine metabolism is key to the regulation of thyroid hormone bioavailability during 
fetal development. The low T3 and high rT3 levels in fetal serum (18,29,35,36) are explained by 
low 01 and high 03 activity in fetal tissues, placenta and uterus (10-16). 02 activity in tissues 
such as brain, placenta and uterus is probably important for local T3 but not for systemic T3 
production (10,12,14,40). Whereas 03 catalyzes the irreversible inactivation of thyroid 
hormone, sulfation may playa role in the reversible thyroid hormone inactivation during fetal 
development. The iodothyronine sulfates that are abundantly present in the human fetal serum 
(18,41-43) are suggested to form a pool of inactive iodothyronines that can be reactivated by 
arylsulfatase-catalyzed desulfation (26-28). The aim of the present stUdy was to delineate the 
role of the different thyroid hormone-metabolizing pathways during fetal development. 
The pattern of 01 and 03 activities in the liver is different from that in humans. Whereas in 
human liver 01 activity is already present in the second trimester (16), we observed that in rat 
liver 01 activity rises just before birth. This is in agreement with previous findings (11,13). We 
confirmed the observation by Huang et al. and Galton et al. that no substantional 03 activity is 
present in the fetal rat liver (11,15), whereas significant hepatic 03 activity is present in the 
human fetus (16). Our findings, therefore, demonstrate that the rat is not the ideal model for the 
ontogeny of 01 and 03 expression in fetal human liver. 
The remarkable pattern of ORO activity in the intestine is consistent with earlier 
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observations (11,15), and seems evolutionary conserved: the ontogenic profile of 01 activity in 
the rat intestine is similar to that of ORO 02 activity in the amphibian Rana calesbeiana. In the 
frog, ORO activity was highest during the thyroid hormone-dependent metamorphosis climax 
(44). In fetal rats there may be a peak in intestinal T3 level (at E21), as at that stage 01 activity 
is maximal whereas iodothyronine sulfotransferase activity has become undetectable. The 
reason for this putative T3 peak at E21 is unclear. Intestinal differentiation is subject to major 
changes at various stages of development, such as villi formation at day 17-19 (45). More so 
than in tissues such as liver and kidney, intestinal protein expression pattems determined by 
SOS-PAGE differ between development stages (data not shown). In the rat, intestinal 
maturation is not achieved until after weaning (45). The high 01 activity Bates et al. found at 10 
days after birth may represent a second peak of 01 activity during intestinal development (14). 
03 expression is similar at all developmental stages. Further studies are needed to determine 
in which parts of the intestine the different enzymes are expressed and to identify the factors 
regulating their expression. 
Although 03 activity was undetectable in the fetal rat heart as a whole, it is still possible 
that 03 activity is present in specific parts of the fetal rat heart. In the fetal human heart, 
Richard et al. found low but significant 03 activity (Richard et aI., unpublished observations). 
Furthermore, it is interesting to note that monocrotaline-induced heart failure due to obstruction 
of lung blood flow in rats leads to reexpression of various fetal genes, among which 03 (46, 
Simonides et aI., unpublished observations). In this monocrotaline model 03 activity was 
highest in the right ventricle. 
We found significant 03 expression in the fetal and neonatal skin. Literature data indicate 
that skin 03 increases after birth, reaching a maximum at two weeks after birth (14). As the rat 
is born immature, and placental and uterine 03 is not available to protect the newborn from 
excessive thyroid hormone, it would be interesting to also study 03 expression in tissues such 
as liver, heart and lung in the first three weeks after birth. Concerning brain 03, Kodding et al. 
found elevated 03 activities in various regions of the rat brain, including cerebellum, basal 
ganglia, brain stem and hypothalamus, immediately after birth (47). In the human brain the 
pattern of deiodinase expression of the fetus differs from that of the adult: while in the adult 
brain 03 activity is present in all brain regions except the cerebellum and pons (48), in the fetal 
cerebellum 03 activity is >2.S-fold higher than in any other region of the brain (49). 
T4 and T3 are present in fetal rat serum before the fetal thyroid starts secretion at E17.S-18 
(36). Whereas serum T4 steadily increases after the onset of fetal thyroid function until birth, i.e. 
from 0.5 to 4.6 ng/ml, serum T3 level shows only a modest increase from 0.05 to 0.09 ng/ml 
(13,36). The low rat fetal hepatic 01 activity and the high 03 activity in rat placenta, uterus and 
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fetal brain may contribute to this low fetal serum T3. It should be noted, however, that although 
the fetal serum T3 level is low compared to the adult, the difference between the fetal and adult 
T3 level may be smaller when free T3 levels are compared. Furthermore, the ratio of T3 vs T4 
may not be lower in the fetus than in the adult. 
Sulfation of iodothyronines has been demonstrated in human liver and kidney as well as 
with recombinant isoenzymes of the human SULT1 family, including SULT1A1, 1A3, 1B1, and 
1 E1 (22-24). In contrast to the activity of human SULT1A1, rat SULT1A1 does not catalyze the 
sulfation of these compounds (21). Both rat SULT1 B1 and 1C1 as well as the above-mentioned 
human enzymes use 3,3'-T2 as the preferred substrate, although human estrogen 
sulfotransferase SUL T1 E1 equally prefers 3,3'-T2 and rT3. By immunoblot analysis, Richard et 
al. have recently shown that SULT1A1 is similarly expressed in human fetal and neonatal liver 
at levels roughly half of that in the adult liver. In contrast, SULT1A3 is present in the fetal liver, 
but becomes undetectable after birth (50). They also studied the ontogeny of iodothyronine 
sulfotransferase activity in the human fetal liver. Comparison of the 3,3'-T2 sulfation pattern with 
the SULT expression pattern led to the conclusion that SULT1A1 is predominantly involved in 
3,3'-T2 sulfation (50). This conclusion is supported by our characterization of iodothyronine 
sulfation by human liver cytosol in comparison with that by the different recombinant SUL T1 
isoenzymes (23). In the rat, Hurd et al. found T3 sulfotransferase activity in various fetal tissues 
(51), but the ontogenic profile of iodothyronine sulfotransferase activity in different tissues has 
not been studied before. The considerable sulfotransferase activities that were found, which 
varied in a tissue-specific and development stage-dependent manner, suggest that sulfation 
plays a role in thyroid hormone inactivation in the developing fetal rat. Rat SULT1B1 and 1C1 
expression are low at birth (52-54). Rat SULT1 B1 expression starts to increase after two 
weeks, a maximum being reached in male as well as in female rats older than two months (52). 
Rat SUL T1 C1 expression remains low in females, but increases dramatically after 30 days in 
male rats (53). By northern blot analysis rat SULT1B1 and 1C1 mRNA were undetectable in 
fetal tissues, whereas the different mRNAs were identified in adult rat liver (results not shown). 
The undetectable rSULT1B1 and 1C1 expression before birth suggests that also other 
isoenzymes are involved in iodothyronine sulfation in the fetal rat. 
In the placenta and developing brain, where insignificant sulfotransferase activities but high 
03 activities were found, irreversible inactivation by 03 seems to be a predominant pathway of 
iodothyronine metabolism. In the liver, sulfotransferase activity is present from E17, when 01 
activity is still absent. As explained above, when 01 activity is low, thyroid hormone sulfates 
may accumulate and form a reservoir of inactive thyroid hormone, from which active hormone 
may be liberated in a tissue-specific and development stage-dependent manner by the action of 
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arylsulfatases. So far. 6 members of the arylsulfatase family have been identified (ARSA-
ARSF) in humans (55). We previously found that the lysosomal arylsulfatases ARSA and ARSB 
do not catalyze iodothyronine sulfate hydrolysis. However, we also demonstrated that the 
microsomal arylsulfatase ARSC, which is abundantly present in the human placenta, catalyzes 
the hydrolysis of iodothyronine sulfates in human placenta microsomes (Chapter 4). Although 
iodothyronine sulfatase activity has been detected in the microsomal fractions of different 
tissues in adult humans and rats (56, Chapter 4), very little is known about the regulation of 
these sulfatase activities. Santini et al. observed some T3S sulfatase activity in fetal liver and 
brain (18), Huang et al. found that T3S sulfatase activity in the liver progressively increases 
after birth until two months of age (57). In the present study we investigated the ontogeny of the 
iodothyronine sulfatase activities in different rat tissues. The negligible sulfatase activities we 
observed in fetal and neonatal rat tissues as well as the low T3S and T 4S levels in fetal rat 
serum at E20 (Schuur et aI., unpublished observations) suggest that sulfation of T3fT4 is not 
important as pathway of reversible thyroid hormone inactivation in the fetal rat. 
In general, we can conclude from this study that, compared to the adult, 01 activity in the 
fetal liver and kidney are low and that 03 activity is high in placenta, pregnant uterus en fetal 
brain. Besides deiodination by 03, sulfation seems important to protect the fetus from excessive 
T3. However, the role of sulfation in the reversible inactivation of thyroid hormone during fetal 
development of rats remains unclear. 
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Characterization of rat iodothyronine sulfotransferases 
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Abstract 
Sulfation appears an important pathway for the reversible inactivation of thyroid hormone 
during fetal development. The rat is an often used animal model to study the regulation of fetal 
thyroid honmone status. The present stUdy was done to determine which sulfotransferases are 
important for iodothyronine sulfation in the rat, using radioactive T4, T3, rT3, and 3,3'-T2 as 
substrates, 3'-phosphoadenosine-5'-phosphosulfate (PAPS) as cofactor, and rat liver, kidney 
and brain cytosol, and recombinant rat SUL T1A 1, 1 B1, 1 C1, 1 E1, 2A 1, 2A2 and 2A3 as 
enzymes. Recombinant rat SUL T1A 1, 1 E1, 2A 1, 2A2 and 2A3 failed to catalyze iodothyronine 
sulfation. For all tissue sulfotransferases and for rSULT1 B1 and rSULT1C1, 3,3'-T2 was by far the 
preferred substrate. Apparent Km values for 3,3'-T2 amounted to 1.9 ~M in male liver, 4.4 ~M in 
female liver, 0.76 ~M in male kidney, 0.23 ~M in male brain, 7.7 ~M for SULT1B1, and 0.62 ~M 
for SUL T1 C1, while apparent Km values for PAPS showed less variation (2.0-6.9 ~M). Sulfation of 
3,3'-T2 was inhibited dose-dependently by other iodothyronines, with similar structure-activity 
relationships for most enzymes except for the sulfotransferase activity in rat brain. The apparent 
Km values of 3,3'-T2 in liver cytosol were in between those detenmined for SULT1B1 and 1C1, 
supporting the importance of these enzymes for the sulfation of iodothyronines in rat liver, with a 
greater contribution of SUL T1 C1 in male than in female rat liver. The results further suggest that 
rSULT1 C1 also contributes to iodothyronine sulfation in rat kidney, whereas other, yet unidentified 
forms appear more important for the sulfation of thyroid honmone in rat brain. 
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Introduction 
Sulfation is a metabolic reaction which facilitates the excretion of endogenous and 
exogenous hydrophobic compounds in bile and urine, by increasing their water solubility (1-3). 
Biliary excretion of iodothyronines is also increased by sulfation. More importantly, however, 
sulfation appears to be a key step in the inactivation of thyroid hormone. The prohormone 
thyroxine (T4) is converted by outer ring deiodination (ORO) to the biologically active 3,3',5-
triiodothyronine (T3), or by inner ring deiodination (IRO) to the inactive 3,3',5'-triiodothyronine 
(rT3) (4). By sulfation, T3 loses its affinity for the thyroid hormone receptors (5). Additionally, 
T3S is subject to accelerated degradation as sulfation facilitates the IRO of T3 by type I 
deiodinase (01) (6,7). Sulfation also facilitates the inactivating IRO of T4 by 01, whereas the 
activating ORO of T4 by 01 is completely blocked by sulfation (6,7). Therefore, an important 
function of sulfation is to facilitate the irreversible degradation of thyroid hormone. Furthermore, 
under conditions in which the deiodinative clearance of sulfates is impaired, sulfation may be 
reversed by sulfatases. As T3S and T4S levels in the human fetal circulation are high (8-10), it 
has been speculated that sulfation is a mechanism to protect the fetus from excessive T3 and 
that sulfation/desulfation plays an important role in the regulation of thyroid hormone bioactivity 
during fetal development (11-13). The exact mechanism for the increased iodothyronine sulfate 
levels in the fetal circulation is unclear but the reversible nature of this inactivation step 
contrasts with the irreversible nature of 03-catalyzed IRO, which is also extensive during fetal 
development (14-18). 
Sulfation is catalyzed by cytosolic sulfotransferases present in a wide range of tissues. The 
sulfotransferases transfer the sulfuryl group of 3'-phosphoadenosine-5'-phosphosulfate (PAPS) 
to usually OH groups of their substrates (3,19). All cytosolic sulfotransferases are members of a 
single gene superfamily termed SULT. A systematic nomenclature is in preparation, but not yet 
finalized. It is already widely used for human SULTs, but not for rat SULTs. Table 1 indicates 
the designations of the rat SULTs used in the present study together with synonymous names 
that have been used elsewhere. On the basis of amino acid sequence, two families of 
sulfotransferases have been identified in humans, the SUL T1 family, which primarily represent 
phenol sulfotransferases, including hSULT1A1, 1A2, 1A3, 1B1, 1C2, 1C4 and 1E1 (20-33) and 
the SUL T2 family, which usually prefer alcoholic substrates (including hydroxysteroids) (3,34-
37). In the rat, the phenol sulfotransferases rSULT1A1, 1B1, 1C1, 1C2, 1C3, 101, 1E1 and 1E2 
have been cloned (1,38-44), and the hydroxysteroid sulfotransferases rSULT2A1, 2A2 and 2A3 
(45-47). For several human and rat phenol sulfotransferases allelic variants have been 
identified (2,3,48,49). Another important observation is that the sulfotransferases may not only 
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exist as homo- but also as heterodimers (50). 
Alignment of the amino acid sequences of SULT enzymes revealed at least two areas of 
highly conserved amino acids (1,49,51,52). Recently the crystal structures of mouse SUL T1 E1, 
human SULT1A3 and human SULT2A1 have been elucidated (53-56). Based on these crystal 
structures, and on stte-directed mutagenesis experiments, the N-terminal motif TYPKSGT and 
the conserved amino acids RKGXXGXXK near the C-terminal end are suggested to be involved 
in PAPS binding (57-60). 
Sulfation of iodothyronines is catalyzed by phenol sulfotransferases. Recently, we identified 
hSULT1A1, 1A3, 1B1 and 1E1 as human iodothyronine sulfotransferases (61,62). Because the 
rat is the most frequently used animal model for in vivo studies of iodothyronine metabolism, we 
set out to characterize the sulfation of different iodothyronines by rat liver, kidney and brain 
cytosol, and by recombinant preparations of rSULT1A1, 1 B1, 1C1, 1E1, 2A1, 2A2 and 2A3, to 
identify which sulfotransferases are important for iodothyronine sulfation in the rat. 
Table 1. Designation of rat sulfotransferases 
Designation used in Designation used in other GenBank Accession Number of 
this publication publications Number (Protein) amino acids 
SULT1A1 ST1A 1, P-PST IV, AST-IV CAA37065 291 
SULT1B1 ST1B1 AAB31318 299 
SULT1C1 ST1C1, HAST-I A49098 304 
SULT1C1var' not published 304 
SULT1C2' SULT1C2 CAB41460 296 
SULT1C3 ' SULT1C2A CAB41461 296 
SULT1D1 ' not published AAC99890 308 
SULT1E1 ST1E2, rEST-1, rEST-3 AAA41128 295 
SULT1E2 ' ST1 E6, rEST-2, rEST-6 AAB33442 295 
SULT2A1 ST2A 1, ST-20/21 A34822 284 
SULT2A2 ST2A2, ST -40/41, STa BAA03632 284 
SULT2A3 ST2A5, ST-60 BAA03634 284 
SULT4A1' rBR-STL AAF61198 284 
1 Not investigated in the present study. 
, The cDNA-deduced amino acid sequence differs from A49098 in three residues (S2A, T60A, S96P). 
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Materials and Methods 
Materials 
Male and female Wistar rat liver cytosols and male kidney and brain cytosols were obtained 
as previously described (63). Rat SULT1 C1 cDNA (40) was kindly provided by Dr. Y. Yamazoe, 
and expressed in V79 cells as previously described (64). rSUL T1A 1 cDNA (65) was kindly 
provided by Dr. C.N. Falany, and expressed in Salmonella typhimurium (48). rSULTZA1 (ST-
20), rSULT2A2 (ST-41) and rSULTZA3 (ST-60) were cloned and expressed in S. typhimurium, 
and rSULTZA1 was also expressed in V79 cells (64,66). rSULT1B1, a rSULT1C1 variant 
containing amino acid substitutions SZA, T60A and S96P, rSULT1 E1 and rSULTZA3 were 
cloned by RT-PCR and expressed in Salmonella typhimurium (48). V79 and bacterial cell 
cytosols were prepared as previously described (48). 
[3',5'-125IJT4 and [3'_1251]T3 were obtained from Amersham (Amersham, UK); T4, rT3, T3, 
3,5-, 3,3'- and 3',5'-diiodothyronine (T2), 3- and 3'-iodothyronine (T1) and thyronine (TO) were 
purchased from Henning Berlin GmbH (Berlin, Germany); 3'-phosphoadenosine-5'-
phosphosulfate (PAPS) was obtained from Sigma (SI. Louis, MO, USA); and Sephadex LH-20 
were obtained from Phanmacia (Woerden, The Netherlands). 3,[3'-125IJT2 and [3',5,-1251]rT3 were 
prepared by radioiodination of 3-T1 and 3,3'-T2, respectively, as previously described (67). 
Sulfotransferase assays 
lodothyronine sulfotransferase activities were analyzed by incubation of usually 0.1 or 1 ~M 
T4, T3, rT3 or 3,3'-T2 and 105 cpm of the 1251-labeled compound for 30 min at 37 C with the 
indicated amounts of liver, kidney or brain cytosol or recombinant sulfotransferase in the 
presence or absence (blank) of 50 ~M PAPS in 0.2 ml 0.1 M phosphate (pH 7.2), 2 mM EDTA. 
The reactions were stopped by addition of 0.8 ml 0.1 M HC!. The mixtures were analyzed for 
iodothyronine sulfate fonmation by chromatography on Sephadex LH-20 minicolumns as 
previously described (68). Enzymatic sulfation was corrected for background radioactivity 
detected in the blanks. 
Results 
Figure 1 shows the sulfation of 0.1 ~M T4, T3, rT3 and 3,3'-T2 by male and female rat liver 
cytosol, male rat kidney and brain cytosol, rSULT1B1 and 1C1 in the presence of 50 ~M PAPS. 
All enzyme preparations show a substrate preference for 3,3'-T2. Rates of 3,3'-T2 sulfation are 
>50-fold higher than those of T3 and rT3 sulfation; T4 is the poorest substrate for all enzyme 
preparations. rSULT1E1, ZA1, 2A2 and ZA3 did not catalyze iodothyronine sulfation (data not 
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Fig. 1. Sulfation of iodothyronines by male and female rat liver cytosol, male rat kidney and 
brain cytosol, rSULT1B1 and rSULT1C1. Reaction conditions were 0.1 J..LM 1251-labeled T4, 
T3, rT3 or 3,3'-T2, 0.1 mg protein/ml, 50 fJ.M PAPS, and 30 min incubation. Results are the 
means of triplicate determinations from a representative experiment 
Figure 2 shows the sultation of 3,3'-T2 by female rat liver, male rat liver, male kidney or brain 
cytosol as a function of the substrate concentration. Maximum sultation rates were obtained at 
-10 ~M 3,3'-T2 in male and female rat liver cytosol, at -2 ~M in male rat kidney cytosol and at 
-1 ~M in male rat brain cytosol. Rat brain cytosol showed clear substrate inhibition for 3,3'-T2 at 
concentrations above 1 ~M. K", and V",", values for the different tissue cytosols were calculated 
from the linear double-reciprocal plots of sulfation rate versus 3,3'-T2 concentration and are 
presented in Table 2. Vm", values decreased in the order male liver> female liver> brain> kidney. 
Km values for T3 sultation by the tissue cytosols, which were determined under the same 
conditions, were >50-fold higher than for the sulfation of 3,3'-T2 (data not shown). 
Figure 3 depicts the sulfation of 3,3'-T2 by rSULT1B1 or rSULT1C1 as a function of the 
substrate concentration. For rSULT1C1 maximum sultation rates were obtained at lower 3,3'-T2 
concentrations than for rSULT1 B1. The decrease in sulfation rate for rSUL T1 C1 at concentrations 
above 1 ~M indicated substrate inhibition. The apparent Km values calculated from the 
Lineweaver-Burk plots amounted to 7.7 ~M for rSULT1B1 and 0.62 ~M for rSULT1C1 (Table 2). 
As crude cytosols of rSULT1 B1-expressing Salmonella cells and rSULT1C1-expressing V79 cells 
were tested, the V",", values for the different enzymes are not representative for their ~t values. 
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Table 2. Kinetic parameters of rat iodothyronine sulfotransferases 
Enzyme source K" V mru; 
(~M) (pmoUminlmg protein) 
SUbstrate: 3,3'-T2 
Male Liver cytosol 1.85 ± 0.45 2042 ± 400 
Female Liver cytosol 4.35 ± 0.59 1516 ± 214 
Kidney cytosol 0.76 ± 0.05 15.6 ± 1.9 
Brain cytosol 0.23 ± 0.01 32.0 ± 0.3 
rSUL T1 B1 (Salmonella) 7.74 ± 1.46 6029 ± 1146 
rSULT1C1 (V79 cells) 0.62 ± 0.16 251 ± 93 
Substrate: T3 
rSULT1B1 (Salmonella) 142 ± 9 1156 ± 133 
rSULT1C1 (V79 cells) 100 ± 6 50.8 ± 6.3 
Data are presented as the means ± SO of 2-6 experiments. Incubations were done with 50 IJM PAPS. 
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Fig. 2, Effects of substrate concentration on the sulfation of 3,3'~T2 by female or male rat liver cytosol, 
male kidney or brain cytosol. The insets show the double reciprocal plot Reaction conditions were 0.1-
25 J.lM 3,[3'_1251]T2, 25 (male liver), 50 (female liver and male brain) or 250 (male kidney) J.l9 protein/ml, 
50 J.lM PAPS, and 30 min incubation. Results are the means of triplicate determinations from a 
representative experiment 
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The kinetic parameters for T3 sulfation by the different isoenzymes are also presented in Table 2. 
Compared to 3,3'-T2, apparent Km values for T3 were 20 to 150-fold higher. The apparent Km 
value determined for 3,3'-T2 sulfation by the rSULT1C1 variant (5.8 ~M) was 10-fold higher than 
for wild-type rSULT1C1. 
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Fig. 3. Effects of substrate concentration on the sulfation of 3,3'MT2 by rSULT1 B1 and rSULT1C1. The insets show the 
double reciprocal plot Reaction conditions were 0.1-30 )1M 3,[3'_1251]T2, 10 (rSULT1B1) or 25 (rSULT1C1) )19 
protein/ml, 50 )1M PAPS, and 30 min incubation. Results are the means of triplicate determinations from a 
representative experiment 
Figure 4 depicts the sulfation of 1 ~M 3,3'-T2 by male rat liver cytosol at different PAPS 
concentrations (1-100 ~M). Maximum sulfation rates were reached at PAPS concentrations 
~30 ~M. Its apparent Km value, calculated from the Lineweaver-Burk plot, was 4.7 ~M. The Km 
values for the other enzyme preparations were also in the low ~M range, i.e. 3.8 ~M for female rat 
liver, 2.2 ~M for male rat kidney and 3.5 ~M for brain cytosol, 2.0 ~M for rSULT1 B1 and 6.9 ~M 
for rSUL T1 C1. 
Figure 5 shows the effects of increasing concentrations (1-100 ~M) of unlabeled 
iodothyronines on the sulfation of 3,[3'-12'I]T2 by male rat liver cytosol. 3,5-T2 had no effect; all 
other iodothyronines inhibited the sulfation of labeled 3,3'-T2 dose-dependently, in the order 
3,3'-T2 - 3'-T1 > 3',5'-T2 > rT3 > T4 > TO - 3-T1 - T3. 
Figure 6 compares the effects of 1 0 ~M unlabeled iodothyronines on the sulfation of 1 ~M 
3,[3,-12'I]T2 by male and female liver and male kidney and brain cytosol, rSULT1B1 and 1C1. 
3,3'-T2 sulfation by rSULT1C1 was affected most by the different iodothyronines. Sulfation of 
3,3'-T2 by female rat liver cytosol was inhibited less potenW by the different analogs than 3,3'-T2 
sulfation by male rat liver. The structure activity relationships for inhibition of T2 sulfation by 
analogs were similar for female and male liver, kidney, rSULT1B1 and 1C1. In general, 
iodothyronines without iodine substituent in the outer ring (TO, 3-T1, 3,5-T2) and those with two 
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Fig. 4. Effect of PAPS concentration on the sulfation of 3,3'-T2 by male rat liver cytosol. 
The inset shows the double reciprocal plot Reaction conditions were 1 J..lM 3,[3'_'2SI]_T2, 
1-100 !-1M PAPS, 20 jJg protein/ml, and 30 min incubation. Results are the means of 
triplicate determinations from a representative experiment 
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Fig. 5. Effects of 1-100 !JM unlabeled iodothyronines on the sulfation of 3,[3'_'2SIJT2 by 
male rat liver cytosol. Reaction conditions were 105 cpm 3,I3'-'251]T2, 251J9 protein/ml, 50 
IJM PAPS, and 30 min incubation. Results are the means of triplicate determinations from 
a representative experiment 
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Fig. 6, Effects of 10 IJM unlabeled iodothyronines on the sulfation of 1 !-1M 3,[3'_1251]T2 by male and 
female rat liver cytosol, mare rat kidney and brain cytosol, and by rSULT1B1 and rSULT1C1. Data 
represent the surfation of 3,[3'_125[]T2 in the presence of unlabeled iodothyronines as percentage of 
the control (without addition of unlabeled iodothyron·lnes). Results are the means of 2-3 experiments. 
iodines in the inner ring (3,5-T2, T3, T4) showed little or no inhibition. In other words, 
iodothyronines that showed significant inhibition had 0 or 1 iodine substituent in the inner ring and 
1 or 2 iodines in the outer ring. 
The inhibition profiles for rat liver and kidney were significantly correlated with those for 
SULT181 and 1C1, with coefficients varying between 0.869 and 0.990. However, in contrast to all 
other enzyme preparations, 3,3'-T2 sulfation by rat brain cytosol was poorly inhibited by 3'-T1 and 
3' ,5' -T2, and the inhibition profile for rat brain cytosol also showed weaker correlations with those 
for rSULT1 81 (r = 0.814) and 1C1 (r = 0.633). 
Discussion 
In previous studies human SULT1A1, 1A2, 1A3, 181, 1C1 and 1E1 have been identITied as 
important enzymes for iodothyronine sulfation in humans (61,62,69-72). Rat SULT1A1, 181, 1C1 
and 1E1 show 79,74,63 and 70%, respectively, amino acid sequence identity with their human 
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homologs; and about 50% identity among themselves. Sulfation ofT3 by rat SULT181 and 1C1 
has been reported previously (39,73,74). In this study we compared kinetic parameters and 
substrate specificities for the different rat enzymes with these characteristics for male and female 
rat liver cytosol and male rat kidney and brain cytosol, in an attempt to determine which enzyme 
forms are involved in iodothyronine sulfation in the different tissues. We used mammalian V79 
cells and bacterial S. typhimurium cells as expression systems for the different SUL T enzymes. 
Previous studies showed that the different systems give similar results for the various human 
SULT enzymes (61). 
lodothyronine sulfotransferase activities in rat liver and kidney and of rat SULT181 and 1C1 
showed very similar substrate specificities. The higher maximum sulfation rates observed in male 
than in female rat liver cytosol are in agreement with earlier reports on the sex-dependence of T3 
sulfation in rats, which is explained by the male-dominant expression of rSULT1C1 (75-79). 
rSULT1C1 is predominantly expressed in male liver, kidney and spleen, whereas rSULT1B1 
expression in liver, kidney and intestine is equal in male and female rats (80-82). The apparent Km 
of 3,3'-T2 in liver cytosol is in between the Km values for SUL T181 and 1 C1; in male liver closer to 
that for 1 C1 and in female liver closer to that for 1 B1, supporting a greater contribution of 1 C1 in 
male versus female rat liver. The apparent Km of 3,3'-T2 in kidney is similar to the Km for 
SULT1C1, suggesting that 1C1 is a more important enzyme than 181 in rat kidney. It should 
however be noted that besides 1B1 and 1C1, 1C2, 1C3 and 1D1 may also contribute to 
iodothyronine sulfation in the different tissues. Furthermore, rat phenol sulfotransferases have 
been demonstrated to exist not only as homodimers but also as heterodimers (50). Thus, besides 
181/1B1 and 1C1/1C1 homodimers, tissues such as liver may contain various other 
heterodimers. Although 1A 1 homodimer does not possess sulfotransferase activity towards 
iodothyronines, it is not excluded that 1A1/1B1 and 1A1/1C1 heterodimers catalyze iodothyronine 
sulfation. It is clear that substrate specificities and apparent Km values determined in tissue 
represent average values for mixtures of homo- and heterodimeric iodothyronine 
sulfotransferases. Substrate preference and Km value of 3;3'-T2 in rat brain are different from 181 
and 1C1. Therefore, other enzyme form(s) seem to be involved in iodothyronine sulfation in rat 
brain. A possible candidate is the recently cloned rat brain sulfotransferase-like protein rSUL T4A 1 
(83). Compared with liver and kidney, the inhibition profile for rat brain cytosol showed weaker 
correlations with those for SULT181 and 1C1, also indicating the involvement of different 
enzymes. However, assessment of inhibition profiles may be biased if inhibitors are extensively 
sulfated themselves by the enzymes under study or other sulfotransferases, resulting in a 
decrease in their inhibitory potency. For instance, the weaker inhibition of 3'-T1 in rat brain may 
be explained by its sulfation by different enzymes present in brain. 
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Concerning the rSUL T1 C1 variant, mutational analysis should reveal which amino acid 
subst~ution (S2A, T60A or S96P) contributes most to the 10-fold lower affinity of the rSUL T1 C1 
variant enzyme compared to the wild-type rSULT1C1. Previous studies showed that hSULT1A1 
efficiently sultates iodothyronines, whereas the rat SULT1A1 homolog does not catalyze 
iodothyronine sulfation (74). The estrogen sulfotransferase hSULT1E1 also efficiently catalyzes 
iodothyronine sulfation (62). However, since estrone and estradiol are inefficient substrates for the 
rat homolog rSULT1 E1 (43,44), ~ is not surprising that no catalytic activity toward iodothyronines 
was detected for this enzyme. Still, iodothyronine sulfation by rSUL T1 E2 is not excluded. In rats 
as well as in humans (Kester et aI., unpublished observations) hydroxysteroid sulfotransferases 
do not appear to contribute importantly to iodothyronine sultation. 
In conclusion, rSUL T1 B1 and 1 C1 appear to be important enzyme forms for sultation of 
iodothyronines in rat liver and kidney, with proportionally greater contributions in kidney than in 
liver, and in male than in female liver. Other, still unidentified enzymes appear to be responsible 
for iodothyronine sultation in rat brain. Further studies are needed to determine the role of these 
sulfotransferases in the regulation of (fetal) thyroid hormone status. 
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Characterization of iodothyronine sulfatase activities in 
human and rat liver and placenta 
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Abstract 
In conditions associated with high serum iodothyronine sulfate concentrations, e.g. during 
fetal development, desulfation of these conjugates may be important in the regulation of thyroid 
hormone homeostasis. However, little is known about which sulfatases are involved in this 
process. Therefore, we investigated the hydrolysis of iodothyronine sulfates by homogenates of 
V79 cells expressing the human arylsulfatases ARSA, ARSB and steroid sulfatase ARSC, as well 
as tissue fractions of human and rat liver and placenta. We found that only the microsomal 
fraction from liver and placenta hydrolyzed iodothyronine sulfates. Among the recombinant 
enzymes only the endoplasmic reticulum-associated ARSC showed activity towards iodothyronine 
sulfate; the soluble lysosomal ARSA and ARSB were inactive. Recombinant ARSC as well as 
human placenta microsomes hydrolyzed iodothyronine sulfates with a substrate preference for 
3,3'-diiodothyronine sulfate (3,3'-T2S) - T3S » rT3S - T4S, whereas human and rat liver 
microsomes showed a preference for 3,3'-T2S > T3S » rT3S - T4S. ARSC and the tissue 
microsomal sulfatases were all characterized by high apparent K" values (>50 ~M) for 3,3'-T2S 
and T3S. lodothyronine sulfatase activity determined using 3,3'-T2S as a substrate was much 
higher in human liver microsomes than in human placenta microsomes, although ARSC is 
expressed at higher levels in human placenta than in human liver. The ratio of E1 S vs T2S 
hydrolysis in human liver microsomes (-0.2) differed largely from that in ARSC homogenate (80) 
and human placenta microsomes (150). These results suggest that ARSC accounts for the 
relatively low iodothyronine sulfatase activity of human placenta, and that additional 
arylsulfatase(s) contribute to the high iodothyronine sulfatase activity in human liver. Further 
research is needed to identify these iodothyronine sulfatases, and to study the physiological 
importance of the reversible sulfation of iodothyronines in thyroid hormone metabolism. 
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Introduction 
Sulfation is an important metabolic pathway which facilitates the inactivation and elimination 
of lipophilic exogenous and endogenous compounds, including thyroid hormones, by increasing 
their water solubility (1-3). A more important purpose for the sulfation of thyroid hormones is to 
facilitate their degradation by the type I iodothyronine deiodinase (01) (4-7). 01 catalyzes the 
outer ring deiodination (ORO; activation) of T4 to T3 as well as the inner ring deiodination (lRO; 
inactivation) of T4 to rT3 and of T3 to 3,3'-diiodothyronine (TZ) (5). Since IRO of sulfated T4 and 
T3 by 01 is accelerated 40 to ZOO-fold, whereas ORO of T4 sulfate (T4S) is completely blocked 
(4-7), sulfation has an important role in the irreversible inactivation of thyroid hormone by 01. 
However, when 01 activity is low or clearance of iodothyronine sulfates is impaired otherwise, 
inactivation of thyroid hormone by sulfation may be reversible due to the expression of 
arylsulfatases in different tissues (8-10), or the presence of bacterial sulfatases in the intestine 
(11). Strongly elevated iodothyronine sulfate concentrations have been found in fetal and 
neonatal serum, and amniotic fluid in humans and sheep (1Z-16). Thyroid hormone is essential 
for the normal fetal development of several organs, such as the brain (17-Z0). Therefore, it has 
been speculated that these iodothyronine sulfates, in particular T3S, function as a pool of inactive 
thyroid hormone, from which the active hormone is released in a tissue-specific and development 
stage-dependent manner (7,9, 1Z, 14,Z1). lodothyronine sulfatase activities are present in human 
fetal liver and lung, and become undetectable in lung after birth (ZZ). In rats, which are bom 
immature compared with humans, hepatiC T3S sulfatase activity progressively increases after 
birth until two months of age (Z3). 
Hydrolysis of sulfate conjugates is an enzymatic process, and multiple arylsuWatases have 
now been identified (Z4). Arylsulfatase A (ARSA) and arylsulfatase B (ARSB) are soluble 
enzymes, localized in Iysosomes. So far, sulfated glycolipids have been identified as endogenous 
substrates for ARSA, while ARSB has a known substrate specificity for dermatan suWate and 
chondroitin sulfate (Z5). These sulfatases are widely distributed, although in the pig ARSA activity 
is ZO to 60 times higher in the thyroid than in other tissues (Z6). Arylsulfatase C (ARSC), also 
termed steroid sulfatase, is located in the endoplasmic reticulum, and hydrolyzes steroid sulfates 
such as dehydroepiandrosterone sulfate (OHEAS), estrone sulfate (E1S) and cholesterol sulfate 
(Z5). We have recently demonstrated that iodothyronines are good substrates for estrogen 
sulfotransferase (Z7). Therefore, it seems logical to assume that iodothyronine sulfates are also 
good substrates for the steroid sulfatase ARSC. This isoenzyme is expressed in many tissues, 
among which placenta and liver (Z8-31). In the placenta, ARSC plays a major role in estrogen 
biosynthesis from OHEAS, which is mainly produced in the fetal adrenal gland and converted to 
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16-a-hydroxy-DHEAS by the fetal liver (32). Recently, a group of novel ARS genes was identified, 
clustered on Xp22.3 (33-35), near the ARSC gene. ARSDa and ~ and ARSF have been localized 
in the endoplasmic reticulum, whereas ARSE is located in the Golgi apparatus (35,36). The 
endogenous substrates for these arylsulfatases remain to be identified, although neither ARSE 
nor ARSF hydrolyzes steroid sulfates (33-36). ARSD does not appear to act as a conventional 
arylsulfatase since no such activity has yet been determined for the recombinant protein (34,35). 
They also differ from ARSC in that they are thermolabile. 
Earlier studies demonstrated T3S sulfatase activities in human and rat liver microsomes, and 
in rat hepatocytes (9,21). However, not much is known about which sulfatases are responsible for 
the hydrolysis of sulfated iodothyronines. Therefore, we studied the arylsulfatases ARSA, ARSB 
and ARSC, and the sulfatase activities in human and rat liver and placenta, USing iodothyronine 
sulfates as substrates, to determine if these arylsulfatases are involved in hydrolysis of thyroid 
hormone sulfates in tissues. 
Materials and Methods 
Materials 
Cytosolic and microsomal fractions of male Wistar rat and human liver were obtained as 
previously described (4,37). Normal human placental tissue was obtained at spontaneous, full-
term delivery, and rat placenta after cesarean section at gestational age E20. Approval was 
obtained from institutional committees. Cytosol and microsomes were prepared as described for 
human liver (4). Human ARSA, ARSB and ARSC cDNA clones were kindly provided by Prof. K. 
von Figura (University of G6ttingen, G6ttingen, Germany) and expressed in V79 Chinese hamster 
lung fibroblast cells as previously described (25). 
T4, rT3, 3,3'-T2 and 3-iodothyronine (3-T1) were obtained from Henning (Berlin, Germany); 
T3, estrone sulfate (E1S), 6-n-propyl-2-thiouracil (PTU) and bis-tris propane (BTP) from Sigma 
(St. Louis, MO); [3',5'-"'ITf4, [3'-ml]T3 and fH]E1S were obtained from Amersham (Amersham, 
UK); [3',5'-"'I]rT3 and 3,[3'-"'I]T2 were prepared by radioiodination of 3,3'-T2 and 3-T1, 
respectively (5). "'I-labeled and unlabeled T4S, rT3S, T3S and 3,3'-T2S were prepared by 
reaction of labeled and unlabeled T4, rT3, T3 and 3,3'-T2 with chlorosulfonic acid in 
dimethylformamide. They were purified by LH-20 chromatography (38). 
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Sulfatase assay 
lodothyronine sulfatase activity was assayed by incubation of usually 0.1 I'M unlabeled and 
100,000 cpm 12'I-labeled T4S, rT3S, T3S or 3,3'-T2S, and usually 0.1 or 1 mM PTU (to block 01 
activity), for 60 min at usually 37 C with the indicated amounts of tissue cytosol or microsomes or 
V79 cell homogenate in 0.2 ml buffer. Optimal assay conditions for the different sulfatases were 
detenmined by testing different buffers (0.1 M sodium acetate, sodium citrate, TrislHCI, sodium 
phosphate or BTP/HCI), pH values and temperatures. The reactions were started by addition of 
enzyme in ice-cold buffer, and stopped by addition of 0.8 ml 0.1 M HC!. The mixtures were 
analyzed for T4, rT3, T3 or 3,3'-T2 fonmation by chromatography on Sephadex LH-20 
minicolumns as previously described (39). Oesulfation in complete reaction mixtures was 
corrected for background radioactivity detected in the corresponding Sephadex LH-20 fractions of 
control incubations without enzyme. 
Estrogen sulfatase activity was analyzed by incubation of 0.1 ~M fH]E1S for 0 (blank) or 
30 min at 37 C with the indicated amounts of tissue microsomes or V79 cell homogenate in 0.1 ml 
0.1 [vl Tris/HCI (pH 7.2). The reactions were stopped by the addition of 0.4 ml 0.1 M Tris/HCI 
(pH 8.8), and the mixtures were extracted with 2.5 ml chlorofonm. Sulfate hydrolysis was 
quantified by counting 0.25 ml of the aqueous phase. 
Results 
Figure 1 shows the pH profiles of the desulfation of 0.1 I'M 3,3'-T2S by rat liver and human 
liver microsomes and recombinant human ARSC which were obtained using acetate and 
BTP/HCI buffers. Rat liver microsomal sulfatase showed an optimum at pH 6.0-6.5, human liver 
microsomal sulfatase at pH 6.0-7.5, and ARSC around pH 7.0. At neutral pH, the different 
enzymes showed similar sulfatase activities in BTP/HCI and Tris/HCI buffers but much lower 
activities in phosphate buffer (Fig. 2A). At acidic pH values, incubations of the different enzymes, 
in particular human liver, in citrate buffer strongly inhibited their 3,3'-T2S sulfatase activities 
compared with incubations in acetate buffer (Fig. 2B). Similar results were obtained in buffers with 
or without 2 mM EOTA (not shown). 
Figure 3 demonstrates the effects of temperature on the desulfation of 0.1 I'M 3,3'-T2S by 
human and rat liver microsomes. The optimal temperature for human liver microsomes is 50 C 
and for rat liver microsomes even 70 C or higher. 
Figure 4 presents the desulfation of 0.1 I'M T4S, T3S, rT3S and 3,3'-T2S by recombinant 
human ARSC and human and rat placenta and liver microsomes at pH 7.2. ARSC showed similar 
activities towards 3,3'-T2S and T3S, whereas both rT3S and T4S were poor substrates for this 
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Fig. 1. Effects of pH on 3,3'-T2S desuJfation by rat liver or human liver microsomes or ARSC. Reaction 
conditions were: 0.1 ).lM 125J_labeJed 3,3'-T2S, 0.25 (rat liver, ARSC) or 0.05 (human liver) mg protein/ml, 
0.1 mM PTU, and 60 min incubation in 0.1 M sodium acetate or BTP/HCL Results are the means of 
triplicate determinations from a representative experiment 
enzyme. The substrate specificity of human placenta microsomes was similar to that of ARSC. 
Very high desulfation rates were observed in human liver microsomes, with a strong substrate 
preference for 3,3'-T2S which was hydrolyzed -4 times faster than T3S (i.e. desulfation rates of 
-7.2 and 1.8 pmoVmin/mg) and >10 times faster than the relatively poor substrates rTIS and 
T4S. Rat liver microsomes also showed a substrate preference for 3,3'-T2S which was desulfated 
2 times more rapidly than T3S; in rat placenta microsomes low desulfation rates (i.e. <0.1 
pmol/min/mg) were observed with all iodothyronine sulfates. We also tested steroid sulfatase 
activities of ARSC and of human placenta and liver microsomes. Table 1 compares E1S and T2S 
sulfatase activities of ARSC and the different human tissue microsomes. The low ratio of E1S vs 
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Fig. 2. Effects of buffer on 3,3'-T2S desulfation by rat liver and human liver microsomes, and ARSC at pH 7.2 (A) or 5.5 
(B). Reaction conditions were: 0.1 fJ.M 1251-labeled 3,3'-T2S, 0.25 (rat liver, ARSC) or 0.05 (human liver) mg protein/ml, 
0.1 mM PTU, and 60 min incubation in 0.1 M sodium phosphate (pH 7.2), 0,1 M TrislHCI (pH 7.2), 0.1 M sodium 
acetate (pH 5.5) or 0.1 M sodium citrate (pH 5.5). Results are the means of triplicate determinations from a 
representative experiment 
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Fig. 3. Effects of temperature On desulfation of 3,3'-T2S by human or rat liver microsomes. 
Reaction conditions were: 0.1 J.lM 3,[3,_125IjT2S, 0.25 (rat liver) or 0.025 (human liver) 
mg protein/ml, 1 mM PTU, and 60 min incubation in 0,1 M TrislHCI (pH 7,2) at 20-70 C. Results 
are the means of two closely agreeing experiments. 
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Fig. 4. Desuffation of iodothyronine sulfates by ARSC, human or rat liver microsomes, or human 
or rat placenta microsomes. Reaction conditions were: 0.1 IlM 1251-labeled T4S, T3S, rT3S or 
3,3'-T2S, 0.25 (ARSC and rat liver), 0.05 (human liver) or 0.5 (human and rat placenta) mg 
protein/ml, 0.1 mM PTU, and 60 min incubation in 0.1 M Tris/Hel (pH 7.2). Results are the 
means of triplicate determinations from a representative experiment 
Table 1. Hydrolysis of E1S and 3,3'-T2S by human ARSC, liver and placenta 
Enzyme source 
ARSC-V79 homogenate 
human liver microsomes 
human placenta microsomes 
Hydrolysis 
E1S 3,3'-T2S E1S/3,3'-T2S 
-----(pmol/min/mg) 
100 
1.6 
52 
1.3 
7.2 
0.34 
81 
0.21 
150 
Reaction conditions were: 0.1 11M 3,[3,_125IjT2S, 0.1 mM PTU and 0.25 (ARSC), 0.05 (liver) or 
0.5 (placenta) mg protein/ml, or 0.1 ~M fH]E1S and 0.005 (ARSC), 0.5 (liver) or 0.01 (placenta) 
mg protein/ml, and 60 min incubation in 0.1 M TrislHCI (pH 7.2). Results are the means of 
triplicate determinations from a representative experiment 
T2S hydrolysis in liver microsomes differs largely from the high preference for E1S vs T2S 
hydrolysis by ARSC and human placenta microsomes. Tested at their optimum pH 5.5, the 
soluble ARSA and ARSB as well as rat and human liver cytosols, showed very low activity 
towards all iodothyronine sulfates (results not shown). 
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Fig. 5. Effects of substrate concentration on the desulfation of 3,3'~T2S by ARSC, human placenta 
or human liver microsomes. Reaction conditions were: 1-50 )..lM 3,[3')251]T2S, 0.05 (liver), 0.25 
(ARSC) or 0.5 (placenta) mg protein/ml, 1 mM PTU. and 60 min incubation in 0.1 M Tris/HCI (pH 
7.2). Results are the means of triplicate determinations from a representative experiment. 
Figure 5 shows the desullation 01 3,3'-T2S by ARSC, human liver and human placenta 
microsomes as a lunction 01 the substrate concentration. As no saturation was reached even at 
the highest concentration 01 50 flM, K", and V m~ values could not be calculated. Similar results 
were obtained when T3S was used as substrate. Apparently, all these sulfatases have low affinity 
for iodothyronine sulfates, with K", values higher than 25 flM. 
Discussion 
Normally, serum T4S and T3S levels are low (12,40,41). This is explained by the very rapid 
deiodination of these conjugates, since sullation strongly induces the 01-catalyzed IRO 01 both T4 
and T3 (7). However, under certain (patho)physiological conditions, e.g. during fetal development 
and non-thyroidal illness, possibly due to diminished 01 activity, plasma concentrations of 
iodothyronine sulfates are increased (12,13,16,41). T3S is considered to be biologically inert, as it 
has lost its affinity for the T3 receptors (42). It could however serve as a reservoir, lrom which 
active thyroid hormone is regenerated by tissue sulfatases or bacterial sullatases in the intestine 
(8-11). 
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Recently, much research has been done to develop inhibrtors of steroid sulfatase (ARSC) 
because of their potential for the treatment of estrogen-dependent breast cancers (43-54). These 
studies have revealed some important structure-activity relations for compounds binding to the 
active site of ARSC. Furthermore, the crystal structures of arylsulfatases A and B have recently 
been elucidated (55,56). Although the overall amino acid sequence homology is only about 20-
30% between different arylsulfatases, the protein structures of all sulfatases share some 
important features. The active site of eukaryotic sulfatases contains a metal ion, probably Mg2• 
(56,57), and a formylglycine, generated by post-translational modification of a cysteine residue 
(58-61). Residues interacting with the Mg" and the formylglycine are conserved among the 
members of the sulfatase family. Uhlhorn-Dierks et al. (57) proposed a catalytic mechanism for 
the hydrolysis of sulfates by sulfatases based on their structure and mutational analyses. An 
intermediate enzyme-sulfate complex is formed by the covalent binding of sulfate to the hydrated 
formylglycine (i.e. dihydroxy-alanine). When the active site formylglycine is replaced by a serine 
(i.e. hydroxy-alanine), the intermediate enzyme-sulfate complex is trapped (62), which indicates 
that the second hydroxyl group of hydrated formylglycine is needed for sulfate release (57,62). 
Crystallographic analyses (55,56,63) also revealed structural homology between alkaline 
phosphatases and arylsulfatases. A functional relationship between the enzymes was shown by 
O'Brien et al. (64), who demonstrated that alkaline phosphatase exhibits a low level of sulfatase 
activity. They also showed inhibition of the phosphatase as well as the sulfatase activities of 
alkaline phosphatase by inorganic phosphate (64). Anderson et al. reported on steroidal and non-
steroidal phosphates which inhibrted steroid sulfatase activity (43). We demonstrated inhibition of 
the iodothyronine sulfatase activities by inorganic phosphate and citrate. Perhaps, these anions 
block the active site of iodothyronine sulfatases. An altemative explanation is that citrate and 
phosphate inhibit iodothyronine sulfatase activity by complexing the enzyme-bound Mg2<. 
However, we did not observe inhibition of iodothyronine sulfatase activity in the presence of 
EDTA. Our results strongly suggest that iodothyronine sulfatase activities determined in 
phosphate buffers as reported by others (9,23) represent a marked underestimation of true 
enzyme levels. 
We showed a pH optimum for rat liver microsomes at pH 6.0-6.5, for human liver microsomes 
at pH 6.0-7.5 and for arylsulfatase C at pH 7.0. The broader peak for the human and rat liver 
microsomes might indicate that different sulfatases, with different pH optima, are involved in the 
desulfation of 3,3'-T2S. Kung et al. (9) observed T3S sulfatase activities in human and rat liver 
microsomes. E1S and DHEAS, both substrates for ARSC, inhibited T3S hydrolysis with IC" 
values of -10 f'M. The fact that high levels of E1S only partially inhibited T3S desulfation, 
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whereas high DHEAS concentrations produced complete inhibition, support the involvement of 
multiple sulfatases, among which possibly ARSC (9). However, these analyses were done in 
phosphate buffer, which may strongly affect the contribution of different sulfatases. 
The optimal temperature of iodothyronine sulfatase activities amounts to 50 C in human liver 
microsomes and to at least 70 C in rat liver microsomes. The high thermostability of these 
sulfatases is in agreement with the temperature optimum of 60 C for ARSC (65). ARSC and the 
sulfatase activities in human liver and placenta microsomes have high Km values for iodothyronine 
sulfates. The different substrate specificity of the iodothyronine sulfatase activity in human liver 
versus ARSC and placenta, plus the finding that the ratio between E1 Sand T2S hydrolysis in 
human liver differs largely from that in ARSC and placenta, suggest that in human liver additional 
sulfatases to ARSC contribute to hydrolysis of iodothyronine sulfates, in particular T2S. However, 
ARSD, ARSE and ARSF are no likely candidates, as a) both ARSE and ARSF are thermolabile, 
whereas iodothyronine sulfatase activity appears thermostable (33,34) and b) ARSD does not 
possess arylsulfatase activity (34,35). 
It is remarkable that, while 3,3'-T2 is the preferred substrate for sulfotransferases, 3,3'-T2S is 
the preferred substrate for (human liver) sulfatase. Thus, reversible sulfation/desulfation seems a 
more important metabolic pathway for 3,3'-T2 than for T4, T3 and rT3. This may reflect 
restrictions in the active sites of the sulfotransferase and sulfatase concerned to accomodate 
bulky substrates with more than 2 iodine substituents. However, a physiological role for 3,3'-T2 is 
not excluded. Although its affinity for the nuclear thyroid hormone receptors is low (17), 3,3'-T2 
has been shown to stimulate mitochondrial respiration in different tissues (66). 
In conclusion, we have identified arylsulfatase C as a high-Km iodothyronine sulfatase, which 
is most likely the main enzyme responsible for the hydrolysis of iodothyronine sulfates in human 
placenta and to some extent in human liver. Further investigations are needed to determine the 
possible importance of other, still unidentified, microsomal sulfatases in hydrolysis of 
iodothyronine sulfates in the liver and perhaps other tissues. This information may contribute to 
the understanding of the role of sulfation-<1esulfation in the regulation of thyroid hormone 
bioactivity, in particular during fetal development. 
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Abstract 
Sulfation is an important pathway of thyroid hormone metabolism that facilitates the 
degradation of the hormone by the type I iodothyronine deiodinase, but little is known about which 
human sulfotransferase isoenzymes are involved. We have investigated the sulfation of the 
prohormone T4, the active hormone T3 and the metabolites rT3 and 3,3'-diiodothyronine (3,3'-T2) 
by human liver and kidney cytosol as well as by recombinant human SULT1A1 and SULT1A3, 
previously known as phenol-preferring and monoamine-preferring phenol suifotransferase, 
respectively. In all cases, the substrate preference was 3,3'-T2 » rT3 > T3 > T4. The apparent 
Km values of 3,3'-T2 and T3 (at 50 ).lM 3'-phosphoadenosine-5'-phosphosulfate (PAPS)) were 
1.02 and 54.9 ).lM for liver cytosol, 0.64 and 27.8 ).lM for kidney cytosol, 0.14 and 29.1 ).lM for 
SULT1A1, and 33 and 112).lM for SULT1A3, respectively. The apparent Km value of PAPS (at 
0.1 ).lM 3,3'-T2) was 6.0 ).lM for liver cytosol, 9.0 ).lM for kidney cytosol, 0.65 ).lM for SULT1A1 and 
2.7 ).lM for SULT1A3. The sulfation of 3,3'-T2 was inhibited by the other iodothyronines in a 
concentration-dependent manner. The inhibition profiles of the 3,3'-T2 sulfotransferase activtties 
of liver and kidney cytosol obtained by addition of 10 ).lM of the various analogs were better 
correlated with the inhibition profile of SUL T1A 1 than wtth that of SUL T1A3. These results 
indicate similar substrate specificities for iodothyronine sulfation by native human liver and kidney 
sulfotransferases and recombinant SULT1A1 and SULT1A3. Of the latter, SULT1A1 clearly 
shows highest affinity for both iodothyronines and PAPS, but it remains to be established if it is 
the prominent isoenzyme for sulfation of thyroid hormone in human liver and kidney. 
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Introduction 
Sulfation is a detoxication reaction, which increases the water solubility of a variety of 
endogenous and exogenous lipophilic compounds, thus facilitating their excretion in bile andlor 
urine (1-3). Sulfation is also an important pathway for the metabolism of thyroid honmone, 
increasing the hydrophilicity and the biliary excretion of the hormone. However, the major purpose 
of sulfation of thyroid honmone is to facilitate its degradation by the type I iodothyronine 
deiodinase (01) (4,5). This selenoenzyme catalyzes the outer ring deiodination (ORO) as well as 
the inner ring deiodination (IRO) of different iodothyronines, including the ORO of the prohonmone 
T4 to the active honmone T3, and the IRO of T4 and T3 to the inactive metabolites rT3 and 
3,3'-diiodothyronine (3,3'-T2), respectively (6,7). The preferred substrate for 01 is rT3, which is 
converted by ORO to 3,3'-T2 (6,7). 
An intriguing characteristic of 01 is that its deiodination of a number of iodothyronines is 
accelerated by sulfation of their phenolic hydroxyl group (4,5). Thus, IRO of both T4 sulfate (T4S) 
and T3 sulfate (T3S) by rat 01 is 40-200 times faster than the deiodination of the nonsulfated 
substrates. In contrast, ORO ofT4 by rat 01 is completely blocked by sulfation (4,5). This is not a 
general phenomenon since ORO of rT3 by rat 01 is not affected by sulfation, whereas ORO of 
3,3'-T2 by rat 01 is accelerated -50-fold by sulfation of this compound (4,5). Similar findings have 
been obtained with human and dog 01 (8,9). The facilitated deiodination of sulfated 
iodothyronines is a unique property of 01. Neither the type 11 iodothyonine deiodinase (02), which 
catalyzes only ORO, e.g. T4 to T3 and rT3 to 3,3'-T2, nor the type III iodothyronine deiodinase 
(03), which catalyzes only IRO, e.g. T4 to rT3 and T3 to 3,3'-T2, is capable of catalyzing the 
deiodination of sulfated iodothyronines (10,11, T.J. Visser and E. Kaptein, unpublished work). 
Serum concentrations ofT4S, T3S, rT3S and 3,3'-T2S are low in nonmal human subjects, but 
they are high in fetal and cord blood, in patients with nonthyroidal illness, and in patients treated 
with propylthiouracil or iopanoic acid, both inhibitors of 01 (12-19). The serum T3SIT3 ratio is also 
increased in hypothyroid patients (13). High serum T4S, T3S, rT3S and 3,3'-T2S levels have also 
been detected in serum, bile, allantoic fiuid and amniotic fiuid of fetal sheep (19-22). The high 
serum iodothyronine sulfate levels during nonthyroidal illness, hypothyroidism and fetal 
development have been ascribed to a low peripheral 01 activity in these conditions (4,5,11). 
These results are in accordance with experimental findings in rats, showing marked increases in 
the serum concentration and biliary excretion of iodothyronine sulfates in animals with impaired 
hepatic and renal 01 activities due to administration of 01 inhibitors or selenium deficiency (23-
27). These changes are not caused by an increased sulfation of iodothyronines but, rather, by a 
decreased clearance of the sulfated iodothyronines by 01 (24,28). Thus, sulfation is a primary 
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step leading to the irreversible degradation of T4 and T3 by 01. However, if 01 activity is low, 
inactivation of thyroid hormone by sulfation is reversible due to expression of sulfatases in 
different tissues and by intestinal bacteria (11,29-31). It has been speculated that especially in the 
fetus T3S has an important function as a reseNoir from which active T3 may be released in a 
tissue-specific and time-dependent manner (S, 11). 
Sulfation of the hydroxyl group of a variety of substrates is catalyzed by a family of 
homologous sulfotransferases, located in the cytoplasmic fraction of different tissues, such as 
liver, kidney, intestine and brain (1-3). All of these isoenzymes use 3'-phosphoadenosine-S'-
phosphosulfate (PAPS) as sulfate donor (1-3). On the basis of substrate specifiCity and amino 
acid sequence homology, two sulfotransferase families have been recognized in human tissues, 
i.e. phenol sulfotransferases (induding estrogen sulfotransferases) and hydroxysteroid 
sulfotransferases (1-3). It is not known which sulfotransferases are involved in the sulfation of 
iodothyronines in human tissues. Previous studies have suggested a role for the enzymes termed 
phenol-preferring phenol suWotransferase (P-PST) and monoamine-preferring phenOl 
sulfotransferase (M-PST), in the sulfation of T3 in human liver and intestine (32-33). Recently, a 
large number of human and rat sulfotransferases have been cloned and characterized, including 
human SULT1A1 and SULT1A3, which represent P-PST and M-PST, respectively (34-36), under 
a new nomenclature system. Here we report the results of a comparison of the kinetic profiles of 
the sulfation of iodothyronines by human liver and kidney cytosol and by recombinant 
preparations of human SULT1A1 and SULT1A3. 
Materials and Methods 
Materials 
[3',S'-"'1]T4 and [3'-"'I]T3 were obtained from Amersham (Aylesbury, UK); T4, T3 and PAPS 
from Sigma (St. Louis, MO); rT3, 3,S-T2, 3,3'-T2, 3',S'-T2, 3- and 3'-iodothyronine (T1) and 
thyronine (TO) from Henning (Berlin, Germany); and Sephadex LH-20 from Pharmacia (Woerden, 
The Netherlands). 3,[3'-"'1]T2 and [3',S'-"'I]rT3 were prepared by radioiodination of 3-T1 and 3,3'-
T2, respectively, as previously described (37). 
Normal adult human liver and kidney tissue was obtained at surgery for liver and kidney 
tumors. Approval was obtained from the Medical Ethical Committee of the Erasmus University 
Medical School and Hospital. Tissue was homogenized in 0.2S M sucrose, 10 mM HEPES (pH 
7.0) and 1 mM dithiothreitol, and cytosol was prepared as previously described (8). SULT1A1 
cDNA cloned by Wilborn et al. (34) and SULT1A3 cloned by Ganguly et al. (36) were kindly 
provided by Dr. C.N. Falany (University of Alabama, Birmingham, AL) and expressed in 
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Salmonella typhimunum as previously described (38). Human SUL T1A3 eDNA was also cloned 
from human platelets and expressed in V79 cells (35). Bacterial and V79 cell cytosol was 
prepared for characterization of recombinant sulfotransferase activities (35,38). Protein was 
measured with the Bio-Rad protein assay (Bio-Rad, Veenendaal, The Netherlands) using BSA as 
the standard. 
Sulfolransferase assay 
lodothyronine sulfotransferase activities were analyzed by incubation of usually 0.1 ~M T4, 
T3, rT3 or 3,3'-T2 and 100,000 cpm of the "'I-labeled compound for 30 min at 37 C with the 
indicated amounts of liver or kidney cytosol or recombinant sulfotransferase preparation in the 
presence or absence (blank) of 50 ~M PAPS in 0.2 ml 0.1 M phosphate (pH 7.2) and 2 mM EDTA 
(39). Similar results were obtained in the absence of EDTA. The reactions were started by 
addition of enzyme diluted in ice-cold buffer, and stopped by addition of 0.8 ml 0.1 M HC!. The 
mixtures were analyzed for sulfoconjugate formation by chromatography on Sephadex LH-20 
minicolumns as previously described (39). Sulfation in reaction mixtures with PAPS was corrected 
for background radioactivity detected in the corresponding Sephadex LH-20 fractions of the 
blanks. Incubations were carried out in triplicate, and the coefficient of variation was less than 
10%. 
Results 
Figure 1 shows the sulfation of 0.1 ~M T4, T3, rT3 and 3,3'-T2 by human liver and kidney 
cytosol, SULT1A1 and SULT1A3 in the presence of 50 ~M PAPS. All enzyme preparations 
display a strong substrate preference for 3,3'-T2, which is sulfated approximately 2 orders of 
magnitude more rapidly than T3 and rT3, whereas T4 is a poor substrate for these human 
sulfotransferases. 
Figure 2 presents the sulfation of 3,3'-T2 by human liver cytosol in the presence of PAPS as a 
function of incubation time and cytosolic protein concentration. Under the conditions used, 3,3'-T2 
sulfation was linear with incubation time up to 45 min, when about 50% of the substrate was 
converted (Fig. 2A). The subsequent decrease in sulfation rate probably is due to depletion of 
substrate rather than depletion of cofactor, since PAPS was added in large excess (50 ~M). 
Initially, 3,3'-T2 sulfation showed a more than proportional increase with the cytosolic protein 
concentration (Fig. 2B). For instance, an increase in the cytosolic protein concentration from 25 to 
50 ~g/ml resulted in a 3-fold increase in 3,3'-T2S formation. Further increases in protein 
concentration resulted in roughly linear increases in 3,3'-T2 sulfation until significant substrate 
80 
Characterization of human iodothyronine sulfotransferases 
depletion occurred. Similar results were obtained when 3,3'-T2 sultation by human kidney cytosol 
was analyzed as a function of the cytosolic protein concentration (data not shown). 
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CJJ rT3 
=:::J T2 
Fig. 1. Sulfation of iodothyronines by human liver and kidney cytosol, SULT1A1 and 
SULT1A3. Reaction conditions: 0.1 !J,M 125J~JabeJed T4, T3, rT3 or 3,3'-T2, 0.1 mg 
protein/ml, 50 !J,M PAPS, and 30 min incubation. Results are the means of triplicate 
determinations from a representative experiment. 
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Fig. 2. Effects of incubaflon time (A) and protein concentration (8) on the sulfation of 3,3'-T2 by human liver cytosol. 
Reaction conditions: 1 ).LM 3,[3,_125IjT2, 50 ).Lg protein/mJ (A), 50 ).LM PAPS, and 20 min incubation (8). Results are the 
means of triplicate determinations from a representative experiment 
Figure 3 shows the sultation of 3,3'-T2 by human liver (A) and kidney (8) cytosol as a function 
of the substrate concentration. In both tissues, saturation kinetics were observed in the range of 
the 3,3'-T2 concentrations tested, with maximum sulfation rates being obtained at 3 ~M 3,3'-T2. At 
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higher 3,3'-T2 concentrations a decrease in sulfation rate was observed, suggesting substrate 
inhibition. The double-reciprocal plots of sulfation rates vs 3,3'-T2 concentration were linear, 
allowing the calculation of apparent 1<", values for 3,3'-T2 and V_ values. Table 1 presents the 
kinetic parameters for 3,3'-T2 sulfation by human liver and kidney cytosol at 50 ~M PAPS 
detenmined in different experiments. The mean apparent Km value for 3,3'-T2 amounted to 
1.02 ~M in liver and 0.64 ~M in kidney cytosol. The data presented were obtained using 
3 different kidney samples and 2 different cytosol preparations from the same liver, while very 
similar results were obtained with 59 other liver samples (R.A.H. Gilissen, M.W.H. Coughtrie, 
E. Kaptein, T.J. Visser, unpublished work). Table 1 also gives the kinetic parameters for the 
sulfation of T3 determined under similar conditions. Compared with 3,3'-T2, apparent 1<", values 
for T3 were approximately 50-fold higher, i.e. 54.9 ~M in liver and 27.8 ~M kidney, while apparent 
V_values were roughly 10-fold lower. 
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Table 1. Kinetic parameters of human iodothyronine sulfotransferases 
Enzyme source 
Variable substrate: 3,3'-T2 (50 pM PAPS) 
Liver cytosol 
Kidney cytosol 
SULT1A1 (Salmonella) 
SULT1A3 (Salmonella) 
SULT1A3 0179 cells) 
Variable SUbstrate: T3 (50 pM PAPS) 
Liver cytosol 
Kidney cytosol 
SULT1A1 (Salmonella) 
SULT1A3 (Salmonella) 
Variable substrate: PAPS (0.1 pM 3,3'-T2) 
1.02±0.11 
0.84 ± 0.17 
0.12 ± 0.05 
31.2 ± 2.0 
34.7 ± 6.1 
54.9 ± 2.6 
27.8 ± 2.6 
29.1 ± 12.3 
112 ± 23 
Liver cytosol 6.00 ± 0.25 
Kidney cytosol 8.95 ± 0.39 
SULT1A1 (Salmonella) 0.65 ± 0.12 
SULT1A3 0179 cells) 2.70 ± 0.19 
Data are presented as the means ± SO of 2-5 experiments. 
v_ 
(pmol/min/mg protein) 
337 ± 88 
38.5±18.1 
465 ± 184 
782 ± 239 
2097 ± 474 
22.7 ± 8.6 
2.7 ± 0.1 
239 ± 82 
158 ± 94 
21.4 ± 3.4 
5.8 ± 5.2 
1n ± 34 
4.9 ± 0.2 
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Fig. 3. Effects of substrate concentration on the sulfation of 3,3'-T2 by human liver (A) or kidney cytosol (8). The insets 
show the double-reciprocal plot Reaction conditions: 0.1-3 IlM 3,I3'_12!i1]T2, 50 (A) or 100 (6) 119 protein/ml, 50 IlM 
PAPS, and 60 min incubation. 
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Fig. 4. Effects of substrate concentration on the sulfation of 3,3'-T2 by SULT1A1 (A) and SULT1A3 (6). The insets 
show the double-reciprocal plot Reaction conditions: 0.1-100 IlM 3,[3,_1251jT2, 5 (A) or 100 (8) )19 protein/ml, 50 )1M 
PAPS, and 30 min incubation. 
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Figure 4 depicts the sulfation of 3,3'-T2 by SULT1A1 (A) and SULT1A3 (8) as a function of 
the substrate concentration. Maximum sultation rates were obtained at lower 3,3'-T2 
concentrations for SUL T1A 1 than for SUL T1A3, with SUL T1A 1 showing clear substrate inhibition 
at 3,3'-T2Ievels above 1 I'M. From the linear double-reciprocal plots apparent Km and Vm~ values 
were calculated. Since the enzymes expressed in Salmonella and V79 cells were tested as crude 
cytosol, the maximum sultation rates determined in these experiments are not representative of 
the differences in k..t values between the different isoenzymes. The kinetic parameters 
determined in different experiments are summarized in Table 1, showing mean Km values of 
0.14 and 33 I'M for 3,3'-T2 sulfation by SULT1A1 and SULT1A3, respectively. Apparent Km 
values were identical for SUL T1A3 expressed in either Salmonella or V79 cells. Again, T3 
sulfation was characterized by much higher apparent Km values, i.e. 29.1 I'M for SULT1A1 and 
112 I'M for SULT1A3, and lower apparentV~ values compared wtth 3,3'-T2 (Table 1). 
Figure 5 shows the effects of increasing PAPS concentration on the sultation of 0.1 I'M 
3,3'-T2 by human liver (A) and kidney (8) cytosol. Sultation approached maximum rates at PAPS 
concentrations of 30 I'M or more. The double-reciprocal plots of these data were linear, from 
which Km and V~ values (at 0.1 I'M 3,3'-T2) were calculated. Table 1 summarizes the results 
from different experiments. The mean apparent Km value for PAPS amounted to 6 I'M in liver and 
9 I'M in kidney cytosol. 
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Fig. 5. Effects of cofactor concentration on the sulfation of 3,3'-T2 by human liver (A) or kidney (8) cytosol. The insets 
show the double-reciprocal plot. Reaction conditions: 0.1 ).1M 3,[3'·1251]T2, 50 (A) or 100 (8) ).19 protein/ml, 1-100 )lM 
PAPS, and 30 min incubation. 
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Fig. 6. Effects of cofactor concentration on the sulfation of 3,3'-T2 by SULT1A1 (A) and SULT1A3 (6). The insets show 
the double-reciprocal plot Reaction conditions: 0.1 !lM 3,[3'_125I]T2, 5 (A) or 100 (6) !lg protein/ml, 1-100 !lM PAPS, 
and 30 min incubation. 
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Fig. 7. Effects of 1-100 !lM unlabeled iodothyronines on the sulfation of 3,[3'_1251]T2 by 
human liver cytosol. Reaction conditions: 1 !lM 3,[3,_125IjT2, 50 !l9 protein/ml, 50 !lM PAPS, 
and 30 min incubation. Results are the means of triplicate determinations from a 
representative exper·lment. 
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Figure 6 presents the sulfation of 0.1 flM 3,3'-T2 by SULT1A1 (A) and SULT1A3 (8) as a 
function of the PAPS concentration. The PAPS concentration required for maximum sulfation 
rates was lower for SUL T1A 1 than for SUL T1A3. The apparent K" values for PAPS (at 0.1 flM 
3,3'-T2) calculated from the linear Lineweaver-Burl< plots, amounted to 0.65 and 2.7 flM, 
respectively. 
Figure 7 demonstrates the effects of increasing concentrations (1-100 flM) of unlabeled 
iodothyronines on the sulfation of 3,[3'-"'ljT2 (1 flM) by human liver cytosol. TO had no effect, 
while 3-T1 and 3,5-T2 produced only 10-20% inhibition at the highest concentration tested. All 
other iodothyronines inhibited the sulfation of labeled 3,3'-T2 dose-<:lependently, with potencies 
decreasing in the order 3,3'-T2 > rT3 > 3',5'-T2 > 3'-T1 > T3 - T4. 
Table 2. Inhibition of the sulfation of 3,3'~T2 by iodothyronine analogs 
lodothyronine % Inhibition 
Liver Kidney SULT1A1 SULT1A3 
T4 17±3 7±5 32±7 0±1 
T3 4±2 3±4 24±4 1±2 
rT3 43±4 42± 10 86± 1 1 ± 1 
3',5'-T2 47±7 41 ± 14 86±2 6±1 
3,3'-T2 87±2 88±2 95 ± 1 19 ±2 
3,5-T2 5±7 -2 ± 2 5±2 -1 ± 1 
3'-T1 71 ± 12 61 ± 18 99 ± 1 38±2 
3-T1 5 ± 10 1 ± 1 3±2 -1 ± 1 
TO -1 ±2 0±1 -2 ± 6 -2± 1 
1 )lM 3,[3'_1251]T2 was incubated for 30 min at 37 C with appropriate amounts of enzyme protein in the 
absence or presence of 10 J.LM unlabeled iodothyronine. Percentage inhibition is calculated from the 
3,[3'1251]T2 sulfation rate in the presence vs that in the absence of analog. Data are presented as the 
means ± SO of 3-6 experiments using 3 liver and 3 kidney samples. 
Table 2 compares the effects of unlabeled iodothyronines (10 flM) on the sulfation of 
3,[3'-"'ljT2 (1 flM) by human liver and kidney cytosol, SULT1A1 and SULT1A3. In general, the 
magnitude of inhibition of the sulfotransferase activities by the various iodothyronine analogs 
decreased in the order SUL T1A 1 > liver - kidney> SUL T1A3. The inhibition profiles of the tissue 
sulfotransferase activities were better correlated with the inhibition profile of SUL T1A 1 than with 
that of SULT1A3 (liver vs SULT1A1: r=0.936, p<0.01; liver vs SULT1A3: r=0.793, p<0.01; kidney 
vs SULT1A1: r=0.920, p<0.01; kidney vs SULT1A3: r=0.751, p<0.01). 
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Discussion 
Several human phenol sulfotransferases have been cloned and characterized, including 
SULT1A1, SULT1A2, SULT1A3, SULT181 and SULT1C1 (1-3,34-36,40-50). SULT1A1 
represents what has been known for some time as the phenol-preferring phenol sulfotransferase 
(P-PST), while SULT1A3 was previously known as the monoamine-preferring phenol 
sulfotransferase (M-PST) (1-3). The SULT1A isoenzymes are equally large proteins consisting of 
295 amino acids. A significant degree of homology exists between the human SULT1A proteins, 
with 92% amino acid identity between SUL T1A 1 and SUL T1A3, and an even greater degree of 
homology between SULT1A1 and SULT1A2, the genes of which are located closely together on 
chromosome 16 (2,34-36,40-46). Specifically, SULT1A1 and SULT1A2 differ in 11-15 amino acid 
positions, SULT1A1 and SULT1A3 differ in 20-23 amino acid positions, and SULT1A2 and 
SULT1A3 differ in 30-31 amino acid positions. Different allelic variants have been identified for 
SULT1A1 and SULT1A2 but sofar not for SULT1A3 (2,34-36,40-46). 
Sulfp<',o of T3 by P-PST and M-PST purified from human liver and intestine has been 
reported prev,~. _iy (32,33), but it remains to be determined which SULT1A isoenzyme is most 
important for thyroid hormone sulfation in human liver and other tissues. In addition to the 
members of the SULT1A family, two other human phenol sulfotransferases, SULT1B1 (49,50) 
and SULT1C1 (47,48), have been cloned recently. Whereas it is unknown if isoenzymes 
homologous to SULT1A2 and SULT1A3 exist in rats, the rat homologs of human SULT1A1, 
SUL T1 B1 and SUL T1 C1 have been cloned and characterized regarding their activity towards 
iodothyronines (51-53). These studies have demonstrated that both rat SULT1B1 and SULT1C1 
catalyze the sulfation of different iodothyronines, in particular 3,3'-T2, whereas rat SULT1A1 is 
completely inactive. Human SULT1B1 has recently also been shown to have sulfotransferase 
activity towards iodothyronines (50), but sulfation of iodothyronines by human SULT1C1 has not 
yet been reported. 
We demonstrate that both human SULT1A1 and SULT1A3 are capable of catalyzing the 
sulfation of iodothyronines. This is not surprising since the sulfation of T3 by P-PST and M-PST 
purified from human liver and intestine has been reported previously (32,33). We have also 
recently demonstrated effective sulfation of iodothyronines by human SULT1A2 (M.HA Kester, 
M.W.H. Coughtrie, H.R. Glatt, T.J. Visser, unpublished work). It appears that small differences in 
amino acid sequence can effect large differences in sulfotransferase activity. The high activity of 
human SUL T1A 1 in contrast to the complete lack of iodothyronine sulfotransferase activlly of rat 
SULT1A1 is remarkable, considering the high degree of amino acid sequence identity (80%) 
between these orthologous proteins (2,51). Likewise, the smaller (8%) difference in amino acid 
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sequence between human SUL T1A 1 and SUL T1A3 (34-36,46) is associated with a more than 
200-fold difference in K" value for 3,3'-T2, a 4-fold difference in K" value for T3, and 4-fold 
difference in K" value for PAPS. It should be noted that the apparent Km value of 3,3'-T2 for 
SULT1A1 presented here is about 10-fold lower than that mentioned earlier (53), which may be 
due to partial inactivation through oxidation (54) of the enzyme preparation used previously. 
The main purpose for comparing the substrate specificities and kinetic parameters of native 
iodothyronine sulfotransferase activities in human liver and kidney with these properties of 
recombinant sulfotransferases is to try to identify the isoenzymes which contribute most to the 
sulfation of thyroid hormone in these tissues. The iodothyronine sulfotransferase activities of 
human liver and kidney cytosol are characterized by similar apparent K" values for both 3,3'-T2 
and PAPS as well as similar substrate specificities, suggesting the involvement of similar 
isoenzymes. The substrate specificities of the hepatic and renal sulfotransferase activities showed 
a better correlation with SUL T1A 1 than with SUL T1 A3, suggesting that SUL T1A 1 is a prominent 
iodothyronine sulfotransferase in human liver and kidney. However, the different iodothyronines 
showed a lower apparent affinity for the native sulfotransferases than for recombinant SUL T1A 1, 
which may be due to the presence of iodothyronine-binding proteins in the tissues. Sulfation of 
thyroid hormone in human liver and kidney (and possibly other tissues) involves contributions of at 
least SULT1A1, SULT1A2, SULT1A3 and SULT1B1, and perhaps also SULT1C1. The 
complexity is further increased by the polymorphic variation in these isoenzymes (2,55) and their 
tissue-specific expression (56). In addition, it has been demonstrated that functional rat phenol 
sulfotransferases may either consist of two identical (homodimer) or two different subunits 
(heterodimer) (57). Our findings of a more than linear increase in' iodothyronine sulfotransferase 
activity with an increase in hepatic or renal cytosolic protein concentration may refiect this 
requirement for protein dimerization. 
The native and recombinant sulfatransferases tested in this study show a marked preference 
for 3,3'-T2 as the substrate. Both SULT1A1 and SULT1A3 are much less efficient in catalyzing 
the sulfation of T3, which does not imply that these isoenzymes are not important for T3 sulfation 
in vivo. This is supported by the significant sulfation of T3 in both human liver and kidney cytosol. 
Sulfation of T4 is almost undetectable, not only with recombinant SULT1A1 and SULT1A3 but 
also in human liver and kidney. Nevertheless, high serum T4S levels have been detected in 
human newboms (14,15), suggesting sulfation of T4 by other isoenzymes. 
In conclusion, we have identified SULT1A1 and SULT1A3 as low Km and high K" human 
iodothyronine sulfotransferases, respectively, and obtained evidence that the sulfation of 
iodothyronines in human liver and kidney is catalyzed by similar enzymes. Further investigations 
are required to determine the possible importance of other isoenzymes, such as SULT1A2, 
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SULT1B1 and SULT1C1, and of polymorphic variations in the different sulfotransferases for the 
sulfation of thyroid hormone in human tissues. This information is essential for the investigation of 
the regulation of this important pathway of thyroid hormone metabolism under 
(patho)physiological conditions, in particular during fetal development. 
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Abstract 
Sulfation is one of the pathways by which thyroid hormone is inactivated. lodothyronine 
sulfate concentrations are very high in human fetal blood and amniotic fluid, suggesting important 
production of these conjugates in utero. Human estrogen sulfotransferase (SUL T1 E1) is 
expressed among other tissues in the uterus. Here we demonstrate for the first time that 
SULT1 E1 catalyzes the facile sulfation of the prohormone T" the active hormone T, and the 
metabolites rT, and 3,3'-diiodothyronine (3,3'-T.;) with preference for rT, - 3,3'-T, > T3 - T,. Thus, 
a single enzyme is capable of sulfating two such different hormones as the female sex hormone 
and thyroid hormone. The potential role of SUL T1 E1 in fetal thyroid hormone metabolism needs 
to be considered. 
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Introduction 
Thyroid hormone is essential for the development of different tissues, in particular the brain, 
and requires the binding of the active hormone T, to nuclear receptors (1). Sulfation is one of the 
pathways by which T, and other iodothyronines, including the prohormone T" are metabolized 
(2). This is an inactivating pathway since T, sulfate (T,S) has lost ITS affinity for the T, receptors 
(3). Moreover, sulfation of T, and its prohormone T, strongly facilitates their degradation through 
inner ring deiodination by the type I iodothyronine deiodinase in liver (2). lodothyronine sulfate 
concentrations are very high in the human fetal circulation and in the amniotic fluid (4), suggesting 
important production of these conjugates in utero. Human estrogen sulfotransferase (SUL T1 E1) is 
known to be expressed, among others, in the endometrium (5,6). In this study we tested the 
possible sulfation of T" T, and the metabolITes rT, and 3,3'-diiodothyronine (3,3'-T,) by 
recombinant human SUL T1 E1 in comparison with the sulfation of estrone (E,) and 17~-estradiol 
(E,). 
Materials and Methods 
Materials 
[3',5'-12511T" [3'-12511T" fH1E, and fH1E, were obtained from Amersham (Amersham, UK); 
T" E, and 3'-phosphoadenosine-5'-phosphosulfate (PAPS) from Sigma (St. Louis, MO); T" rT, 
and 3,3'-T, from Henning Berlin GmbH (Berlin, Germany); and E, from Ikapharm (Ramat, Israel). 
3,[3'-12511T, and [3',5,-'2511rT, were prepared as previously described (7). Human SULT1E1 was 
expressed in S. typhimurium as previously described (8) and used WIThout further purification. 
Expression in E. coli and purification of human SUL T1A 1, SUL T1A3 and SUL T1 E1 have also 
been described previously (9,10). Cloning, expression and purification of human SULT1B1 (11) 
will be described in detail elsewhere. Briefly, the clone was isolated from human liver cDNA by 
PCR, cloned into the vector pET11a and expressed in E. coli. Protein was purified as described 
(9,10). 
Sulfotransferase assays 
lodothyronine sulfotransferase activities were analyzed by incubation of usually 0.1 ;tM T" T" 
rT, or 3,3'-T, and 105 cpm of the 1251-labeled compound for 30 min at 37 C with the indicated 
amounts of recombinant sulfotransferase in the absence (blank) or presence of 50 ;tM PAPS in 
0.2 ml 0.1 M phosphate (pH 7.2) and 2 mM EDTA. The reactions were stopped by addition of 0.8 
ml 0.1 M HCI, and the mixtures were analyzed for sulfate formation as previously described (7). 
Estrogen sulfotransferase activity was analyzed by incubation of 1-3 nM 'H-Iabeled E, or E, for 
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30 min at 37 C with the indicated amount of recombinant SULT1 E1 in the absence (blank) or 
presence of 50 I"M PAPS in 0.2 ml phosphate-EDTA buffer. The reactions were stopped by 
addition of 2 ml ice-cold water, and the mixtures were extracted with 2 ml dichloromethane. 
Sulfate formation was quantified by counting 1 ml of the aqueous phase. Enzymatic sulfation was 
corrected for background radioactivity estimated in the blanks. Kinetic parameters were 
determined by Lineweaver-Burk analysis of the sulfation of varying substrate concentrations. 
Apparent K, values were calculated from the change in slope of the Lineweaver-Burk plot in the 
presence of a fixed inhibttor concentration. 
Results and Discussion 
Figure 1 shows the sulfation of E" E" T" T" rT, and 3,3'-T, by recombinant human SULT1 E1 
as a function of the enzyme concentration. The results show that not only the estrogens but also 
the different iodothyronines are sulfated by human SULT1E1. Under the conditions used, 
sulfation of E, and E, requires the lowest enzyme concentrations. Substantially more enzyme is 
needed for sulfation of 3,3'-T, and rT" while sulfation of T, and T, requires the highest enzyme 
concentrations. 
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Fig. 1. Sulfation of estrogens and iodothyronines by increasing concentrations 
of human $ULT1E1. Reaction conditions: 3 nM E, or~! 0.1 f.l.M T4! Ts, rTs or 
3,3'-T2' 50 11M PAPS, and 30 min incubation. 
Significant sulfation of iodothyronines, in particular 3,3'-T" has been demonstrated previously 
in human liver and kidney as well as with recombinant human SULT1A1, SULT1A3 and SULT1B1 
(11,12). Figure 2 compares the sulfation of the different iodothyronines by purified recombinant 
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human SULT1A1 (13), SULT1A3 (14), SULT181 (11) and SULT1E1 (15). In agreement with 
previous studies, 3,3'-T, is by far the preferred substrate for SULT1A1, SULT1A3 and SULT181, 
its sulfation rates being orders of magnitude higher than those for T, and rT" whereas sulfation of 
T, is negligible. Although 3,3'-T, is a better substrate for SULT1A1 than for SULT1E1 and T, is 
sulfated at similar rates by the different isoenzymes, SUL T1 E1 is much more effective in 
catalyzing the sulfation of T, and, in particular, rT, than any other isoenzyme tested. 
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Fig. 2. Sulfation of iodothyronines by purified human sulfotransferases. Reaction 
conditions: 0.1 flM iodothyronines, appropriate concentrations of enzymes, 50 )lM 
PAPS, and 30 min incubation. 
Figure 3A shows the Lineweaver-Burk analysis of the sulfation of the iodothyronines by 
human SULT1E1, and the values for the kinetic parameters are presented in Table 1. The 
apparent Km values for the different iodothyronines are in the micromolar range. They are 5-10 
times lower while Vmro< values are 2-8 times higher for rT, and 3,3'-T, than for T, and T,. Reflecting 
catalytic efficiency, the V".,/Km ratio decreases in the order rT, - 3,3'-T, > T, - T,. Lineweaver-
Burl< analysis of the sulfation of E, by SUL T1 E1 yielded an apparent Km value of 4 nM (Table 1) in 
close agreement with reported data (15,16). Similar Km and V_ values were obtained using E, as 
substrate (not shown). Although V_ values are lower for E, and E, than for rT, and 3,3'-T" their 
-10'-fold lower apparent Km values indicate that the estrogens have much higher affinily for 
SULT1 E1 than the iodothyronines. 
The different iodothyronines dose-dependently inhibited the sulfation of estrogens by human 
SUL T1 E1. The nature of this inhibition was studied by Lineweaver-Burk analysis (Fig. 3B). The 
results demonstrate that the iodothyronines are mixed-type inhibitors of E, sulfation. The apparent 
K; values for the iodothyronines are in agreement with their apparent Km values (Table 1). 
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However, the apparent K" value for T, is higher than its apparent ~ value, which may be due to 
significant protein binding of T, at the higher protein concentrations required for its sulfation than 
for E, sulfation. Conversely, E, and E, were found to be potent inhibitors of the sulfation of 
iodothyronines, using 3,3'-T, as the substrate (not shown). That iodothyronines are not pure 
competitive inhibitors of the sulfation of estrogens by SUL T1 E1 may be explained by recent 
findings of two substrate-binding sites on human SUL T1 E1, the active site as well as an allosteric 
binding site (16). 
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Fig. 3. Kinetics of human SULT1E1. A Lineweaver-Burl< analysis of the sulfation of iodothyronines. Reaction 
conditions: 0.3-.30 I.IM iodothyronine, 10-100 ~g protein/ml, 50 IlM PAPS, and 30 min incubation. B. Uneweaver-Burk 
analysis of the inhibition of the sulfation of ~ by iodothyronines. Reaction conditions: 1-10 nM E2 , 0,05 ~g protein/ml, 
SO J.lM PAPS, and 30 min incubation in the absence or presence ofS-10 ~M T4 , 20 J.lM Ts, 2 ~M rTs, orS J.lM 3,3'-T2' 
Table 1. Kinetic parameters of iodothyronine and estrogen sulfation by human SUL T1 E1 
Substrate! ~ Km V_ 
competitor (J.!M) (J.!M) (nmoVmin/mg) 
E, 0.003 - 0.006 1.1-2.8 
3,3'-T2 3.0 - 4.3 3.5 - 6.0 8.9 - 15.3 
rT, 0.6 - 0.9 1.7-2.6 4.5 - 8.0 
T, 12.3 -18.8 15.3 - 36.1 2.2 - 4.4 
T, 2.3 - 2.4 22.6 - 24.6 1.4-1.4 
Data are presented as the range of values from 2-3 experiments. 
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These studies indicate that thyroid hormone is sulfated importantly by human SULT1E1. 
Although the estrogens E, and E. are clearly the preferred substrates for this isoenzyme, T, and 
especially rT, are sulfated much better by human SULT1 E1 than by any other known 
sulfotransferase. Whereas human SULT1A1, SULT1A3 and SULT1B1 show an obvious 
preference for 3,3'-T, as the substrate, rT, is sulfated by human SULT1E1 as fast as 3,3'-T,. The 
Km values of the estrogens and iodothyronines for SULT1E1 appear unrelated to their 
concentrations e.g. in amniotic fluid (17). The preference of SUL T1 E1 for estrogens is reflected in 
their higher sulfatedlfree ratios in amniotic fluid compared with iodothyronines (4,17). 
The purpose of the rapid sulfation of 3,3'-T, and rT, by human SUL T1 E1 is unknown. Both 
metabolites have little affinity for the nuclear T, receptors (1). However, 3,3'-T, has been shown to 
stimulate mitochondrial respiration in different tissues (18) and rT, may regulate actin 
polymerization in brain cells (19), actions which are not mediated by the nuclear T, receptors. The 
possibility that rT" 3,3'-T, or their sulfates serve a physiological function in the fetus is, therefore, 
not eXCluded. It is intriguing in this respect that rT, and 3,3'-T, are the products of T, and T, 
deiodination, respectively, by the type III iodothyronine deiodinase which is abundantly expressed 
in placenta (20) as well as the pregnant uterus (21). 
It is astonishing that a single enzyme is capable of conjugating two such completely different 
hormones as the female sex hormone and thyroid hormone. E, is inactivated by sulfation, which is 
a reversible process as free E, is liberated by hydrolysis of the sulfate by steroid sulfatase 
expressed in different tissues (5,6). Similarly, in the human fetal circulation, T,S and in particular 
T ,S may represent a reservoir of inactive thyroid hormone, from which active hormone may be 
liberated by action of sulfatases expressed in a tissue-specific and developmental stage-
dependent manner (2). Our results suggest that the iodothyronine sulfates in the human fetal 
circulation and amniotic fluid may be derived at least in part from sulfation of thyroid hormone by 
SUL T1 E1 in the uterus. This may represent another route for the supply of maternal thyroid 
hormone to the fetus in addition to placental transfer (22). There is one report suggesting that 
SUL T1 E1 is also expressed in human placenta (23). SUL T1 E1 expression in human 
endometrium is up-regulated by progesterone (5,6). Preliminary findings suggest low levels of 
SULT1E1 expression in the uterus during the first 13 weeks of pregnancy, but further studies are 
needed to explore SUL T1 E1 expression in human endometrium throughout gestation. 
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Abstract 
Polychlorinated biphenyls (PCBs) are persistent environmental pollutants which exert a 
variety of toxic effects in animals, including disturbances of sexual development and reproductive 
function. The estrogenic effects of PCBs may be mediated in part by hydroxylated PCB 
metabolites (PCB-OHs), but the mechanisms by which they are brought about are not 
understood. PCBs as well as PCB-OHs show low affinities for both (J. and ~ estrogen receptor 
isoforms. In the present study we demonstrate that various environmentally relevant PCB-OHs 
are extremely potent inhibitors of human estrogen sulfotransferase, strongly suggesting that they 
indirectly induce estrogeniC activity by increasing estradiol bioavailability in target tissues. 
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Introduction 
The endocrine-disrupting effects of PCBs have received much attention recently, in particular 
their estrogenic activity which is thought to play an important role in the impaired sexual 
dtfferentiation and reproductive dysfunction observed in exposed birds, fish, reptiles and 
mammals (1-5). Also in humans, an increase has been observed over the last 50 years in the 
incidence of testicular cancer and of abnormal male reproductive tract development in some 
developed countries (4). Decreasing trends in semen quality and sperm counts have also been 
reported, but this may not be universal (4). Since similar abnormalities in sexual differentiation 
and reproductive function have been encountered in male offspring of women treated during 
pregnancy with the potent estrogen diethylstilbestrol (DES) to prevent miscarriage (6), it has been 
hypothesized that increased exposure to estrogenic and other endocrine-active chemicals, in 
particular during fetal and neonatal life, may contribute to the above-mentioned defects. This 
hypothesis is supported by laboratory animal studies showing disruption of endocrine pathways in 
the adult animal after in utero or early postnatal exposure to a variety of environmental 
contaminants including PCBs, polychlorinated dibenzodioxins and dibenzofurans, pesticides such 
as 2,2-bis(4-chlorophenyl)-1, 1, 1-trichloroethane (DDT), plastic additives such as bisphenol A, and 
detergent additives such as alkylphenols (3,4). 
Specific PCB congeners exhibit estrogeniC activities in experimental animals, whereas other 
congeners are associated with anti-estrogenic activities (1,2). There is evidence that the 
estrogenic (and anti-estrogenic) activities of PCBs are mediated at least in part through 
hydroxylated metabolites (1,2,7), but the mechanism by which PCB-OHs exert their effects has 
not been established. It has been shown previously for a large number of PCB-OHs that their 
affinity for both (J. and ~ estrogen receptor subtypes is low (8,9), suggesting that they have little 
activity as estrogen receptor agonists. However, it is possible that PCBs or PCB-OHs indirectly 
exert estrogenic activity by inhibiting estradiol (E2) metabolism, thus enhancing cellular E2 
bioavailability. Sulfation by estrogen sulfotransferase (EST) is an important pathway for E2 
inactivation (10). In this study, we investigated the potential inhibition of human EST (hEST) by 
hydroxylated PCBs. 
Materials and Methods 
Materials 
fH]E2 (3.22 MBqinmol) was obtained from Amersham (Amersham, UK); ["S]pAPS (52.9 
MBqif\mol) from NEN (Boston, MA); unlabeled E2 and PAPS from Sigma (St. Louis, MO). The 
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sources of the various PCB-OHs have been described previously (8,11). Recombinant hEST (12) 
was expressed in S. typhimurium as previously described (13). Cytosolic preparations from these 
bacteria were used wrthout further purification. EST accounted for 5-7% of the cytosolic proteins. 
Similar results were obtained wrth hEST expressed in E. coli and purified as previously described 
(14). 
Su/fofransferase assays. 
Estrogen sulfot,ansferase activrty was analyzed by incubation of 1 nM ['HJE2 for 30 min at 
37 C with recombinant hEST (0.1 ~g protein/ml) in the absence (blank) or presence of 50 ~M 
PAPS in 0.2 ml 0.1 M sodium phosphate (pH 7.2), 2 mM EDTA and 1 mM dithiothreitol. The 
reactions were stopped by addrtion of 2 ml ice-cold water, and the mixtures were extracted with 2 
ml dichloromethane. Sulfate formation was quantified by counting 1 ml of the aqueous phase. 
Enzymatic sulfation was corrected for background radioactivity estimated in the blanks. Kinetic 
parameters were determined by lineweaver-Burl< analysis (15) of the sulfation of varying 
substrate concentrations. Apparent t<; values were calculated from the change in slope of the 
Lineweaver-Burk plot in the presence of inhibitor (15). 
Results and Discussion 
The effects of increasing concentrations (0.01-1000 nM) of various PCB-OHs were tested on 
the sulfation of 1 nM E2 by recombinant hEST. The compounds are numbered as explained in 
Table 1. The nonhydroxylated compound 1 (PCB77) did not affect EST activity even at the 
highest concentration tested (1000 nM). However, hydroxylation of one of the phenyl rings 
induced strong inhibitory activity that was dependent on the posrtions of the substituents in this 
ring. Figure 1A shows the results with PCB-OHs having the same 3',4'-dichloro-substituted 
nonphenolic ring. Although the orlho-hydroxylated compounds 28 and 30 were relatively weak 
inhibitors, increasing potencies were observed with the meta-hydroxylated compounds 23 and 26, 
and even higher inhibitory activities were observed with para-hydroxylated compounds, in 
particular 13 and 18. Concentrations as low as 0.1 nM of the latter PCB-OHs significantly inhibrted 
EST activity. Also from the potencies of other PCB-OHs it is concluded that an OH group in the 
para position with two adjacent CI substrtuents is required for maximum EST inhibrtory potency. 
(Table 1). 
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Fig. 1. Inhibition of the sultatian of 1 nM E2 by recombinant hEST by increasing concentrations of PCB-OHs with a 
3' ,4'-dichloro-substituted nonphenolic ring (A) or with a 4-hydroxy-3,5-dichloro-substitllted phenolic ring. Results are the 
means of 2-4 experiments. 
Figure 1 B compares the effects of PCB-OHs with an identical 4-hydroxy-3,5..<:Jichloro-
substituted phenolic ring. Potent inhibition was observed irrespective of whether the nonphenolic 
ring was substituted with two (3',4' or 3',5') or three (2',3',4' or 3',4',5') CI atoms, but a marked 
reduction in inhibitory potency was observed with four (2',3',4',5') CI substituents. Further analysis 
of other PCB-OHs indicated that in general the substitution of both ortho (2' and 6') positions or of 
two diametrically opposite (2' and 5') positions negatively affects EST inhibitory potency (Table 1). 
This suggests that binding of PCB-OHs to hEST is favored by a coplanar structure of the inhibitor 
and/or that there are steric constraints for accommodation of the substituted nonphenolic ring. 
However, other di-ortho (2,6 and 2,2') CI substitutions did not decrease EST inhibitory potency, 
suggesting that the dimensions of the substituted nonphenolic ring are critical. From the 
concentration-inhibition relationships, IC" values (concentrations producing 50% inhibition) were 
determined which are presented in Table 1. IC" values for several PCB-OHs (13, 14, 15, 16, 18 
and 19) are in the subnanomolar range. All these compounds are characterized by a 4-hydroxy-
3,5-dichloro substitution pattem. Compound 31, having such a pattem in both rings, is the most 
potent inhibitor identified in this study, with an IC" value of 0.1 nM (Fig. 1 B, Table 1). 
To further appreciate the contributions of each phenolic and nonphenolic ring to the inhibitory 
activity of PCB-OHs towards hEST, the possible effects of a series of single-ring halogenated 
phenols were tested at a concentration of 1 f1M. Figure 2 shows that phenol itself had little effect 
on EST activity, but halogenation resulted in the generation of marked inhibitory activity. In 
general, the potency of the halophenols increased with the number and size (I > Br > CI > F) of 
the halogen substituents, suggesting that hydroxylated metabolites of polybromobiphenyls (16) 
may be even more potent inhibitors of hEST than the corresponding PCB-OHs. 
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Table 1. Potency of inhibition of hEST activity by PCB-OHs 
Compound IC", (nM) 
1 3,4,3',4'-tetraCB >1000 
2 4-OH-2',4',6'-triCB 610 - 670 
3 4-OH-2',3',4',S'-tetraCB 640 - 6S0 
4 4-0H-2,2',4',6'-tetraCB 230 - 260 
5 4-0H-2,2',3',4',S'-pentaCB 260 - 370 
6 4-OH-2,2',3',4',6'-pentaCB 1S0 - 29S 
7 4-OH-2,2' ,3' ,S' ,6'-pentaCB 280 - 430 
8 4-0H-3,3',4'-triCB 4.3 - 7.8 
9 4-0H-3,2' ,4' ,6'-tetraCB 220 - 240 
10 4-OH-3,2',3',4',S'-pentaCB 100 - 120 
11 4-0H-3,2',3',4',6'-pentaCB 170 - 200 
12 4-OH-3,2',3',S',6'-pentaCB 260 - 370 
13 4-OH-3,S,3',4'-tetraCB 0.21 - 0.61 
14 4-0H-3,S,3',S'-tetraCB 0.47 - 1.00 
15 4-OH-3,S,2',3',4'-pentaCB 0.28 - 0.30 
16 4-OH-3,S,3',4',S'-pentaCB 0.38 - 0.50 
17 4-0H-3,5,2',3',4',S'-hexaCB 20 - 30 
18 4-OH-2,3,S,3',4'-pentaCB 0.15 - 0.25 
19 4-0H-2,3,5,2',3',4'-hexaC 0.27 - 0.7S 
20 4-0H-2,3,S,2',4',S'-hexaCB S.8 - 14 
21 4-OH-2,3,S,2' ,3' ,4' ,5'-hexaCB 25 - 26 
22 4-0H-2,3,5,6,2',4',5'-heptaCB 6.8 - 30 
23 3-OH4,S,3',4' -tetraCB 210 - 410 
24 3-OH4,S,2',3',4'-pentaCB 400 - 580 
25 3-0H4,5,3',4',5'-pentaCB 2S0 - 380 
26 3-OH-2,4,5,3',4'-pentaCB 21 - 24 
27 3-OH-2,4,5,2',3',4',5'-heptaCB 9.0 - 13 
28 2-0H-3,4,3',4'-tetraCB >1000 
29 2-OH-3,4,2',3',4'-pentaCB >1000 
30 2-OH4,S,3',4'-tetraCB 720 - >1000 
31 4,4'-(OH),-3,5,3',S'-tetraCB 0.10 - 0.19 
32 3,3'-(OH),4,4'-diCB 35 - 52 
The substitution pattern in the phenolic ring is indicated in bold. 
Data are presented as the range of values detennined in 2-4 experiments. 
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The inhibitory potency of 2,6-dichlorophenol is much lower than observed tor PCB-OHs with 
identically substituted (4-hydroxy-3,5-dichloro) phenolic rings, indicating that the non phenolic 
ring contributes importantly to the inhibitory effects of PCB-OHs on hEST. It should be noted 
that pentachlorophenol and other chlorophenols are also environmental pollutants resulting 
from their extensive use as preservatives in the wood and paper industry (17). Pentachloro-
phenol, which is also a major metabolite of the fungicide hexachlorobenzene, has been widely 
identified in human blood and urine (18,19). Although pentachlorophenol and other 
halogenated phenols exhibit lower EST inhibitory activity than several PCB-OHs, occupational 
exposure to these chemicals may be sufficiently high to contribute to endocrine-disrupting 
effects in exposed subjects. 
Fig. 2. Effects of different phenols on the sulfation of E2 by recombinant hEST. 
Sulfation of 1 nM E2 in the presence of 1 11M phenol is expressed as a percentage 
of that in the absence of inhibitor. P, phenol; FP, 2-f1uorophenol; CP, 
2--chlorophenol; BP, 2-bromophenol; IP, 2-iodophenol; DC?, 2,6-dichlorophenol; 
DBP, 2,6-tribromophenol; TCP, 2,4,6-trichlorophenol; TBP, 2,4,6-tribromophenol; 
TIP, 2,4,6-triiodophenol; PCP, pentachlorophenol. Results are the means of 
2 experiments. 
The phenolic hydroxyl group in PCB-OHs is essential for potent inhibition of EST activity. 
Since EST catalyzes the sulfation of the phenolic 3-hydroxyl group of E2 (10), this suggests that 
PCB-OHs may also be substrates for this enzyme. To gain more insight in the mechanism of EST 
inhibition by PCB-OHs, the kinetics of this inhibition were studied by Lineweaver-Burk analysis 
(15) for compounds 8, 16, 18,26 and 31) (Fig. 3). The double-reciprocal plots of the rate of E2 
sulfation versus the E2 concentration in the absence or presence of a single concentration of 
different PCB-OHs (Fig. 3A) or different concentrations of a single PCB-OH (Fig. 3B) converged 
at approximately the same pOint on the x-axis. This indicates that these PCB-OHs are 
noncompetitive inhibitors of E2 sulfation and not competitive inhibitors which would be expected if 
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they are also substrates for EST, The K, values derived from these Lineweaver-Burk plots are in 
good agreement with the corresponding ICsa values for the different inhibttors, The noncompetttive 
type of inhibition can be explained by the presence of two substrate-binding sttes on hEST, the 
active site as well as an allosteric site (20), Our results suggest that the potent inhibttion of hEST 
by PCB-OHs is primarily due to binding of these inhibttors to the second, allosteric site, 
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Fig. 3. Llneweaver-Burk plots of the sulfation at E2 by recombinant hEST in the absence or presence of (A) 6 nM 8, 0.5 
nM 16, 22 nM 26 or 0.1 nM 31, or (8) 02, 0.5 or 1 nM 18. Results are representativefor2-4 experiments. 
Binding of hydroxylated PCB metabolites to the estrogen receptor is an obvious mechanism 
by which these compounds could exert their estrogenic activity, However, previous studies have 
demonstrated that the affintty of PCB-OHs for both " and ~ estrogen receptor subtypes is in 
general very low, Among the large number of PCB-OHs tested, compounds 2 and 3 showed by 
far the highest affinities for both estrogen receptors which were still >20-fold lower than the affinity 
of E2 ttself (8,9), The results of our study provide a more attractive explanation for the estrogenic 
activity of PCB-OHs, Several congeners were found to be extremely potent inhibitors of hEST. 
The IC" and K, values of different PCB-OHs are up to 50-fold lower than the Km value of E2 for 
hEST (4 nM) (21), indicating that these inhibitors have much higher affinity for the enzyme than tts 
natural substrate, To our knowledge, inhibition of hEST is the most potent biological effect 
described to date regarding the endocrine-disrupting activity of PCBs or their metabolites, It is 
noteworthy that among the most potent EST inhibitors, 18 has been identified as one of the most 
abundant PCB-OHs in blood and tissues of animals and humans exposed to PCBs (22,23), By 
inhibiting the formation of inactive E2 sulfate, PCB-OHs can increase E2 bioavailability in target 
tissues, thereby exerting an indirect estrogenic effect, This may not necessarily be associated 
with significant changes in circulating levelS of E2 and other estrogens but may take place locally 
in estrogen-sensitive tissues expressing EST, including testis (24), mammary gland (25) and 
endometrium (26), 
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Abstract 
Polyhalogenated aromatic hydrocarbons (PHAHs), such as polychlorinated dibenzo-p-
dioxins (PCDDs) and dibenzofurans (PCDFs), polybrominated diphenylethers (PBDEs) and 
bisphenol A (BPA) derivatives are persistant environmental pollutants, which are capable of 
interfering with reproductive and endocrine function of birds, fish, reptiles and mammals. Part of 
the endocrine-disrupting effects may be mediated by their hydroxylated metabolites 
(PHAH-OHs), the mechanisms of which remain to be identified. PHAH-OHs show low affinity for 
the estrogen receptors. Alternatively, they may exert their estrogenic effects by inhibiting 
estradiol (E2) metabolism. Since sulfation of E2 by estrogen sulfotransferase (SULT1E1) is an 
important pathway for E2 inactivation, inhibition of SULT1 E1 may lead to an increased 
bioavailability of estrogens in tissues expressing this enzyme. Therefore, we studied the 
possible inhibition of human SULT1 E1 by hydroxylated PHAH metabolites, and sulfation of the 
different compounds by SULT1E1. We found marked inhibition of SULT1E1 by various 
PHAH-OHs, in particular by compounds with two vicinal halogen substituents around the 
hydroxyl group which were effective at (sub)nanomolar concentrations. Depending on the 
structure, the inhibition is primarily competitive or noncompetitive. Most PHAH-OHs are also 
sulfated by SULT1 E1. We also investigated the inhibitory effects of the various PHAH-OHs on 
E2 sulfation by human liver cytosol, and found that the effects were strongly correlated w~h 
their inhibitions of recombinant SUL T1 E1 (r = 0.922). Based on these results, we hypothesize 
that hydroxylated PHAHs exert their estrogenic effects at least in part by inhibiting SULT1 E1-
catalyzed E2 sulfation. 
111 
Chapter 8 
Introduction 
Recently, many studies have been done on the interaction of environmental chemicals with 
the endocrine system, which results in reproductive and developmental anomalies in various 
organisms (1-4). Endocrine-disrupting effects have been observed in adult animals which were 
exposed in utero to polyhalogenated aromatic hydrocarbons (PHAHs) such as polychlorinated 
dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and polychlorinated 
biphenyls (PCBs) (5-7). Hilakivi-Clarke et al. demonstrated in rats that exposure to natural 
estrogens in utero advanced puberty onset and increased breast cancer risk in the offspring (8); 
this may also apply for environmental estrogens. In humans, abnormalities in the development 
of the reproductive tract, reduced spenm counts (3,9), and increased incidence of germ cell 
cancer (10) have been related to exposure to endocrine disrupters present in the environment. 
Furthermore, several studies have reported increased levels of PCBs, 2,2-bis-(4-chlorophenyl)-
1,1,1-trichloroethane (DDT) and its metabolite 2,2-bis-(4-chlorophenyl)-1, 1-dichloroethylene 
(DDE) in breast cancer patients (11,12). However, recent epidemiological research does not 
support the hypothesis that women exposed to organochlorines such as PCBs, PCDDs, DDT 
and DDE have an increased breast cancer risk (13-15). 
Hydroxylated metabolites of the PHAHs (PHAH-OHs) may contribute to the afore-
mentioned effects. Hydroxylated metabolites of PCBs (PCB-OHs), PCDDs (PCDD-OHs) and 
PCDFs (PCDF-OHs) and other organohalogens have been identified in blood, bile and urine of 
animals treated with the parent compound, but also in wildlife samples as well as in 
environmentally exposed human subjects (16-20). For PCBs, it has been determined that 
hydroxylated metabolites are partially responsible for the endocrine-disrupting. effects. For 
instance, Crews et al. showed that different hydroxylated PCBs altered the sexual 
differentiation of the turtle (21). 
The mechanisms by which PHAH-OHs exert their estrogenic effects are still not 
understood. Binding affinities for the estrogen receptors ex and ~ are relatively low (22,23). It is 
possible, however, that PHAH-OHs exert part of their estrogenic effects by increasing the 
bioavailability of E2 through inhibition of E2 inactivation in target tissues. Sulfation by the 
specific estrogen sulfotransferase SULT1 E1 is an important pathway for the inactivation of E2 
(24). The human enzyme has a low 1<", value of 4 nM for E2, and is expressed in target tissues 
such as the endometrium, mammary gland and testis, as well as the liver (25-29). Recently, we 
demonstrated potent inhibition of SULT1 E1 by hydroxylated PCB metabolites (30), in particular 
compounds with two vicinal chlorine substituents around the hydroxyl group. Here, we have 
investigated the potency and type of inhibition of human SUL T1 E1 by other important 
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PHAH-OHs, such as PCDD-OHs, PCDF-OHs, and hydroxylated polybromodiphenylethers 
(PBDE-OHs), and halogenated bisphenol A (BPA) derivatives, as well as their sulfation by 
SULT1E1. To determine the relevance of our findings using recombinant enzyme, we also 
studied the inhibition of E2 sulfation by native SUL T1 E1 in human liver cytosol (29). 
Furthermore, we analyzed the sulfation of the various PHAH-OHs by SUL T1 E1 and SUL T1A 1, 
another phenol sulfotransferase abundantly expressed in human liver (31,32). 
Materials and Methods 
Materials 
E2 and 3'-phosphoadenosine-5'-phosphosulfate (PAPS) were obtained from Sigma 
(St. Louis, MO), ['HJE2 (3.22 MBq/nmol) was obtained from Amersham (Amersham, UK), and 
["SjPAPS (52.9 MBq/~mol) was purchased from NEN (Boston, MA). The sources of the various 
hydroxylated organohalogens have been described previously (23,33,34). Human SULT1E1 
(35) and SULT1A1 (31) were expressed in S. typhimurium as previously described (36,37). 
Cytosolic fractions were prepared and used without further purification (36,37). SUL T1 E1 
accounted for 5-7% of the cytosolic proteins. Similar results were obtained using recombinant 
SUL T1 E1 expressed in E. coli and purified as previously described (38). Normal human liver 
was obtained at surgical resection of liver tumors, and cytosol was prepared as previously 
described (39). Approval was obtained from the Medical Ethical Committee of the Erasmus 
University Medical Center. 
Estrogen sulfotransferase assay 
Estrogen sulfotransferase activity was analyzed by measuring the formation of water-soluble 
fHJE2 sulfate after incubation of 1 nM ['HJE2 for 30 min at 37 C with recombinant SULT1 E1 
(0.1 ~g total cytosolic protein/ml) in the presence or absence (blanks) of 50 ~M of the cofactor 
PAPS in 0.2 ml 0.1 M sodium phosphate (pH 7.2), 2 mM EDTA and 1 mM dithiothreitoi. The 
reactions were stopped by addition of 2 ml ice-cold water, and unreacted ['HJE2 was removed 
by extraction with 2 ml dichloromethane. Sulfate formation was quantified by liquid scintillation 
counting of 1 ml of the aqueous phase. Enzymatic sulfation was corrected for background 
radioactivity estimated in the blanks. Inhibition of E2 sulfation by PHAH-OHs was assessed by 
addition of 0.01 nM-1 0 ~M of these compounds to the reaction mixtures. Kinetic parameters for 
E2 sulfation were determined by Lineweaver-Burk analysis (40) of the sulfation of varying 
substrate concentrations. Apparent K, values for inhibitors were calculated from the change in 
slope of the Lineweaver-Burk plot in the presence of a fixed inhibitor concentration (40). 
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Sulfation of PHAH-OHs 
The above assay of estrogen sulfotransferase activity is based on the sulfation of limited 
concentrations of radioactive E2 by excess unlabeled PAPS. Since radioactive PHAH-OHs are 
not available, their sulfation was analyzed in comparison with E2 by determining the transfer of 
"SO; from f'S]PAPS to an excess of unlabeled substrate. Sulfation of PHAH-OHs by 
SULT1E1 was compared with their sulfation by the human phenol sulfotransferase SULT1A1. 
Assay mixtures contained 1 ~M PHAH-OH or E2, 0.3 ~M ["S]PAPS and 15 ~g (recombinant 
SULT1E1) or 100 ~g (recombinant SULT1A1) of total cytosolic proteinlml in a total volume of 
150 ~I 10 mM potassium phosphate (pH 7.4), and were incubated for 30 min at 37 C. The 
formation of sulfated products was analyzed using the BaSO, precipitation method of Foldes 
and Meek (41) as well as by HPLC. In the former method, un reacted ["SjPAPS and protein 
were precipitated by successive addition of 200 ~I 0.1 M barium acetate, 200 ~I 0.1 M barium 
hydroxide, and 200 ~I 0.1 M zinc sulfate. The presumably soluble sulfated products were 
quantified by liquid scintillation counting of 500 IJI of the supernatant Sulfation was corrected 
for background radioactivity determined in blanks without substrate. For HPLC analysis, the 
reactions were stopped by the addition of 150 ~I ice-cold methanol. After centrifugation, 1 00 ~I 
of the supernatant were injected onto a 4.6 x 250 mm Symmetry C18 column connected to an 
Alliance HPLC system (Waters Chromatography BV, Etten-Leur, The Netherlands), and eluted 
with a gradient of acetonitrile in 50 mM triethyl ammonium acetate (pH 6.8) at a flow of 1.0 
mllmin. The proportion of acetonitrile was increased linearly from 35% to 65% in 15 min and 
further to 90% in an additional 10 min. The radioactivity in the eluate was determined using a 
Radiomatic A-500 flow scintillation detector (Packard, Meriden, CT). 
Results and Discussion 
Structure-activity relationship of SULT1 E1 inhibition by PHAH-OHs 
We previously showed that various PCB-OHs potently inhibit E2 sulfation by human 
SULT1E1 (30). This finding suggested that endocrine-disrupting chemicals may act by 
increasing the bioavailability of hormones through inhibition of hormone-conjugating enzymes in 
target tissues (30,42). In this study we tested the effects of 0.01 nM-1 0 ~M of different classes 
of PHAH-OHs on the sulfation of 1 nM E2 by SUL T1 E1. Figure 1 presents the core structures of 
the tested compounds, and their exact structural formulas are listed in Table 1. Figure 2 shows 
the concentration-dependent inhibition of SULT1E1 activity by subsets of the various types of 
PHAH-OHs, i.e. PCOO-OH (Fig. 2A), PCOF-OH (Fig. 2B), PBOE-OH (Fig. 2C), and BPA 
(Fig. 20) derivatives. From these concentration-inhibition curves the concentrations causing 
114 
Inhibition of E2 sultation by PHAH-OHs 
1 9 
2~O~8 
3~o~Jl 
HO 4 , 
PCDD-OH 
5 6 6' 5' 
HO' rE{ rOH 
3 2 2' 3' 
BPA 
Fig. 1. Core structures of hydroxylated polychlorinated dibenzo~p-dioxjns (PCDD-OH), 
polychlorinated dibenzofurans (PCDF-OH), polyhalogenated diphenylethers (PHDE-OH) 
and bisphenoJ A (SPA). The position of the hydroxyl group varies between the different 
PHAH-OHs. Halogen substituents are not indicated. 
50% inhibition (IC" values) were determined. Table 1 presents the IC" values and relative 
potencies compared to the cognate substrate E2 for all compounds tested. 
Figure 2A shows the results with PCDD-OHs having the hydroxyl group in position 2, and 
the same 7,8-dichloro substitution pattern in the nonphenolic ring. Increasing potencies were 
observed as the number of chlorine substituents surrounding the hydroxyl group increased from 
o to 2, with mean IC" values of 300 nM for 2-0H-7,8-DiCDD, 30 nM for 2-0H-3,7,8-TrCDD and 
4 nM for 2-0H-1,3,7,8-TeCDD (Table 1). Figure 2B presents the concentration-inhibition 
relationships for PCDF-OHs with the hydroxyl group in the 2 or 3 position, para or meta to the 
furan oxygen, respectively. Again, the potency increased with increasing number of chlorine 
substituents adjacent to the hydroxyl group. Furthermore, 3-0H-PCDFs appeared to be slightly 
more potent inhibitors than 2-0H-PCDFs possessing comparable chlorine substitution patterns. 
Of all the PCDF-OHs tested, 3-0H-2,4,7,8,9-PeCDF was the most potent inhibitor of E2 
sulfation. With a mean IC" value of as low as 0.18 nM this compound has a >30-fold higher 
affinity for SULT1E1 than the natural substrate E2 (Table 1). As demonstrated in Fig. 2C, all 
PBDE-OHs tested were relatively weak inhibitors of E2 sulfation by SULT1 E1, with IC" values 
>200 nM (Table 1). Also, the one hydroxylated, polychlorodiphenylether tested, 2-0H-4,2',4'-
TrCDE, only inhibited SULT1E1 activity at micromolar concentrations (Table 1). BPA did not 
affect E2 sulfation at concentrations <1 ~M, whereas its derivatives having halogens at all 
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positions vicinal to the two hydroxyl groups, 3,5,3',5'-TeCBPA and 3,5,3',5'-TeBBPA, were 
relatively potent inhibitors, with mean IC" values of 40 and 20 nM, respectively (Fig. 2D, 
Table 1). 
Table 1. Potency 01 inhibITion of human SUL T1 E1 activity by PHAH-OHs 
Compound Code IC", (nM) Relative 
potency 
E2 3.8 - 7.1 
2-hydroxy-7,8~dichlorodibenzo-p-dioxin 2-0H-7,8-DiCDD 200 - 390 0.02 
2-hydroxy-3,7,8-trichlorodibenzo-p-dioxin 2-0H-3,7,8-TrCDD 28 - 40 0.17 
2-hydroxy-1 ,3,7 ,8-tetrachlorodibenzo-p-dioxin 2-0H-1 ,3,7,8-TeCDD 2.4 - 6.1 1.4 
4-hydroxy-1 ,3,6,7 -tetrachlorodibenzoluran 4-0H-1,3,6,7-TeCDF 6.6 - 6.7 0.S4 
3-hydroxy-2, 6, 7, S-tetrach lorodibenzoluran 3-0H-2,6,7,S-TeCDF 5.6 - 9.1 0.76 
3-hydroxy-2, 4, 7, 8-tetrachlorodibenzofuran 3-0H-2,4,7,S-TeCDF 0.68 - 2.2 4.0 
3-hydroxy-2,4,7,S,9-pentachlorodibenzofuran 3-0H-2,4,7,8,9-PeCDF 0.16 - 0.20 31 
2-hydroxy-7,8-dichlorodibenzoluran 2-0H-7,8-DiCDF 230 - 560 0.02 
2-hydroxy-6,7,8-trichlorodibenzofuran 2-0H-6,7,8-TrCDF 350 - 800 0.01 
2-hydroxy-1 ,3,7,8-tetrachlorodibenzoluran 2-0H-1,3,7,8-TeCDF 5.6 - 6.2 0.97 
1-hyd roxy-2,4,7, 8-tetrach lorodibenzofuran 1-0H-2,4,7,8-TeCDF 240 - 280 0.02 
4-hydroxy-2',3,4',5,6'-pentabromodiphenylether 4-0H-3,5,2',4',6'-PeBDE 200 - 240 0.03 
4-hydroxy-2',3,4',6'-tetrabromodiphenylether 4-0H-3,2',4',6'-TeBDE >1000 <0.01 
4-hydroxy-2',4',6'-tribromodiphenylether 4-0H-2',4',6'-TrBDE 7S0 - >1000 <0.01 
2-hydroxy-2',4,4'-trichlorodiphenylether 2-0H-4,2',4'-TrCDE 850 - >1000 <0.01 
4,4'-isopropylidenediphenol (bisphenol A) BPA >10000 <0.001 
3,3',5,5'-tetrachlorobisphenol A 3,5,3',5'-TeCBPA 29 - 53 0.15 
3,3',5,5'-tetrabromobisphenol A 3,5,3',5'-TeBBPA 12 - 33 0.30 
leso values are presented as the range of values from 2-4 experiments. 
Relative potencies are calculated as ratio of the ICso value of E2 over that of inhibitor. 
These results demonstrate that, in all classes of PHAH-OHs tested, those with divicinal 
halogen substituents around the OH group are the most potent inhibitors of E2 sultation by 
SULT1 E1, which is in agreement with the structure-activity relationship found for SULT1 E1 
inhibition by single-ring halogenated phenols and hydroxylated PCBs (30). A possible 
explanation for the increase in potency by vicinal halogen substitutions is the increased 
dissociation of the OH group. The potency of inhibitors with this substitution pattern decreases 
in the order PCDF-OH > PCDD-OH > BPA > PBDE-OH derivatives. The planar structures of 
PCDD-OHs and PCDF-OHs versus the non-planar structures of BPAs and PBDE-OHs may 
play a role in this, since the patterns for inhibition of SUL T1 E1 by PCB-OHs suggested 
preferred binding of coplanar compounds to the enzyme (30). This finding fits with the primarily 
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planar structure of the natural ligand E2. Recently, the crystal structure of the mouse estrogen 
sulfotransferase has been elucidated (43). Mouse and human SULT1E1 show 77% amino acid 
sequence identity; both orthologous enzymes have K", values in the nanomolar range (25,44). 
The modeling of hydroxylated PHAHs in E2 binding sites of mouse SULT1E1, or human 
SUL T1 E1, when its crystal structure also becomes available, should further our understanding 
of the structural requirements for inhibition of SUL T1 E1. 
A 
~'::t.~~ ~ I i :: \\\ \ ::: ::::::. ~ 2: t ~~ I 2~H·1378 
0.1 10 100 1000 
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-.- 2~OH-7,8 
-0- 2.0H-6,7,8 
-oIt.- 2-0H-1 ,3,7,8 
-~- 3->OH-2,5,7,8 
-e- 3-0H-2,4,7,8 
-0- 3-0H-2,4,7,8,9 
Fig. 2. Inhibition of E2 sulfation by recombinant human SULT1E1 by (A) 0.1-1000 nM PCOD-OHs, (8) 0.01-
1000 nM PCOF·OHs. (C) 1·1000 nM PSOE·OHs, or (0) 1-10000 nM SPA or halogenated SPA. Reaction 
conditions: 1 nM fH]E2, 0.1 1-19 of total cytoso!ic protein/ml, 50 IJM PAPS, and 30 min incubation. Results are the 
means of 24 experiments; the coefficient of variation was Jess than 20 %. 
Regarding the varying potencies of the different groups of (hydroxylated) PHAHs, it should 
be noted that levels of exposure are also different for the various PHAHs. The plasticizer BPA is 
commonly used in consumer products. Microgram amounts were found in the liquid from 
vegetable cans with plastic linings; TBBPA and TCBPA are high production volume chemicals 
which are widely used in consumer electronics and many other products as flame retardants 
(45). A mean total PBDE level of 5.4 pmol/g lipid weight has been measured in human serum 
(46). Koistinen et a/. found that PCDE levels in human adipose tissue range between 2 and 8 
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nglg lipid weight; concentrations of PCDD and PCDF congeners in the same human samples 
varied from <2 to 7700 pglg lipid weight (47). 
Kinetics of SUL T1 £1 inhibition by PHAH-OHs 
The type of inhibition of E2 sulfation by the different PHAH-OHs was studied by 
Lineweaver-Burk analysis (40) (Fig. 3). Figure 3A shows the double-reciprocal plots of the 
sulfation rate versus the E2 concentration in the presence or absence of a fixed concentration 
of different PCDD-OHs and PCDF-OHs. Depending on the structure, different types of inhibition 
were observed. Addition of 2-0H-7,8-DiCDD or 2-0H-7,8-DiCDF changed the slope but had 
little effect on the y-axis intercept of these plots, indicative of competitive inhibition. However, 
2-0H-1,3,7,8-TeCDD and 3-0H-2,4,7,8,9-PeCDF affected both the slope and the y-axis 
intercept, and the plots converged at about the same point on the x-axis, indicating primarily 
noncompetitive inhibition by these potent inhibitors. Figure 3B shows the Lineweaver-Burk 
analysis of the effects of BPA, 3,5,3',5'-TeCBPA and 4-0H-3,5,2',4',6'-PeBDE, indicating that 
they inhibit E2 sulfation primarily in a noncompetitive manner. The K, values derived from these 
plots are in good agreement with the corresponding IC" values for the different inhibitors, 
amounting to 60 nM for 2-0H-7,8-DiCDD, 2 nM for 2-0H-1,3,7,8-TeCDD, 270 nM for 2-0H-7,8-
DiCDF and 0.15 nM for 3-0H-2,4,7,8,9-PeCDF, and to 150 nM for 4-0H-3,5,2',4',6'-PeBDPE, 
14 ~M for BPA and 35 nM for 3,5,3',5'-TeCBPA. 
SULT1 E1 is known to have two substrate-binding sites, the active site as well as an 
allosteric site (24,48). Binding of E2 to the latter site is thought to be largely responsible for the 
phenomenon of substrate inhibition that is observed at increasing E2 concentrations. The 
primarily competitive or noncompetitive nature by which the different PHAH-OHs inhibit the 
sulfation of E2 by SUL T1 E1 may thus be explained by their preferential affinity for the active or 
allosteric site, respectively. 
Sulfation of PHAH-OHs by SUL T1 £1 and SUL T1A 1 
Binding of PHAH-OHs to the active site of SULT1E1 is likely to result in their sulfation, 
which was tested directly by incubating 1 ~M of the various compounds with 0.3 ~M f'S]PAPS 
and SULT1 E1. These experiments also included different PCB-OHs that have previously been 
shown to inhibit E2 sulfation by SULT1 E1 (30). Product formation was analyzed by the method 
of Foldes and Meek (41) which involves the precipitation of remaining ["SjPAPS with BaSO" 
presumably leaving the radioactive sulfated products in solution. The results of this established 
procedure were compared with a method developed in our laboratory based on the separation 
of labeled PAPS and sulfated products by HPLC. Figure 4A shows the HPLC analysis of the 
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Fig. 3. Lineweaver-Burk analysis of the inhibition of the sulfation of 1-20 nM E2 by O.11lg/mJ recombinant human 
SULT1E1 by (A) 250 nM 2-OH-7,8-DiCDD, 4 nM 2-0H-1,3,7,8-TeCDD, 500 nM 2-OH-7,8-DiCDF or 0.2 nM 3-0H-
2,4,7,8,9-PeCDF, or (B) 12 ~M BPA, 60 nM 3,5,3',5'-TeCBPA or 200 nM 4-OH-3,5,2',4',6'-PeBDE. Results are the 
means of 2-4 experiments. 
sulfation of 2-0H-7,8-DiCDF as a representative example, demonstrating the clear separation 
between remaining ["SjPAPS and "S-Iabeled sulfated product Figure 4B shows that there was 
reasonable agreement between the results of the two methods regarding the sulfation of most 
compounds, although in several instances the BaSO, precipitation method significantly 
underestimated the formation of sulfated products in comparison with HPLC analysis. This was 
especially the case with sulfated compounds that were strongly retarded on the C18 column, 
suggesting that relatively nonpolar sulfates are partially lost in the BaSO, precipitation method. 
Table 2 shows the results of the HPLC measurements of the sulfation of the various 
PHAH-OHs by SUL T1 E1 in comparison with the sulfation of these compounds by the human 
phenol sulfotransferase SULT1A1, Estrogenic chemicals such as alkylphenols, diethylstilbestrol 
and BPA have recently been shown to be substrates for human SULT1A1 (49,50), We found 
that most PHAH-OHs tested in this study were sulfated by SULT1E1 as well as by SULT1A1 
(Table 2). It should be noted, however, that these incubations had to be performed with a 
limited PAPS concentration and excess substrate, which is very different from the conditions 
used to test the effects of PHAH-OHs on the sulfation of E2 by SULT1 E1. Sulfation of the 
different PHAH-OHs was tested at a single substrate concentration of 1 ~M, although the IC" 
and K, values for their inhibition of E2 sulfation ranged from <1 nM to >10 ~M, Therefore, the 
findings presented in Table 2 are not representative for the rate of sulfation of the different 
PHAH-OHs by SUL T1 E1 under the conditions where they were tested as inhibitors of E2 
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Fig. 4. (A) HPLC analysis of the sultation of 2-0H-2,7,8-TeCDF by SULT1 E1 using ["SJPAPS. 
(8) Sulfation of PHAH-OHs by SULT1 E1 measured by the BaS04 precipitation method and by 
HPLC analysis. Reaction conditions: 1 ).1M substrate, 15 (SULT1E1) or 100 (SULT1A1) 1-19 of 
total cytosolic protein/ml, 0.3 IJM fSSJPAPS, 30 min incubation. Results are the means of 
triplicate determinations from a representative experiment 
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Table 2. Sulfation of PHAH-OHs by human SULT1E1 and SULT1A1 
Compound Sulfation 
4-OH-3,3',4'-TrCB 
4-0H-2.3,S,3',4'-PeCB 
4-0H-3,2',3' ,4' .S'-PeCB 
3-0H-4,S,3',4'-TeCB 
2-0H-4,S,3',4'-TeCB 
4,4'-(OH),-3,S,3',S'-TeCB 
2-0H-7,S-DiCDD 
2-0H-3,7,8-TrCDD 
2-0H-1,3,7,S-TeCDD 
4-0H-1 ,3,6.7 -TeCDF 
3-0H-2,6,7.8-TeCDF 
3-0H-2,4,7,S-TeCDF 
3-0H-2,4,7,S,9-PeCDF 
2-0H-7,S-DiCDF 
2-0H-6,7,8-TrCDF 
2-0H-1.3,7,S-TeCDF 
1-0H-2,4,7,S-TeCDF 
4-0H-2',4',6'-TrBDE 
4-0H-3,2',4',6'-TeBDE 
4-0H-3,S,2',.f,6'-PeBDE 
2-0H-4,2',4'-TrCDE 
BPA 
3,S,3',S'-TeCBPA 
3,S,3',S'-TeBBPA 
(% of PAPS added) 
SULT1E1 SULT1A1 
9.9 ± 1.0 
0.6 ± O.S 
17.6 ± 2.0 
33.4 ± 3.3 
19.4 ± 2.S 
1.0 ± 1.1 
70.6 ± 2.7 
22.7 ± 9.5 
2S.2 ± 3.5 
6.9 ± 0.3 
7.9±1.1 
2.5 ± 0.2 
1.0 ± 0.0 
S2.4±1.7 
S1.1 ± 3.1 
7.0 ± 1.4 
0.0 ± 0.0 
2.5 ± 1.4 
43.1±6.1 
13.3± 1.9 
S9.2 ± 5.1 
23.6 ± 2.9 
7.7 ± 2.S 
S.S ± o.S 
19.3± 1.S 
0.7 ± 1.0 
6.6 ± 3.1 
10.5 ± 3.2 
19.0 ± 4.7 
1S.3 ± 2.S 
74.1 ± 10.1 
11.4 ± 1.4 
31.7 ± 6.9 
10.7 ± 1.4 
7.3 ± 4.7 
3.1 ± 1.1 
1.0 ± 0.3 
31.6 ± 4.4 
55.2 ± S.7 
3.3 ± 2.3 
24.S ± 3.4 
10.7 ± 0.9 
30.4 ± 6.2 
0.7 ± 0.7 
SO.5 ± 7.6 
62.0 ± 3.2 
26.2± 1.1 
1S.9 ± 0.7 
Data are presented as the means ± SO from 2-3 experiments. 
sulfation. Also, in view of the large variation in saturation of the low-Km SUL T1 E1 and the high-
K" SULT1A1 at 1 ~M of the various substrates, the data reported in Table 2 are not 
representative for the substrate preferences of these isoenzymes at lower, more relevant 
PHAH-OH concentrations. The in vivo significance of sulfation of hydroxylated PHAHs in PHAH 
metabolism remains to be established. 
Effects of PHAH-OHs on E2 sulfation by human liver cytosol 
We also studied the inhibition of E2 sulfation by various PHAH-OHs using human liver 
cytosol as a source of native human SULT1 E1. Figure 5 compares the effects of different 
PHAH-OHs (0.1 or 1 ~M) on E2 sulfation by SULT1 E1 and human liver cytosol, showing a 
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strong correlation between the inhibitions of the recombinant and native enzymes (r = 0.922). In 
general, human liver enzyme was less potently inhibited than recombinant human SUL T1 E1. 
Although SUL T1 E1 is the better enzyme for E2 sulfation, with a K", value of -4 nM, SULT1A1 
also catalyzes E2 sulfation, with a K", value of 2-5 ~M (51). The potencies of inhibition of 
SUL T1 E1 differ by orders of magnitude from those by which the different PHAH-OHs inhibit 
human SUL T1A 1 activity, which is characterized by apparent ~ values in the micromolar range 
(33). The non-linear relationship between the rates of E2 sulfation by recombinant SUL T1 E1 
and human liver cytosol in the presence of various PHAH-OHs may be explained by the 
presence also of SULT1A1 in human liver. However, at nanomolar concentrations, E2 is 
predominantly sulfated in human liver by SULT1E1 (29), suggesting that the non-linear 
relationship is not due to significant sulfation of E2 in human liver by SUL T1A 1. A more likely 
explanation is suggested by our findings that the PHAH-OHs are sulfated by hSULT1 E1 as well 
as by hSULT1A1. Therefore, compared to recombinant SULT1E1, larger amounts of the 
PHAH-OHs will be metabolized in human liver cytosol, decreasing their inhibitory effects on 
native SUL T1 E1. An additional explanation may be that, compared to recombinant SUL T1 E1, 
human liver cytosol contains more proteins to which PHAH-OHs bind, diminishing their 
availability for native SULT1 E1. 
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Fig. 5. Sulfation of E2 by human liver cytosol vs hSULT1E1 in the presence of different 
PHAH-OHs. Reaction conditions: 1 nM fHJEZ, 0.1 or 1 ~M PHAH-OH, 0.1 (SULT1E1) 
or 10 (human liver) !-I9 total cytosolic protein/ml, 50 IJM PAPS, and 30 min incubation. 
The PHAH-QHs tested were the PCDO-OHs and PCDF-OHs listed in Table 1 as well as 
12 different PC8-0Hs (compounds 5, 8, 10, 14, 16, 17,23,24,26,28, 31 and 32 from 
Ref, 30). Results are expressed as percentage of control E2 sulfation in the absence of 
inhibitor, and presented as the means of 2-4 experiments (SULT1 E1) or as the means of 
triplicate determinations from a representative experiment (human liver cytosol). 
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Concluding remarks 
In this study, we have demonstrated that E2 sulfation catalyzed by recombinant human 
SUL T1 E1 and by human liver sulfotransferase are both potently inhibited by different classes of 
PHAH-OHs, with IC" values for recombinant SULT1 E1 inhibition in the low- or even sub-
nanomolar range. The potent inhibitors 2-0H-3,7,S-TrCDD, 2-0H-1,3,7,S-TeCDD, 3-0H-
2,4,7,S-TeCDF and 3-0H-2,4,7,S,9-PeCDF, with IC" values of 34, 4.1, 1.4 and 0.1S nM, 
respectively, have been identified in mammalian species (20). The most potent inhibitors have 
an even higher affinity for human SULT1E1 than its cognate substrate E2 which has a K", value 
of 4 nM for the enzyme (25). Therefore, we hypothesize that part of the estrogenic activity of 
PHAHs is explained by an increase in E2 bioavailability through inhibition of human SULT1 E1 
by hydroxylated PHAH metabolites. Such a mechanism for the pseudo-estrogenic activity of 
PHAH-OHs is particularly relevant for estrogen-responsive tissues which express SULT1 E1, 
such as the endometrium, mammary gland and testis (26-2S). The effects of PHAH-OHs on the 
regulation of local estrogen levels in these tissues will depend on a variety of factors, such as 
the supply or local generation of the various PHAH metabolites, their potency in inhibiting 
SULT1E1, their rate of inactivation by SULT1E1 and other isoenzymes such as SULT1A1, their 
urinary or biliary excretion rates, and also on the reversal of the sulfation of E2 and the 
inhibitors by local estrogen sulfatase expression (52). 
PHAHs are known also to affect the thyroid hormone system. In laboratory animals, plasma 
T 4 is markedly decreased as a result of competitive binding of the hydroxylated metabolites to 
the plasma carrier transthyretin and induction of hepatic UDP-glucuronyltransferases by the 
PHAHs themselves (53). PHAH-OHs have also been reported to inhibit the in vitro deiodination 
of thyroid hormone by the type I iodothyronine deiodinase as well as the sulfation of the 
hormone by human SULT1A 1 (33). During human fetal development, sulfation is an important 
pathway of thyroid hormone inactivation (54). We have recently demonstrated that human 
SUL T1 E 1 also effiCiently catalyzes the sulfation of iodothyronines, among which the 
prohormone T4 and the active hormone T3 (25). Inhibition of SULT1 E1 may thus also have 
thyroid hormone-disrupting effects during fetal development. Further studies should determine 
to what extent estrogen and possibly thyroid hormone levels are disrupted by hydroxylated 
PHAHs through inhibition of estrogen sulfotransferase. 
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General discussion 
Ontogeny of iodothyronine sulfotransferases and deiodinases; 
importance of thyroid hormone sulfation during fetal development 
Thyroid hormone metabolism is one of the mechanisms regulating fetal thyroid status. To 
test the hypothesis that sulfation is an important reversible pathway of thyroid hormone 
inactivation during fetal development, we analyzed the expression of the various thyroid 
hormone metabolizing enzymes in different fetal rat tissues (Chapter 2). I n general, D3 activities 
were high in placenta and fetal brain, and highest D1 activities were found in the liver at late 
fetal stages, the D1 expression level just before birth being comparable to that of the adult liver. 
Also for sulfotransferase activities tissue-specific and development stage-dependent patterns 
were found, but sulfatase-catalyzed iodothyronine sulfate hydrolysis was negligible. These 
findings suggest, besides the important inner ring deiodination by D3, an additional role for 
sulfation in the inactivation of thyroid hormone during fetal development. Desulfation seems not 
to be important in thyroid hormone reactivation in the rat. In the human this situation may be 
different, since in human fetal serum and amniotic fiuid high concentrations of iodothyronine 
sulfates have been demonstrated (1-5), and besides considerable sulfotransferase activities 
also significant iodothyronine sulfatase activities were found in fetal human tissues such as the 
liver (6). 
So far, arylsulfatase C (ARSC, also called steroid sulfatase) is the only member of the 
arylsulfatase family known to catalyze iodothyronine sulfate hydrolysis (Chapter 4). Human 
ARSC is predominantly expressed in tissues such as placenta, liver and brain (7). In the 
placenta the enzyme is principally involved in estrogen biosynthesis (8). We characterized 
iodothyronine sulfatase activities of human ARSC and of human placenta and liver, and 
demonstrated that ARSC is the main sulfatase for iodothyronine sulfate hydrolysis in the 
placenta, whereas in the liver, at least in the adult, also other, still unidentified sulfatases are 
involved. 
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lodothyronine sulfation is catalyzed by various cytosolic phenol sulfotransferases, which are 
located in tissues such as liver, kidney, brain and intestine (9,10). In contrast to the human 
SULT1A isoenzymes, rat SULT1A1 does not catalyze the sulfation of iodothyronines (11). 
However, iodothyronines are sulfated by both rat SULT1 B1 and 1C1. Since expression of these 
isoenzymes is low before birth (12-14), whereas considerable iodothyronine sulfotransferase 
activities are found in fetal tissues such as the liver (Chapter 2), additional isoenzymes seem to 
be involved in iodothyronine sulfation in the fetal rat, which remain to be identified. Richard et 
al. studied the ontogeny of the human sulfotransferases hSULT1A1 and 1A3 (6). They found 
higher hSULT1A1 expression in the fetal than in the postnatal liver and lung. Also in the fetal 
human brain high hSULT1A1 expression was observed, which was localized in the choroid 
plexus (6). Highest hSULT1A3 expression was found in the liver early in development, 
decreasing in the late fetal and early neonatal period (6). The different tissues were also tested 
for 3,3'-T2 sulfation, and strong correlations between hSULT1A1 expression and 3,3'-T2 
sulfation were found, indicating that in these tissues hSULT1A1 is largely responsible for the 
sulfation of 3,3'-T2 (6). The ontogeny of other human phenolic sulfotransferases catalyzing 
iodothyronine sulfation remains to be investigated. 
In humans, all members of the phenol sulfotransferase family were found to catalyze the 
sulfation of iodothyronines (15, Chapters 5 and 6). For most of these enzymes 3,3'-T2 is by far 
the preferred iodothyronine substrate (i.e. 3,3'-T2»T3-rT3>T4). However, human SULT1E1 
equally prefers 3,3'-T2 and rT3 (i.e. 3,3'-T2-rT3>T3-T4). Biochemical characterization of the 
different sulfotransferases was usually done on crude cytosols of recombinant sulfotransferase-
expressing cells (Chapters 3, 5 and 6). When purified recombinant hSULT1A1, 1A3, 1B1 and 
1E1 are compared, the receptor-active T3 appears to be sulfated at similar rates by the different 
isoenzymes (Chapter 6: Fig. 2). Further kinetic analysis of purified enzymes, e.g. hSULT1C1, is 
necessary to elucidate their relative importance for iodothyronine sulfation. 
Although iodothyronines are metabolized importantly by hSUL T1 E1, it should be noted that 
the estrogens estrone (E1) and estradiol (E2) are clearly the preferred substrates for this 
isoenzyme, also called human estrogen sulfotransferase (hEST). Km values of iodothyronines 
are in the ~M range for the different iodothyronine sulfotransferases, including hSULT1 E1, the 
Km values of E1 and E2 for hSULT1 E1 are around 5 nM (Chapter 6). The higher ratio of 
sulfated vs free estrogens compared to iodothyronines also reflect this enzyme's preference for 
estrogens (16-18). Nevertheless, given the facile sulfation of iodothyronines by hSULT1E1, in 
addition to its principal role in reversible estrogen inactivation, a physiological role for the 
enzyme in thyroid hormone metabolism cannot be excluded. 
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Is the uterus important in thyroid hormone metabolism during fetal 
development? 
The high D3 activities in the placenta have been demonstrated to limit transplacental 
passage of maternal T4 and T3 to the fetus, and to contribute to the [ow T3 and high rT3 
concentrations during fetal life (19-21). [n addition to the placenta, the role of the uterus in the 
regulation of thyroid hormone bioactivity during fetal development is intriguing. Nothing is 
known about expression of D3 in the normal and pregnant human uterus, but it has recently 
been demonstrated that in the pregnant rat uterus expression of D3 is extremely high (22). 
During pregnancy, D3 is initially localized at the implantation site in uterine decidual tissue (E9) 
and later (after E12 and E13) in the single epithelial cell layer lining the uterine lumen (22). 
A[though SULT1 E1 expression in reproductive tissues of the pregnant rat is [ow to 
undetectable, SUL T1 E1 is highly expressed in pregnant mouse uterus, localized in the decidua 
basalis (23). SUL T1 E1 has also been observed in the human endometrium, where it is up-
regulated by progesterone (24,25). Therefore, besides the high D3 activity in placenta and fetal 
tissues and the iodothyronine su[fotransferase activity in fetal tissues (Chapter 2), also D3 and 
SULT1 E1 in the pregnant uterus may contribute to the [ow plasma T3 and high plasma rT3 and 
iodothyronine sulfate levels in the human fetus (Fig. 1). Possibly, the pregnant uterus protects 
the fetus from excessive thyroid hormone by catalyzing the reversible (SULT1E1) and 
irreversible (D3) inactivation of the hormone. However, in addition to placental transfer, a role 
for the uterus in the supply of thyroid hormone (su[fates) from mother to fetus, via the fetal 
membranes and the amniotic fluid, is not excluded. [t is remarkable that the products of thyroid 
hormone deiodination by D3, i.e. rT3 and 3,3'-T2, are also the preferred substrates for 
hSULT1E1, suggesting that T4 and T3 are metabolized in the uterus by successive 
deiodination and su[fation. Since rT3, but not T3, has profound and acute effects on the 
cytoskeleton in brain cells (26), it is possible that rT3 has an important function in fetal brain 
development. The production of rT3 sulfate by the uterus may thus be an important means to 
provide the developing brain with (reversib[y inactivated) rT3, from which active rT3 can be 
formed by action of su[fatases expressed in a tissue-specific and development stage-
dependent manner (27). Further studies are needed to explore the role and expression of 
hSULT1 E1 and D3 in the human endometrium throughout gestation. 
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Fig.1. Human fetal serum thyroid hormone levels during gestation (courtesy of Prof.dr. R. Hume). 
Importance of type III iodothyronine deiodinase (D3) during fetal 
development 
Apart from sulfation, type III iodothyronine deiodinase (03) obviously plays an essential role 
in the regulation of fetal thyroid hormone status. As mentioned before, 03 activity is high in 
placenta and pregnant uterus, and although no significant 03 activity was found in rat fetal liver 
(Chapter 2), considerable 03 activity is found in human fetal liver (28). Figure 1 shows human 
fetal serum levels of FT4, T3, rT3 and T4S throughout gestation. FT4 levels steadily increase 
during fetal development, until similar levels are reached as in the matemal circulation at the 
end of gestation. Serum T3 level is very low in the human fetus compared to the adult (mean 
normal adult level -2 nM), whereas rT3 and T4S levels are >10-fold higher than in the adult 
(mean normal adult levels -0.25 nM and <100 pM, respectively). In contrast to normal adults, in 
the fetus the rT3 level is higher than the level of T3. This combination of high rT3 versus low T3 
has long been considered to be due not only to the high placental 03 activity, but also to a low 
fetal hepatic 01 activity. Indeed, hepatic 01 activity starts to be expressed in late gestational 
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stages in the rat (Chapter 2). However, considerable 01 activity (i.e. about 25% of that in the 
normal adult) is already expressed in the human fetal liver after the first trimester (28). 
Therefore, in addition to the high 03 activity in placenta and pregnant uterus it is rather the high 
hepatic 03 activity than a low hepatiC 01 activity that may contribute to the low T3 and the high 
rT3 levels in the human fetal serum. In agreement with this, studies in the embryonic chicken 
have clearly established a negative correlation between liver 03 expression and serum T3 
levels (27,29). 
Future studies on iodothyronine deiodinase 03 during fetal development 
Future studies are addressed to delineating the role of 03 in the regulation of thyroid 
hormone bioavailability in the fetus. We will stUdy the ontogeny of 03 activity, protein and 
mRNA expression in the pregnant uterus, placenta and fetal tissues, such as the fetal brain. 
Furthermore, we will use human brain, endometrium and placenta cell lines to study the 
mechanisms of regulation of 03 expression, and the functionality and tissue-specificity of 
potential regulatory factors. In vitro and in vivo studies show tissue-specific regulation of 03 
expression by different factors. E.g., 03 activity is induced in cultured astroglial cells and 
preadipocytes by growth factors, hormones as T3 and retinoids as well as the second 
messenger cAMP (30-32). Activation of protein kinase C by the phorbol ester TPA also induces 
03 activity in astroglial cells (30). In vivo studies demonstrated that in rat brain and skin 03 
activity is under positive control of thyroid state (33,34), whereas 03 activity in rat placenta is 
unaffected by hyper- and hypothyroidism (35). In the embryonic chicken an acute 
pretranslational down-regulation of 03 by dexamethasone and growth hormone was 
demonstrated in the liver, but not in the brain (27,29). 
As, at least in the rat, uterine 03 is up-regulated during pregnancy (22), estrogens andlor 
progestins may stimulate uterine 03 expression. Although expression levels of 03 in the normal 
or pregnant human uterus are unknown, we have recently observed high and regulated 03 
expression in ECC-1 human endometrial carcinoma cells (36). 
Recently, the mouse 03 gene has been cloned and characterized (37). The availability of 
the human 03 (h03) gene sequence (BAC clones R-1029J19 and R-796G6) allows us to clone 
the putative h03 gene promoter, and study its regulation. The in vitro and in vivo 
characterization of the h03 promoter region, and the identification of functional transcription 
factor-binding sites therein are essential for understanding the tissue-specific regulation of 03 
expression. Again, this is subject of my future research. 
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Does the potent inhibition of estrogen sulfotransferase by PHAH-OHs in 
vitro contribute to PHAH-related endocrine disruption in vivo? 
Polyhalogenated aromatic hydrocarbons (PHAHs) are environmental chemicals which are 
well known for their endocrine disrupting effects. Most PHAHs and their hydroxylated 
metabolites (PHAH-OHs) show low affinity for both estrogen receptors a and ~ (38-40). In the 
studies on the effects of hydroxylated PHAH metabolites on hSULT1 E1 reported in the 
chapters 7 and 8 it was demonstrated that the estrogen sulfotransferase hSULT1 E1 is very 
potently inhibited by various hydroxylated PHAH metabolites in vitro (Chapters 7 and 8). This 
inhibition of hSULT1 E1 by PHAH-OHs forms an altemative mechanism explaining the 
estrogenic effects of PHAHs, based on the increase of receptor-active estrogens, rather than 
on agonistic estrogen receptor binding (Fig. 2). 
1E1 
PHAH-OH 
z;e 
E2 -7 E2S 
~ 
binding of E2 to ER 
~ 
estrogenic effects 
Fig. 2. Putative mechanism explaining 
pseudo-estrogenic effects of hydroxylated 
PHAH metabolites. 
We also studied the effects of various PHAH-OHs on E2 sulfation by endogenous EST-
expressing Ishikawa endometrial carcinoma cells. E2 sulfation was inhibited, but the inhibition 
was >1 DO-fold less potent than the inhibition of the recombinant hSULT1 E1. This difference in 
potency of the compounds in the different in vitro systems may be explained by the only partial 
cellular uptake of the various compounds. In chapter 8 it was shown that hSUL T1A 1 and 1 E1 
both catalyze the sulfation of different hydroxylated PHAHs. The metabolism of the compounds 
by different enzymes, such as hSULT1A1 and 1E1, present in the Ishikawa cells, forms an 
additional explanation for the difference in potencies. 
We believe that at least part of the estrogenic effects of hydroxylated PHAH metabolites are 
due to the increase of E2 bioavailability by inhibition of hSULT1 E1, also because the PHAH-
OHs have very low affinity for the estrogen receptors (38-40). Still, this a~emative mechanism 
remains to be tested in in vitro and in vivo model systems. In preliminary experiments we did 
not detect E2-potentiating effects of different PHAH-OHs on alkaline phosphatase activity in the 
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Ishikawa cell system (unpublished results). However, to increase the sensitivity of the E2 
response, potential pseudo-estrogenic effects could also be tested in Ishikawa cells 
cotransfected with an hSULT1E1-expression vector and an estrogen response element (ERE)-
reporter construct. Furthermore, Falany et al. developed a mouse xenograft system in which 
hSULT1 E1-expressing and control MCF-7 tumors are grown in athymic mice. They will use this 
system to study the in vivo significance of hSULT1E1-inhibition by PHAH-OHs. Tumor growth 
will be determined of hSULT1E1-expressing and control MCF-7 tumors, grown in the athymic 
nude mice exposed to E2 and PHAH-OHs (C.N. Falany, personal communication). 
Apart from disrupting the estrogen system, PHAHs disrupt the thyroid hormone system in 
several ways (Chapter 1). As we have demonstrated that hSUL T1 E1 also efficiently sulfates 
iodothyronines, inhibition of hSULT1 E1 by hydroxylated PHAHs might also have thyroid 
hormone disrupting effects. Further in vivo experiments should determine to what extent 
estrogen and possibly also thyroid hormone levels are disrupted by inhibition of hSULT1 E1. 
The nitrofen model of congenital diaphragmatic hernia 
The administration of the herbicide nitrofen to pregnant rats induces congenital 
diaphragmatic hernia in the offspring. Recent findings suggest that thyroid hormone as well as 
vitamin A-disrupting mechanisms contribute to the impaired lung development associated with 
nitrofen-induced congenital diaphragmatic hernia. Serum thyroid hormone levels are reduced in 
fetuses of nitrofen-exposed pregnant rats (41,42), and the congenital diaphragmatic hernia-
inducing effect of nitrofen is counteracted by administration of thyroid hormone or vitamin A 
(42,43). In addition, in the Hyt/Hyt mice, which are hypothyroid due to a TSH-receptor mutation, 
fetal and neonatal lung maturation is delayed (44). Vitamin A deprivation during development 
also leads to impaired lung growth (45), and compound retinoic acid receptor (RAR) mutant 
mice show various defects characteristic for fetal vitamin A deprivation, including congenital 
diaphragmatic hernia (46). Moreover, 50% reduced retinol and retinol-binding protein (RBP) 
levels are found in human babies with congenital diaphragmatic hernia (47). 
As was described before, PHAHs and their hydroxylated metabolites interfere with thyroid 
hormone-binding proteins such as the thyroid hormone receptors, the sulfotransferases 
SULT1A1 and 1 E1, type I deiodinase, and the plasma transport protein transthyretin (TTR) (48-
53, Chapters 7 and 8). Furthermore, PHAHs are known to induce uridine diphosphate (UDP)-
glucuronyltransferase expression in tissues such as the liver, thus dramatically increasing the 
hepatic clearance of thyroid hormone and retinol (48). Regarding thyroid hormone plasma 
transport, Meerts et at. found that especially polybrominated diphenylethers (PBDEs) potently 
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inhibit the binding of T 4 to TIR. Various PBOEs have an even higher affinity for TIR than T 4 
(53). Also vitamin A transport is likely to be affected by competitive binding of PHAH-OHs to 
TIR, as the retinol-RBP complex binds to a specific site on TIR, and retinoic acid binds with a 
relatively high affinity to the T4 binding site of TIR (54). As a special po[yha[ogenated 
dipheny[ether nitrofen or its metabolites possibly interfere with the thyroid hormone and vitamin 
A system in a manner similar to other PHAH(-OHs). Because of the strong indications that in 
the nitrofen-induced congenital diaphragmatic hernia model disruption of the thyroid hormone 
and vitamin A system contribute to abnormal fetal lung development, future research on the 
etiology of congenital diaphragmatic hernia should address putative effects of hydroxy[ated 
nitrofen metabolites on the various thyroid hormone and vitamin A-regu[ating mechanisms. 
Concluding remarks 
Given the detrimental effects of exposure to insufficient or excessive levels of thyroid 
hormone during fetal development, strictly regulated thyroid hormone [evels during fetal 
development are of crucial importance. The ontogenic patterns of deiodinase, su[fotransferase 
and sulfatase expression suggest important roles for 03-cata[yzed inner ring deiodination and 
for thyroid hormone su[fation in the regulation of thyroid hormone bioactivity during fetal 
development (6,28, Chapter 2). Whereas 03 prevents the exposure of fetal tissues to excessive 
T3, in the human fetus inactivation of thyroid hormone by su[fation seems reversible (6, 
Chapter 4). 
[n addition to the placenta, the uterus may also be important for the supply of maternal 
thyroid hormone to the fetus, since the iodothyronine deiodinase 03 and the estrogen and 
iodothyronine su[fotransferase hSULT1 E1 are expressed in the uterus (Chapter 6, 22,23,25), 
and thyroid hormone su[fation and inner ring deiodination activities are high in the pregnant 
uterus (22,55). This putative role for the uterus in the regulation of fetal thyroid hormone status 
needs to be further investigated. 
The potent inhibition of hSULT1E1-cata[yzed thyroid hormone and estrogen su[fation by 
hydroxy[ated po[yha[ogenated aromatic hydrocarbons such as PCB-OHs is intriguing (Chapters 
7 and 8). These findings suggest that PHAH-OHs induce indirect estrogenic effects, by 
increasing estradiol bioavailability in target tissues. Because of the possible function of this 
enzyrne in thyroid hormone metabolism, inhibition of hSULT1 E1 by these environmental 
chemicals may also disrupt thyroid hormone levels during fetal development. This potential, 
novel mode of action of endocrine-disrupting chemicals needs to be investigated in in vivo 
model systems. 
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Summary 
Strictly regulated thyroid hormone levels are required for normal organ development; a 
disrupted fetal thyroid hormone status may lead to congenital anomalies. Thyroid hormone 
metabolism is a key process in the regulation of thyroid hormone homeostasis. The 
prohormone thyroxine (T4), which is the major secretory product of the thyroid gland, is 
deiodinated by type I deiodinase (D1) to the receptor-active 3,3',5-triiodothyronine (T3), and by 
type III deiodinase (D3) to the metabolite reverse T3 (rT3). T3 and rT3 are further metabolized 
by D1 and D3 to 3,3'-diiodothyronine (T2). Apart from deiodination, iodothyronines are 
metabolized by glucuronidation or sulfation of the phenolic hydroxyl group. Whereas 
iodothyronine-glucuronidating uridine diphosphate glucuronyltransferases are not expressed 
before birth, enzymes catalyzing iodothyronine sulfation (sulfotransferases) are present in fetal 
tissues such as liver, kidney and brain. We hypothesized that during fetal development sulfation 
is a reversible thyroid hormone-inactivation pathway. lodothyronine sulfates might serve as a 
reservoir of inactive thyroid hormone, from which active T3 is formed by sulfatases in a tissue-
specific and development stage-dependent manner. 
First, the importance of thyroid hormone sulfation during fetal development was 
investigated. Different developmental profiles of deiodinase and sulfotransferase activities were 
found in the various tissues. However, no sutfatase activities were detected in rat tissues, in 
contrast to fetal human tissues such as the liver, where significant sulfatase activities were 
found. Furthermore, unlike the elevated iodothyronine sulfate levels in fetal human serum, 
iodothyronine sulfate levels in fetal rat serum at gestational age E20 were very low. We 
concluded from these studies that reversible iodothyronine sulfation is not important in the fetal 
rat (Chapter 2). 
The characterization of sulfatase activities in human and rat liver and placenta is described 
in chapter 4. In general, sulfatase activities in adult human liver and placenta were higher than 
in adult rat liver and placenta. Human steroid sulfatase arylsulfatase C (ARSC) is the only 
arylsulfatase known to catalyze iodothyronine sulfate hydrolysis. By comparing sulfatase 
activities in human liver and placenta with activities in homogenates of ARSC-expressing V79 
cells, it was demonstrated that ARSC is the main enzyme in iodothyronine sulfate hydrolysis in 
human placenta; in the liver additional sulfatases seem to be involved. 
To further assess the importance of thyroid hormone sulfation, we identified and 
characterized the sulfotransferases involved in iodothyronine sulfation. Whereas the rat phenol 
sulfotransferases rSULT1A1 and 1E1 and hydroxysteroid sulfotransferases rSULT2A1, 2A2 
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and 2A3 failed to catalyze iodothyronine sulfation, the phenol sulfotransferases rSULT1B1 and 
1 C1 catalyzed sulfation of iodothyronines in the order 3,3'-T2 »T3 - rT3 > T4 (Chapter 3). We 
compared Km values and substrate specificities for rat liver, kidney and brain cytosol with those 
for rSULT1B1 and 1C1, and found that rSULT1B1 and 1C1 may be responsible for 
iodothyronine sulfation in rat liver and kidney, whereas other sulfotransferases are involved in 
iodothyronine sulfation in rat brain (Chapter 3). In the studies described in chapters 5 and 6 it 
was found that all human phenol sulfotransferases, including the estrogen sulfotransferase 
hSULT1 E1, catalyze iodothyronine sulfation. Interestingly, although estrone and estradiol are 
clearly the preferred substrates for hSULT1 E1, rT3 and T4 are sulfated much better by this 
isoenzyme than by any other iodothyronine sulfotransferase. Whereas hSUL T1 E1 equally 
prefers 3,3'-T2 and rT3, hSULT1A1, 1A3 and 1 B1 prefer 3,3'-T2 over rT3, T3 and T4. 
It is intriguing that high levels of 03 expression have recently been demonstrated in the 
pregnant rat uterus, and also hSULT1 E1 is expressed in the uterus. 03 catalyzes the 
deiodination of T4 and T3 to rT3 and 3,3'-T2, respectively. Since these products are the 
preferred substrates for hSULT1 E1, T4 and T3 are possibly metabolized in the uterus by 
successive deiodination and sulfation. As iodothyronine sulfate levels are high in the fetal 
serum and amniotic fluid, the uterus may serve as an alternative pathway for the supply 01 
thyroid hormone sulfates from mother to fetus. The possible role of the uterus in the regulation 
of fetal thyroid hormone status needs further research. 
PCBs and other polyhalogenated aromatic hydrocarbons (PHAHs) are known for their 
endocrine-disrupting effects. To assess the potential role of hydroxylated metabolites of these 
chemicals in disruption of thyroid hormone and estrogen sulfation, we studied the effects of a 
wide range of PHAH-OHs, on E2 and iodothyronine sulfation by human SULT1 E1 (Chapters 7 
and 8). We found that hSULT1 E1 is very potently inhibited by various hydroxylated PHAH 
metabolites. This inhibition of hSULT1 E1 by PHAH-OHs forms an alternative mechanism 
explaining the estrogenic effects of these compounds, based on the increase of estrogen 
concentrations, rather than on agonistic estrogen receptor binding. The significance in vivo of 
inhibition of hSUL T1 E1 in estrogen and thyroid hormone disruption remains to be investigated. 
In conclusion, apart from the important inner ring deiodination by 03, sulfation is a 
regulatory pathway of thyroid hormone metabolism during fetal development. We identified 
different iodothyronine sulfotransferases catalyzing the sulfation of thyroid hormones in humans 
and in the rat, and found that thyroid hormone and estrogen sulfation are potently inhibited by 
various PHAH-OHs. 
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Nauwkeuring gereguleerde sChildklierhormoonspiegels zijn vereist voor een normale 
orgaanontwikkeling; een verstoorde schildklierhormoonstatus zou kunnen leiden tot 
aangeboren afwijkingen. Het schildklierhormoonmetabolisme is een belangrijk mechanisme in 
de. regulatie van schildklierhormoonhomeostase. Het prohormoon thyroxine (T4), dat het 
belangrijkste uitscheidingsprodukt van de schildklier is, wordt gedejodeerd door type I dejodase 
01 naar het receptor-aktieve 3,3',5-trijodothyronine (T3) en door type III dejodase (03) naar de 
metaboliet reverse T3 (rT3). T3 en rT3 worden verder gemetaboliseerd door glucuronidering of 
sulfatering van de fenolische hydroxylgroep. Jodothyronine-glucuroniderende uridinedifosfaat-
glucuronyltransferases komen niet tot expressie voor de geboorte, enzymen die sulfatering 
katalyseren (sulfotransferases) zijn daarentegen aanwezig in foetale weefsels zoals lever, nier 
en hersenen. Een te onderzoeken hypothese was dat gedurende de foetale ontwikkeling 
sulfatering een reversibele route van inaktivering van schildklierhormoon is. Jodothyronine-
sulfaten zouden kunnen dienen als reservoir van inaktief schildklierhormoon, waaruit aktief T3 
wordt gevormd op een manier, die weefselspecifiek is en afhankelijk van het 
ontwikkelingsstadium. 
Allereerst werd het belang van schildklierhormoonsulfatering gedurende de foetale 
ontwikkeling onderzocht. Verschillende ontwikkelingspatronen van dejodase- en 
sulfotransferase aktiviteiten werden gevonden in de verschillende weefsels. Er werden echter 
geen sulfatase aktiviteiten waargenomen in rattenweefsels, in tegenstelling tot foetale humane 
weefsels zoals de lever, waarin significante sulfatase aktiviteiten zijn gevonden. Bovendien 
waren jodothyroninesulfaatspiegels in rattenserum op foetale leeftijd E20 (twee dagen voor de 
geboorte) erg laag, in tegenstelling tot de verhoogde jodothyroninesulfaatspiegels in foetaal 
humaan serum. We concludeerden uit deze studies dat reversibele jodothyroninesulfatering 
niet belangrijk is in de foetale rat (Hoofdstuk 2). 
De karakterisering van sulfatase aktiviteiten in humane en rattenlever en -placenta is 
beschreven in hoofdstuk 4. In het algemeen waren sulfatase aktiviteiten in volwassen humane 
lever en -placenta hager dan in volwassen rattenlever en -placenta. Humane steroidsulfatase 
arylsulfatase C (ARSC) is het enige sulfatase waarvan bekend is dat het jodothyroninesulfaat-
hydrolyse katalyseert. Door sulfatase aktiviteiten in humane lever en placenta te vergelijken met 
aktiviteiten in homogenaten van ARSC-expresserende V79-cellen, werd aangetoond dat ARSC 
het belangrijkste enzym is in jodothyroninesulfaathydrolyse in humane placenta, terwijl in de 
lever ook andere sulfatases een rollijken te spelen. 
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Om het belang van schildklierhormoonsulfatering verder uit te zoeken hebben we de 
sulfotransferases die betrokken zijn bij jodothyroninesulfatering ge"identificeerd en 
gekarakteriseerd. Terwijl de rattenfenolsulfotransferases rSULT1A1 en 1E1 en hydroxysteroid· 
sulfotransferases rSULT2A1, 2A2 en 2A3 jodothyroninesulfatering niet bleken te katalyseren, 
katalyseerden de fenolsulfotransferases rSULT1B1 en 1C1 de sulfatering van jodothyronines in 
de volgorde 3,3'·T2 » rT3 - T3 > T4 (Hoofdstuk 3). We vergeleken schijnbare K", waarden en 
substraatspecificiteiten veer rattenlever-, rattennier- en rattenhersencytesol met die veer 
rSULT1B1 en 1C1, en vonden dat rSULT1B1 en 1C1 verantwoordelijk zouden kunnen zijn voor 
jodothyroninesulfatering in rattenlever en ·nier, terwijl waarschijnlijk andere sulfotransferases 
betrokken zijn bij jodothyroninesulfatering in rattenhersenen (Hoofdstuk 3). In de studies 
beschreven in de hoofdstukken 5 en 6 is gevonden dat aile humane fenolsulfotransferases, 
inclusief de oestrogeensulfotransferase hSUL T1 E1, jodothyroninesulfatering katalyseren. 
Hoewel oestron en oestradiol duidelijk de geprefereerde substraten zijn voor hSULT1E1, 
worden rT3 en T 4 veel beter gesulfateerd door dit isoenzym dan door enig ander 
jodothyroninesulfotransferase. Terwijl hSULT1 E1 een voorkeur heeft voor zowel 3,3'·T2 en rT3, 
prefereren hSULT1A1, 1A3 en 1B1 3,3'·T2 boven rT3, T3 en T4. 
Opmerkelijk is dat hoge niveaus van 03·expressie zijn aangetoond in de zwangere 
rattenuterus, terwijl ook hSULT1 E1 tot expressie komt in de uterus. 03 katalyseert de 
dejodering van T4 en T3 naar respectievelijk rT3 en 3,3'·T2. Aangezien deze produkten de 
geprefereerde substraten zijn voor hSULT1E1, worden T4 en T3 mogelijk gemetaboliseerd in 
de uterus door opeenvolgend dejodering en sulfatering. Omdat jodothyroninesulfaatspiegels 
heag zijn in feetaal serum en amnionvleeistof, zou de uterus kunnen dienen als een 
alternatieve route veer de voorziening van schildklierhormoensulfaten van moeder naar foetus. 
De mogelijke rol van de uterus in de regulatie van de foetale sChildklierhormoonstatus vereist 
verder onderzoek. 
PCBs en andere polygehalogeneerde aromatische koolwaterstoffen (PHAKs) zijn bekend 
om hun hormoon·verstorende effecten. Om de potentiele rol van gehydroxyleerde metabolieten 
van deze chemica lien in de verstoring van schildklierhormoon· en oestrogeensulfatering te 
onderzoeken, hebben we de effecten van een grote groep PHAK·OHs en verwante stoffen, 
zoals gehydroxyleerde nitrofen·metabolieten, op E2· en jodothyroninesulfatering door humaan 
SULT1 E1 bestudeerd (Hoofdstukken 7 en 8). We vonden dat hSULT1 E1 zeer sterk wordt 
geremd door verschillende gehydroxyleerde PHAK·metabolieten. De remming van hSULT1E1 
door PHAK·OHs vormt een alternatieve verklaring voor de oestrogene effecten van deze 
stoffen, gebaseerd op de verhoging van concentraties van oestrogenen, in plaats van op 
agonistische oestrogeenreceptor·binding. Het be lang in vivo van remming van hSULT1 E1 voor 
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verstoring van oestrogeen- en schiJdklierhormoonspiegels moet nog onderzocht worden. 
Concluderend: naast de belangrijke binnenring-clejodering door 03 is ook sulfatering een 
regulerende route binnen het schildklierhormoonmetabolisme tijdens de foetale ontwikkeling. 
We identificeerden verschillende jodothyroninesulfotransferases die de sulfatering van 
schildklierhormonen bij de mens en de rat katalyseren, en vonden dat schildklierhormoon- en 
oestrogeensulfatering sterk geremd worden door verschillende gehydroxyleerde PHAK-OHs. 
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